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Abstract 
 
Photo-activatable platinum(IV) diazido complexes with the general formula of 
trans,trans,trans-[Pt(N3)2(OH)(X)(py)(am1)] (X is a hydroxide or carboxylate and 
am1 is an aliphatic/aromatic amine) show dark-stability under physiological 
conditions but can induce a photo-cytotoxic effect in cancer cells after irradiation 
with UVA, blue and/or green light. These platinum(IV) diazido complexes can 
platinate DNA and induce different lesions that are distinctly different from those 
generated by the anticancer drug cis-platin. Through the use of EPR, multinuclear 
NMR, and UV-visible absorption spectroscopy, as well as mass spectrometry and 
some cell studies, this thesis aims to investigate the pathways of photochemical 
decomposition and in particular the release of azidyl ligands and their subsequent 
involvement in photo-cytotoxicity.  
 
 
Firstly, the irradiation of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (40, py = pyridine) 
with blue light in the presence of the spin trap 5,5-dimethyl-1-pyrroline-N-oxide 
(DMPO) led to the detection of a characteristic quartet-of-triplets EPR spectrum, 
assigned to the azidyl radical adduct, DMPO-
14
N3. Irradiation of 
15
N-40, led to the 
detection of a quartet-of-doublets EPR spectrum as assigned to the DMPO-
15
N3 
spin adduct. This confirmed that the 
●
N3 radicals arose from the platinum(IV)-
bound azide. The DMPO-N3 spin adduct was also detected from the photo-
irradiation of trans,trans,trans-[Pt(N3)2(OH)2(MA)(py)] (44, MA = methylamine) 
with blue light.   
 
A greater yield in the DMPO-N3 spin adduct was formed in PBS/D2O. This effect 
was attributed to the Brownian motion of the 
●
N3 radicals. Interestingly, photo-
irradiation in the cell culture medium-, RPMI-1640 led to a reduction in the 
DMPO-N3 spin adduct. This reduction was accredited to the variety of 
components present in the cell culture medium which could behave as radical 
quenchers. Alternative nitrone spin traps, -4-pyridyl-1-oxide-N-tert-butylnitrone 
(4-POBN) and 5-diethoxyphosphoryl-5-methyl-1-pyrroline-N-oxide (DEPMPO) 
also led to the trapping of the azidyl radicals from irradiated 40, forming the 4-
POBN-N3 (triplet-of-quartets) and DEPMPO-N3 (octet-of-triplets) spin adducts 
EPR spectra, respectively. DEPMPO was the most efficient azidyl radical trap; 
with the DEPMPO-N3 spin adduct possessing the longest lifetime in aqueous 
media.  
 
Extending the wavelength of activation to green light (517 nm), also led to the 
detection of DMPO-N3 from the photo-irradiation of 40 in RPMI-1640, 
trans,trans,trans-[Pt(N3)2(OH)(SAD)(py)2] (56,SAD=succinate), 
trans,trans,trans-[Pt(N3)2(OH)(ethyl-methyl-SAD)(py)2] (57) and 
trans,trans,trans-[Pt(N3)2(OH)(N-MI)(py)2] (58, N-MI = N-methylisatoate) in 
H2O/DMF. The DEPMPO-N3 was also detected from the gamma-ray irradiation 
of 40, which appears to be the first report of the activation of a platinum(IV) 
diazido anticancer complex with gamma-rays, a procedure which might be useful 
of clinical use. 
 
The azidyl radicals generated from irradiated 40 were unreactive towards both 
glycine and L-tyrosine. However, in the presence of L-tryptophan the azidyl 
ix 
 
radicals were quenched. Detection of free azide by 
14
N NMR spectroscopy 
confirmed that this quenching mechanism proceeded through a one-electron 
transfer pathway. The photo-cytotoxicity of 40 was supressed in the presence of 
low doses of L-tryptophan in A2780 ovarian cancer cells. From this study, it was 
deduced that the photo-cytotoxicity of 40 is comprised of both an acute (radical) 
and chronic (DNA platination) based mechanisms. Additionally, certain cancers 
have reported on the depleted serum levels of L-tryptophan, in particular ovarian 
cancer cells. This suggests the extent of the photo-cytotoxicity of 40 can be 
controlled in the presence of L-tryptophan.  
 
Photo-irradiation of 40 in the presence of melatonin, an analogue of L-tryptophan 
was also performed. Despite, the structural similarity between L-tryptophan and 
melatonin, the presence of the 5-methoxy substituent present in melatonin induced 
an alternative photo-decomposition pathway of 40. Photo-irradiation of 40 in the 
presence of melatonin with blue light also led to the detection of the quartet EPR 
spectrum assigned to the hydroxyl radical adduct, DMPO-OH. Through 
multinuclear NMR and mass spectrometry the quenching of both the azidyl and 
hydroxyl radicals by melatonin was determined. Additionally, mass spectrometry 
also detected a mass adduct attributed to a platinum(II)-melatonin complex. This 
dual antioxidant and metal-binding ability of melatonin was attributed to the 
observed photo-protective effect in A2780 ovarian cancer cells. Melatonin 
regulates circadian rhythms with a maximum concentration during dark hours. 
Consequently, treatment of antineoplastic tissue with 40 during the hours of 
melatonin production may be ineffective.  
 
Platinum accumulation and absorption has been suggested to be mediated by 
organic cation transporters (OCTs), in particular OCT2. Irradiation of 40 was 
monitored in the presence of cimetidine, an OCT2 inhibitor. A new strong 
absorption band at ca. 354 nm was assigned to an SPtII LMCT band. High 
resolution mass spectroscopy identified a mass adduct assigned to a novel 
platinum(II)-cimetidine species. The loss of coordinated pyridine from irradiated 
40 as detected by 
1
H NMR spectroscopy and the quenching of the azidyl radical 
by cimetidine were correlated with the observed photo-protective effect in HaCaT 
keratinocytes cells.  
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This thesis is concerned with the identification and reactivity of photo-products 
generated from the photo-decomposition of novel photo-activatable platinum(IV) 
diazido anticancer complexes. Current platinum anticancer agents are losing their 
potency due to acquired or intrinsic resistance mechanisms. Novel platinum 
anticancer agents with unique mechanisms of action appear to be essential for future 
chemotherapy. Therefore, in this Chapter a summary on the history of developed 
platinum anticancer complexes is given, followed by an introduction to the concept 
of targeted delivery of platinum anticancer complexes. Finally, attention is focused 
on new phototherapy-based methods.  
 
1.1 Cancer 
Cancer remains a main contribution of deaths worldwide (Figure 1.1). The World 
Health Organistion (WHO) estimates approximately 13.1 million related cancer 
deaths to rise to 22 million by 2030.1 Cancer initation is a multistep process, 
however numerous studies have correlated free radicals and reactive species in the 
formation of pathophysiological diseases including cancer.2 Freidmann reported ca. 
80% of the oxgyen consumed is converted to adenosine triphopshate (ATP) by the 
mitochondria, the remaining 20% is partially reduced to reactive oxygen species 
(ROS).3 Additionally, oxidation of the amino acid L-arginine leads to the formation 
of nitric oxide (NO), a reactive nitrogen species (RNS). Moreover, exposure to 
UV-light, X-rays or gamma radiation can also lead to ROS/RNS generation.4  
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Figure 1.1 Percentage of cancer types contributing to worldwide deaths by 2030 
(data obtained from the WHO).   
 
The term ROS/RNS is used to encompass an arrary of reactive oxygen/nitrogen 
species, some posssessing an unpaired electron referred to as radical species (Table 
1.1). Both ROS and RNS are typically short-lived species (ca. t½ of 10
-9 s) and can 
induce damage to DNA, lipids, membranes, proteins and peptides. Valko reported 
that one human cell is exposed to ca. 1 × 105 oxidative hits/day.5 Consequently, the 
cell has developed various resistance mechanisms to prevent daily damage induced 
from either ROS or RNS present at low concentrations. Resistance mechanisms 
include nucleotide excision repair (NER), mismatch repair (MMR) processes and 
the presence of antioxidants. Intracellular antioxidants such as vitamin C and E, 
glutathione and superoxide dismutase (SOD), amoung others, possess the ability to 
scavenge ROS and RNS preventing cell damage.6 As reported by Sies, the 
imbalance between oxidants and antioxidants favouring the oxidant is defined as 
oxidative stress.7 
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Table 1.1 Classification of both reactive oxgyen species (ROS) and reactive 
nitrogen species (RNS).  
ROS RNS 
●OH (hydroxyl radical) ●N3 (azidyl radical) 
●-O2 (superoxide) NO
● 
●O2R (peroxyl) 
●O2N (nitrogen dioxide) 
●OR (alkoxyl) HNO2 (nitrous acid) 
HOCl (hypochlorous acid) N2O3 
O3 (ozone) NO2
- 
ONOO- (peroxynitrite) NO3
- 
1O2 (singlet oxgyen)  
H2O2 (hydrogen peroxide)  
 
Where ● refers to a paramagnetic species 
 
ROS include the hydroxyl (●OH) radical, singlet oxygen (1O2) and hydrogen 
peroxide (H2O2). The 
●OH radical has been identified as the most reactive and 
damaging ROS.8 It has the ability to react with all DNA nucleobases, resulting in 
numerous products. In contrast, 1O2 has been reported to react specifically with the 
guanine nucleobase of DNA.5 Products of biological damage are termed 
“biomarkers”, a common biomarker, 8-hydroxydeoxyguanosine (8-OH-G), has 
been identified by various spectroscopic techniques.9,10 Interestingly, H2O2 toxicity 
arises in the presence of metal ions,  typically iron(II) or copper(I) which reduce 
H2O2 and generate the reactive 
●OH radical, either through the Haber-Weiss or 
Fenton process.11 Additionally, the majority of RNS are derived from NO●, formed 
from the oxidation of L-arginine. NO● has the ability to readily diffuse through the 
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cytoplasm and plasma membrane NO● reacts with other ROS such as H2O2 and 
HOCl producing a variety of reactive nitrogen derivates. Similar to ROS, RNS 
induce equivalent DNA damage.12  
 
Excessive generation of ROS/RNS in non-maligant tissue(s)/organ(s) is 
unfavourable. However, generation of these reactive species specificially in 
neoplastic tissue offers the potential of DNA damage and thereby inducing cell 
death of tumour tissue. Banerjee et al. recently reported the induction of apoptosis 
in leukemia cells through the formation of both ROS and RNS generated from a 
dibasic hydroxamic acid complex.13 Moreover, the generation of 1O2 has also been 
attributed to cell death and is currently used in Photodynamic Therapy (see section 
1.7.1). Therefore, ROS/RNS can act as potential “tumourgenetic” agents.6 
However, due to their transient nature, detection of these reactive radical species is 
not facile. Currently, the most commonly used technique for radical detection is 
electron paramagnetic resonance (EPR) spectroscopy. This technique is used 
throughout this thesis, therefore a brief description to the theory and data 
characterisation is provided.  
 
1.2 Electron Paramagnetic Resonance  
Electron paramagnetic resonance is the study of unpaired electrons, commonly 
referred to as a radical species. A wide variety of radicals exist ranging from organic 
molecules to inorganic metals. Many divisions of EPR spectroscopy have been 
developed including, electron-nuclear double resonance (ENDOR),14 hyperfine 
sublevel correlation (HYSCORE)15 and spin trapping (ST) EPR spectroscopy. 
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Consequently, EPR has been exploited in numerous research fields ranging from 
archeology16,17 to medicine.18,19 
 
1.2.1 Theory  
EPR possesses the same physical principles as nuclear magnetic resonance (NMR) 
spectroscopy. However the former is concerned with electron spin compared to the 
nuclei spin as with NMR. An EPR spectrum can be acquired in either continuous-
wave (CW) or pulsed mode.20 In CW-EPR, a low power microwave signal ca. 200 
mW is continuously sent to the sample. In this thesis, CW-EPR spectroscopy was 
used. Therefore, subsequent descriptions and discussions are based on CW-EPR, 
unless otherwise stated.  
 
In the absence of a magnetic field (B0 = 0) the two electron spin states α (+ ½, 
aligned opposite the magnetic field) and β (- ½, aligned with the magnetic field) are 
degenerate. However, once a magnetic field is applied (B0 ≠ 0) these spin states are 
no longer equivalent and are energetically separated (ΔE (Eα – Eβ)) as shown in 
Figure 1.2.21 The separation of the two electron spin states in the presence of a 
magnetic field is referred to as the electron Zeeman effect,20 and is defined by 
Equation 1.1, where g is the g value (defined on p 8) and µB is the Bohr Magneton 
(-9.274 ×10-24 J T-1). 
 
            ΔE  = hν = ±
1
2
g|μB|B0           Eq 1.1 
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Figure 1.2 Energy separation of the α and β spin states in the absence (B0 = 0) and 
presence (B0 ≠ 0) of a magnetic field (B0), where the resonance condition is fulfilled 
(solid arrow) and not fulfilled (dashed arrow) (figure adapted from ref 20).  
 
Most EPR spectrometers operate at a constant microwave frequency and scan the 
magnetic field.22 The most common microwave frequency used in EPR is ca. 9-10 
GHz, also known as the X-band.23  EPR spectrometers are classified into different 
bands, dependent on their operating microwave frequency. EPR spectrometers 
lower than X-band are commonly used for in vivo detection, whereas higher than 
X-band e.g. W-band (94 GHz) are used to determine biological distances typically 
in proteins.24 Throughout this thesis, X-band EPR spectroscopy was used.  
 
EPR spectra are presented in the first-derivative, despite the absorption curve being 
recorded. In CW-EPR mode a field modulation with phase-sensitive detection is 
commonly used. This is primarily utilised to enhance the resultant EPR signal and 
allows the EPR spectrometer to differentiate a true EPR signal from noise and/or 
interference. The result is that the slope of the absorption curve is measured due to 
the EPR signal being a function of the external applied field (Figure 1.3).25 
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Figure 1.3 Illustration of an EPR spectrum recorded with field modulation (ΔB0) 
in phase-sensitive detection. Resultant EPR spectrum is the slope of the absorption 
curve (figure adopted from ref 25).  
 
1.2.2 Characterisation of EPR spectra  
1.2.2.1 Hyperfine coupling  
EPR spectra are characterised via two main parameters. Firstly, hyperfine splitting 
(equivalent to the J coupling in NMR) arises from the coupling of an unpaired 
electron with a magnetically active nucleus with spin (I) greater than zero. 
Hyperfine splitting constants are denoted by the symbol “aY”, where y signifies the 
magnetically active nucleus the electron is coupling with and is measured in 
millitesla (mT) or Gauss (G). The number of expected lines in an EPR spectrum 
can be deduced from 2nI+1, where n refers to the number of equivalent 
magnetically active nuclei with a spin (I) greater than zero.26 The standard free 
radical 4-hydroxy-2,2,6,6-tetramethyl-piperidine-1-oxyl (Tempol) generates a 
triplet EPR spectrum. This is produced from the coupling of the unpaired electron 
with the nitroxidic nitrogen possessing a spin (I) of 1 (Figure 1.4).  
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Figure 1.4 Triplet EPR spectrum of the standard free radical Tempol produced from 
the coupling of the unpaired electron with the nitrogen nucleus with I =1 and aNNO 
refers to hyperfine coupling constant of the nitroxide nitrogen measured in Gauss 
units.  
 
The nitroxide (aNO) and β-proton (aH) hyperfine coupling constants have been 
reported to be dependent on the dielectric constant of the solvent.27 The hyperfine 
coupling value is dependent on the solvent and EPR parameter settings, in particular 
the microwave power and modulation amplitude can alter the resultant hyperfine 
splitting value.28 Therefore, unless EPR spectra are recorded under the identical 
EPR parameters, differences in the hyperfine splitting values are possible. 
Additionally, the hyperfine coupling constant(s) can determine the spin density of 
the unpaired electron on each atom present in the spin adduct. This can be calculated 
from the McConnell equation,29 which will be discussed in more detail in Chapter 
III. 
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1.2.2.2 g value  
The second parameter commonly used to characterise EPR spectra is the Landé 
Factor or more commonly known as the g value. This parameter is equivalent to the 
chemical shift (δ) parameter in NMR spectroscopy. It is independent of the 
microwave frequency and is determined from the resonance condition below 
(Equation 1.2), where h is Plank’s constant 6.626×10-34 J.s, ν is the frequency 
(MHz), β is the Bohr Magneton constant (9.274×10-24 J.T-1) and B0 is the magnetic 
field (G).  
g =  
hν
μBB0 
        Eq. 1.2  
The g value is the centre of the EPR spectrum and values of g are usually close to 
the value of the free electron, gE = 2.0023. The g-value varies for each radical 
detected and is commonly regarded as a radical “fingerprint”.30  
 
An application of EPR referred to as EPR spin trapping is ulitilsed in this work for 
the detection of ROS/RNS generated from photo-activatable platinum(IV) diazido 
anticancer complexes. EPR spin trapping is used to detect short-lived radicals, those 
possessing short life-times, ca. < 10-9 s.31 EPR spin trapping is described in more 
detail in Chapter III. Next, a chronological background into the development of 
these novel PtIV chemotherapeutic agents is provided.  
 
1.3 Metals in medicine  
Today, a variety of metal complexes with potential anticancer activity are being 
discovered in research laboratories. Translation of these complexes from “bench to 
clinic” is becoming increasingly difficult, especially since there is a lack of public 
acceptance of the use of “metals in medicine” as recently reported by Mjos.32 This 
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negative attitude towards metal-based therapeutics may be explained by the Bertand 
diagram33 which describes even essential metals become “toxic” at certain levels. 
However, the use of metals for therapeutic treatment can be dated back to ca. 1912, 
involving the use of salvarsan. Developed by Ehrlich, this arsenic-based 
antimicrobial agent was effective in the treatment of syphillis.34 Metals have also 
been successfully incorporated into diagnostic agents for imaging of abnormal 
tissues.35 Additionally, clinical trials investigating the use of metal complexes in 
both therapy and diagnosis are significantly increasing.36 Currently, ca. 50% of 
anticancer treatments involve the use of a platinum-based chemotherapeutic 
agent.37  
 
1.4 Platinum 
1.4.1 PtII complexes  
Platinum has a range of oxidation states from 0 to +6. However, the most common 
oxidation states are +2 and +4. A square-planar structural geometry is exhibited by 
PtII (d8) complexes. This is due to the splitting of the d orbitals, completely filling 
the lower orbitals, leaving the upper most orbitals (dx
2- y
2) empty (Figure 1.5). 
Various isotopes of platinum exist, however 195Pt (33.8% natural abundance)38 is 
the only nuclear magnetically active isotope with a spin (I) of ½.   
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Figure 1.5 Splitting of the d-orbitals of a square-planar PtII (d8) complex possessing 
strong donor ligands.  
 
The arrangement of the ligands coordinated to the platinum centre can give rise to 
cis or trans isomers. To date, cis-diamminedichloroplatinum(II) is the most 
successful metallodrug, accidentally discovered in 1965 by Rosenberg, commonly 
referred to as cis-platin (1, Figure 1.6).39  This complex can also exist as its inactive 
geometrical isomer, trans-platin (2, Figure 1.6).  
           
Figure 1.6 Structures of cis-platin (CDDP, 1) and trans-platin (TDDP, 2).  
 
1.4.2 Cis-platin and its mechanism of action 
Cis-platin (CDDP, 1) was reported to exhibit anticancer activity towards a number 
of cancers including testicular, ovarian and bladder cancers.40 After administration 
of CDDP via infusion or intravenous injection into the blood plasma, it remains 
stable due to the high chloride concentration (ca. 100 mM).41 Under these 
conditions, hydrolysis of CDDP is supressed, as the relatively inactive CDDP is 
readily distributed throughout the entire body.42 Early studies reported that CDDP 
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enters the cell through passive diffusion43 or by active uptake.44 Recently the influx 
of CDDP into the cell has been reported to be mediated via copper transporters, in 
particular the hCtr1.45 Platinum accumulation has also been reported to be mediated 
by organic cation transporters (OCTs),46,47 this will be discussed in more detail in 
Chapter VI.  
 
The intracellular concentration of chloride in the cytoplasm has been reported by 
Jennerwein and Anderson in a variety of human carcinoma cells to range from ca. 
20 – 55 mM.48,49 Consequently, once inside the cytoplasm, CDDP is subject to 
hydrolysis due a reduced chloride concentration. An active postively-charged 
chloroaqua PtII species, [Pt(Cl)(NH3)2(OH2)]
+ is formed. This species is thought to 
induce the observed cytotoxic effect (Figure 1.7).  
 
Figure 1.7 Stepwise hydrolysis of cis-platin occurring in the cytoplasm of the cell 
and the subsequent deprotonation to the hydroxido complexes with respective pKa 
values at 300 K.50  
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It has been reported that under physiological conditions, the majority of 
heteroatoms present in the purine and pyrimindine nucleobases (Figure 1.8) of DNA 
possess the ability to bind to PtII. Numerous reports have identified binding of PtII 
occurs preferentially at the N7 atom of the purine nucleobase guanine (G),51-56 
forming the major 1,2-d(GpG) intrastrand cross links (ca. 60-65%) between two 
adjacent guanines57 (Figure 1.9A). Minor 1,2(ApG) intrastrand crosslinks (20-25%) 
also occur with the nucleobase adenine. Additonally, 1,3-(GpXG) crosslinks (ca. 
2%), which possess an extra base between the guanine resides have been identified. 
Moreover, interstrand crosslinks between two guanine residues on opposite strands 
of the DNA molecule (Figure 1.9B) have also be reported to form.58  
 
 
Figure 1.8 Structures of purine and pyrimidine DNA nucleobases showing () 
possible coordination site(s) to Pt in each nucleobase.  
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Figure 1.9 CDDP-DNA crosslinks showing (A) major 1,2-(GpG) and (B) minor G-
G interstrand crosslinks, where  refers to the guanine nucleobase (figure adapted 
from ref 58).  
 
The formation of the 1,2-(GpG) crosslinks have been determined by both X-ray 
crystallography and nuclear magnetic resonance (NMR) methods.59-61 These 
CDDP-DNA crosslinks distort the DNA molecule resulting in unwinding and 
bending (Figure 1.10),62 altering the structure of the DNA significantly. The 
generation of these CDDP-DNA adducts disrupt cellular replication, and lead to 
apoptosis, a programmed mechanistic cell death pathway.63 To date cis-platin 
remains the most potent anticancer agent for the treatment of a variety of cancers 
with high cure rates. The potency of cis-platin is not without its associated side-
effects. As mentioned above, once CDDP enters the cytoplasm it is subject to 
hydrolysis forming active PtII-species (Figure 1.6). PtII-species exhibit a high 
affinity towards sulfur-containing molecules.64 
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Figure 1.10 Bending of the DNA molecule from a solution structure of DNA 
platinated DNA by cis-platin (figure adapted from ref 62). 
 
In the intracellular milieu an array of sulfur-based molecules exist in amino acids, 
proteins and peptides (Figure 1.11). Glutathione (GSH), a thiol-based tripeptide 
consisting of glutamate (Glu), cysteine (Cys) and glycine (Gly) is one of the most 
abundant peptides in the cell, with concentrations ranging from 0.5 – 10 mM and 
has been shown to interact with cis-platin, forming Pt-S(GS) adducts.65,66 L-
methionine (Met) and L-cysteine (cys) amino acids are present in a wide variety of 
proteins and peptides.67 Formation of these PtII-S based species has been attributed 
to the observed toxic side effects and resistance mechanisms,68 consequently 
reducing the active form of CDDP reaching the designated target, DNA.69 The 
nucleus was reported to possess < 1% of the total platinum dose administered. These 
side-effects have been limiting factors in the continuation of cis-platin therapy in 
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the clinic, in some instances.70 For these reasons, second generation platinum 
anticancer complexes have been developed.  
       
Figure 1.11 Structures of abundant intracellular sulfur-containing molecules.    
 
1.4.3 Second generation PtII anticancer complexes 
In an attempt to overcome the associated side-effects of CDDP, new platinum 
anticancer complexes where labile ligands were replaced for more stable ligands, 
those not readily substituted by water, were developed. Numerous publications of 
new platinum complexes with potential antitumour activity have appeared,71 
however only a few complexes have reached clinical trials.58,72,73 Carboplatin (3, 
Figure 1.12), a second generation PtII-anticancer drug has the two chlorido ligands 
(in cis-platin) replaced by a chelated 1,1-cyclobutanedicarboxylate. This 
substitution rendered carboplatin more stable than CDDP. A consequence of this 
stability is the reduced reactivity and cytotoxicity of carboplatin resulting in higher 
doses (300 – 450 mg m-2) needing to be administered to achieve an equivalent 
potency as CDDP.74 Hydrolysis of carboplatin generates identical active PtII-species 
previously observed from the aquation of CDDP, such that both CDDP and 
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carboplatin are used for the treatment of similar types of cancer. Carboplatin has 
been approved world-wide for the treatment of cancer and has recently been the 
drug of choice in the treatment of ovarian cancer over CDDP. It is currently in 
clinical trials to assess its efficiency in the treatment of salivary gland cancer.75,76  
 
Oxaliplatin (4, Figure 1.12), marketed as Eloxatin is another world-wide approved 
PtII-anticancer complex. The first drug reported to overcome cis-platin resistance 
through the extension of the bulky dach (cyclohexane-1,2-diamine) group into the 
DNA major groove,77 preventing the binding of DNA repair proteins. Additional, 
bi-functional adducts between the N1 of adenine and the N7 of guanine DNA 
nucleobases were formed by oxaliplatin.78 These adducts were another possible 
parameter to contribute to overcoming cis-platin resistance. Related complexes 
include nedaplatin (5, Figure 1.12), lobaplatin (6, Figure 1.12) and heptaplatin (7, 
Figure 1.12) currently unapproved by the Food and Drug Administration (FDA), 
but in clinical use in Japan, China and South Korea.79  
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Figure 1.12 Structures of second generation PtII anticancer complexes.  
 
1.4.4 Trans complexes 
1.4.4.1 Trans-platin  
Trans-platin (2) the structural isomer of cis-platin, was shown to be inactive towards 
tumour cells. This was thought to be due to its inability to form 1,2-(GpG) 
intrastrand crosslinks,80 the major platinated crosslinks inducing cell death. Similar 
to cis-platin, hydrolysis of trans-platin generates both mono and bis-aqua species 
(Figure 1.13), where hydrolysis of trans-platin to its mono-aqua form occurs faster 
than cis-platin. The formation of the bis-aqua species for trans-platin does not 
readily occur due to the trans-effect. This is the effect of the trans ligand on the rate 
of substitution, independent on the nature of the nucleophile. Monofunctional-DNA 
adducts have been reported to be formed from the interaction of trans-platin with 
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DNA. However, facile displacement of these monofunctional-DNA adducts by a 
variety of nucleophiles such as thiourea and GSH may explain its inactivity.81  
          
Figure 1.13 Hydrolysis products of trans-platin showing (A) mono-aqua and (B) 
bis-aqua species with respective rate constants at 298 K.  
 
1.4.4.2 Varying carrier ligands 
Farrell has argued that the rapid displacement of the monofunctional-DNA adducts 
observed for trans-platin can be prevented by replacement of the ammine (NH3) 
groups with more bulky substituents. Complexes of the type trans-[PtCl2L2], where 
L = pyridine or picoline were synthesised (Figure 1.14) and shown to be more 
cytotoxic in the L1210 leukaemia cell line than their corresponding cis-isomers.82 
This led to additional substitutions of the NH3 groups in trans-platin for methyl-
imidazole, quinoline, sulfoxides and iminoether-based ligands. All resultant 
complexes exhibited equivalent or greater cytotoxic profiles than their 
corresponding cis-isomers in both cis-platin sensitive and resistant cell lines.83-88   
             
Figure 1.14 Structures of trans-[PtCl2L2] anticancer complexes where L is (A) 
pyridine and (B) 4-picoline synthesised by Farrell.82 
                                     Chapter I: Introduction 
 
20 
 
A comprehensive review by Kalinowska-Lis describes the numerous trans-
platinum complexes synthesised and their cytotoxic activities.89 The activity of 
these trans-configured complexes in cis-platin resistant cell lines, suggested that 
these geometrical isomers induce their cytotoxic effect through a different 
mechanism of action compared to cis-platin. Consequently, these reports rebutted 
the studies performed by Rosenberg and Cleare, in which they suggested a cis-
configuration a necessary requirement for a chemotherapeutic effect.90-92 New 
mechanisms of action offer potential in overcoming conventional resistance 
mechanisms.93 However, the reactivity of PtII complexes with intracellular based 
nucleophiles (Figure 1.11) still remained, reducing the amount of active PtII 
reaching the target molecule, DNA. Efficient delivery of the PtII active species has 
been investigated through the use of platinum complexes in the +4 oxidation state.    
 
1.4.5 PtIV complexes 
PtIV complexes with six strong field ligands are typically octahedral, low spin, 5d6 
(Figure 1.15). In the +4 oxidation state, platinum complexes are mostly substitution 
inert and thermally stable. Reduction of PtIV is required to generate the active PtII 
species. Reduction can proceed via intracellular reduction with biological reducing 
agents (Figure 1.11). Until reduction occurs, the platinum complex remains inactive 
in the Pt+4 oxidation state, referred to as a “prodrug” form. This kinetic inertness 
prevents unwanted side reactions occurring and has the potential to deliver more 
platinum to the tumour cell.  
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Figure 1.15 Splitting of the d-orbitals of an octrahedral PtIVcomplex (d6) possessing 
strong donor ligands.  
 
This PtIV prodrug strategy was exploited during the development of tetraplatin (10), 
iproplatin (11), satraplatin (12) as shown in Figure 1.16. Both tetraplatin and 
iproplatin were investigated in phase I clinical trials for their anticancer activity. 
The facile reduction of 10 to its PtII active form led to unwanted side-effects in vivo. 
This was attributed to its high reduction potential (E°) of ca. -90 mV (± 20 mV vs 
Ag/AgCl). On the contrary, the slow reduction of 11 with a reported E° value ca.-
730 mV (± 100 mV vs Ag/AgCl ) rendered it an inactive anticancer complex.94 The 
break-through came from the development of satraplatin (12) possessing a 
reduction potential of ca. -250 mV, which appeared to be in a suitable range. 
Satraplatin is reduced by intracellular metal-containing redox proteins to its active 
PtII form (13) at a slower rate than tetraplatin and yet faster than iproplatin. 
Satraplatin has yet to be approved by the FDA but has been involved in numerous 
clinical trials.58,79 It has been reported to be an efficient anticancer agent for the 
treatment of prostate cancer95 and is currently being investigated in combination 
therapy.96   
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Figure 1.16 Structures of tetraplatin, (10); iproplatin, (11); satraplatin, (12) and 
JM118 reduced form of satraplatin (13).  
 
The equivalent or greater cytotoxic profiles of trans-based complexes led to the 
development of numerous trans-PtIV-anticancer complexes. The complex, trans-
[PtCl2(dma)(ipa)(OH)2] (14) was compared to its corresponding Pt
II analogue, 
trans-[PtCl2(dma)(ipa)] (15), where (dma= dimethylamine, ipa= isopropanamine). 
Only 14 demonstrated in vivo cytotoxicity in human ovarian carcinoma xenografts 
in mice, whereas 15 only exhibited in vitro activity.97 Similar comparison studies 
were performed with trans-[PtCl4(NH3)(4-py-MeOH)] (16) and trans-
[PtCl2(NH3)(4-py-MeOH)] (17). Interestingly, 17 was determined to be ca. four-
fold more active than 16.98 The lower activity of 16 was attributed to its slow 
reduction from the inactive PtIV to the active PtII form.  
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Figure 1.17 Structures of trans-platinum(IV) complexes (14 and 16) and their 
corresponding trans-platinum(II) analogues (15 and 17).  
 
Despite the reduced side-effects of these novel PtIV-anticancer complexes relative 
to cis-platin (1), the active PtII-species are still generated through intracellular 
reduction. Chemical reductions can occur throughout the body given the array of 
biological reducing agents present in all cells. Therefore, intracellular reductions 
are not specific to tumour cancer cells resulting in non-malignant tissue being 
damaged. Recent research on the efficient delivery of platinum anticancer 
complexes has focused on the concept of targeted delivery. 
 
1.5 Targeted delivery 
Targeted delivery has the potential to reduce unwanted side-effects whilst 
simultaneously improving the efficiency of the chemotherapeutic agent. Targeted 
delivery exploits the use of a variety of scaffolds such as carbon nanotubes (CNTs), 
liposomes and biodegradable peptides for efficient delivery of the platinum 
anticancer complex to its biological target, typically DNA. Incorporation of the 
platinum formulation into these scaffolds serves to protect the platinum anticancer 
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complex from premature hydrolysis or intracellular reduction. These processes are 
achieved either through passive or active targeted delivery.  
 
1.5.1 Passive drug delivery 
Innovative designs of nano-vectors to achieve efficient drug delivery and their 
complexity are emerging. Min et al. have conjugated a PtIV prodrug (18) to amine-
functionalized PEGylated gold nanorods (AuNRs), reduced to PtII by cellular 
reductants. The PtIV-PEG-AuNRs were most active in the MCF-7 breast cancer 
cells exhibiting an IC50 of 0.18 µM, significantly more potent than free cis-platin, 
with an IC50 of 11.8 µM.
99  
 
 Figure 1.18 PtIV prodrug complex, (18); Active component of oxaliplatin tethered 
to AuNP functionalised with PEG linker, (19, 20). 
 
In similar work, Brown et al. functionalised AuNPs with thiolated PEG tethered to 
the active fragment of oxaliplatin, {Pt(R,R-dach)}2+, (19 and 20). Similarly, these 
Pt-AuNPs were almost six-fold more active towards A549 lung cancer cells than 
free oxaliplatin but ca. five-fold more active, or as active, as free oxaliplatin in 
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various colon cancer cell lines.100 These results demonstrated increased potency of 
platinum complexes conjugated to gold nanoparticles/rods.  
 
1.5.2 Active drug delivery 
Delivery of anticancer agents via nanocarrier scaffolds is efficient for reaching the 
tumour site through the enhanced permeability and retention (EPR) effect.101 
Although the attachment of receptor-binding molecules (particularly for receptors 
over-expressed in cancer tissues) on the surface of NPs can also enhance the uptake 
of the nanocarrier into the tumour cell through receptor-mediated internalisation. 
The most common receptors targeted in nanotechnology include the folate (FR), 
epidermal growth factor (EGF) and the transferrin (TfR) receptors.  
 
1.5.2.1 Epidermal growth factor (EGF) 
The overexpression of the EGF receptor in human tumours, in particular NSCLC 
(non-small cell lung cancer), renders it another potential target. Bhirde et al. 
attached cis-platin (dissolved in DMSO) and EGF to oxidised singled-walled 
carbon nanotubes (SWCNTs) to target squamous cancer. In vivo studies revealed 
SWCNTs-CDDP-EGF (21) to be selective towards HNSCC (head and neck 
squamous cell carcinoma). Tumour growth regression was significant in mice 
treated with SWCNT-CDDP-EGF bearing HNSCC xenografts in contrast to mice 
treated with SWCNT-CDDP.102  
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Figure 1.19 SWCNT bio-conjugated with cis-platin and epidermal growth factor 
(21); PtIV-chlorotoxin conjugate (22); Platinum translocator protein (TSPO) binding 
ligand conjugates with various X groups (23, 24); Mitaplatin (25).   
 
1.5.2.2 Proteins/peptides 
Various peptide sequences can bind preferentially to tumour cells and so can act as 
cancer targeting ligands. For example, chlorotoxin (CTX), a 36-amino acid peptide 
which blocks small-conductance chloride channels, binds to functional proteins 
such as matrix metalloproteinase-2 (MMP2) (overexpressed in glioma and related 
cancers) and chloride ion channels overexpressed in different types of cancers. CTX 
was conjugated to a PtIV-succinato complex (22) for delivery of cis-platin. The 
cytotoxicity of 22 towards MCF-7 breast, A549 lung and HeLa cervical cancer cells 
was less potent than CDDP but more active than both the PtIV precursor and CTX 
alone. The reduced activity of the PtIV complex was attributed to its kinetic 
inertness.103 
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Translocator proteins (TSPOs) are peripheral benzodiazepine receptors (PBRs) 
overexpressed in both human and rat glioma cells. Margiotta et al. conjugated cis-
{PtII(NH3)(X)2} to TSPO-binding ligands (23 and 24). Such conjugates showed 
potency equivalent to that of cis-platin through apoptosis. Both complexes were 
equally active towards sensitive A2780 and resistant A2780cis breast cancer 
cells.104 
 
The Warburg effect, the ability of cancer cells to produce energy through a high 
rate of glycolysis, helps tumour cells survive. The FDA-approved anticancer agent 
dichloroacetate (DCA) can reverse the Warburg effect. The PtIV prodrug Mitaplatin 
(25) contains two DCA units, and once internalised is reduced to cis-platin (1) 
which can attack nuclear DNA, while the DCA can attack mitochondria selectively. 
Mitaplatin alters the mitochondrial membrane potential of cancer cells, promoting 
apoptosis by releasing cytochrome c and translocating apoptosis-inducing factor 
from mitochondria to the nucleus. The cytotoxicity of 25 is equivalent or exceeds 
most well-known PtIV complexes and is comparable to CDDP.105  
 
Cell penetrating peptides (CPPs) are another well-known class of drug carriers due 
to their ability to pass through cell membranes. The TAT peptide is a widely studied 
CPP. Conjugates of the TAT peptide (YGRKKRRQRRR) with a PtIV analogue of 
oxaliplatin generated complexes (26 and 27) were ca. four-fold more potent in 
ovarian, colon and lung cancer cells lines than the free PtIV analogues of oxaliplatin. 
The diconjugate 27 displayed slightly lower cytotoxicity, indicating that an extra 
TAT peptide did not enhance the cytotoxicity.106 
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Figure 1.20 Oxaliplatin-TAT mono- (26) and di- (27) peptide conjugates; Example 
of cis (28) and trans (29) steroidal platinum(II) complexes. 
 
Since the androgen receptor (AR) is up-regulated in breast, ovarian and prostate 
tumour cells, Huxley et al. designed multiple androgenic steroidal ligands with 
various nitrogen-containing heterocyclic rings conjugated to either cis-platin or 
trans-platin (28 and 29) as platinum drug delivery vectors. These 
[PtII(NH3)2Cl(steroid)] conjugates were two- to twelve-fold more cytotoxic than the 
non-steroidal complexes, but in similar activity range as CDDP.107  
 
Despite these many advances in both passive and active delivery of 
chemotherapeutic agents, the development of intrinsic or acquired resistance 
remains a major drawback of platinum anticancer complexes. Zamble et al. reported 
the development of resistance as a main factor contributing to the discontinuation 
of platinum drugs in the clinic.54 The onset of resistance has been attributed to a 
variety of factors including genetic instability, heterogeneity and mutation rate of 
tumour cells. Cellular DNA is protected via five repair pathways, including 
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nucleotide excision repair (NER), mismatch repair (MMR), double strand break, 
base excision repair and direct repair, recently reviewed by Martin et al..6 To 
overcome resistance mechanisms alternative therapeutic therapies such as 
phototherapy have been developed. 
  
1.6 Photochemistry  
The section describes the various processes which occur in coordination complexes 
during a photo-chemical reaction. A photo-chemical reaction commonly involves a 
chemical effect induced in the molecule after the absorption of ultra-violet, visible 
or infrared radiation. Interaction of a molecule in the ground state (A) with radiation 
(hυ) leads to the formation of an excited state (A*). This process is commonly 
referred to as photo-excitation. Photo-excitation occurs only if the energy difference 
between the ground (A) and excited (A*) states is equal to the energy of the photon 
(hυ) absorbed by the molecule:  
EA* - EA = hυ 
The oscillator strength f defines the probability of light absorption for a certain 
transition and is defined by equation 1.3, where: me is the mass of the electron, µ is 
the transition dipole moment, e is the charge of the electron, Ĥ is the dipole moment 
operator and ΨA and ΨA* are the wave-functions of the ground (A) and excited (A*) 
states, respectively.108  
             
For certain transitions, the transition dipole moment (µ) can be zero which results 
in an oscillator strength f of zero, and so the transition is forbidden. Selection rules 
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govern whether transitions are allowed (µ ≠ 0) or forbidden (µ = 0). Forbidden 
transitions are usually observed when:  
 S ≠ 0, transitions between spin states of different multiplicity. 
 l ≠ ± 1  
 Laporte Rule transitions between states of equal parity (g ↔ g, u ↔ u) are 
forbidden. 
 
The Beer-Lambert law describes the absorbance (A) of radiation by a homogenous 
solution and is proportional to the path-length (l, cm) and concentration (c, M):  
A = εcl  
where ε is the extinction coefficient (M-1 cm-1) and its value is used to determine 
the strength of the transition. Various transitions can occur with the promotion of 
an electron from the highest occupied molecular orbital (HOMO) to the lowest 
unoccupied molecular orbital (LUMO). Transitions are termed according to the 
localisation of the electron density transfer. For octahedral complexes, both the 
metal and ligand orbitals can be involved in various transitions, depicted in Figure 
1.21. A variety of electronic transitions can occur namely ligand-field (LF) and 
charge-transfer transitions typically ligand-to-metal charge transfer (LMCT), 
metal-to-ligand charge transfer (MLCT), charge-transfer-to-solvent (CTTS), 
intraligand-charge transfer (ILCT).  The selection rules (p 30) determine which 
transitions are allowed.  
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Figure 1.21 Molecular orbital diagram for an octahedral complex and the variety 
of electronic transitions that can be induced. 
 
1.6.1 Electronic Transitions 
1.6.1.1 Ligand-Field (LF)  
The redistribution of electrons within partially filled d-orbitals is commonly 
referred to as ligand-field (LF) or d ↔ d transitions. As shown in Figure 1.15, in an 
octahedral complex the five d-orbitals are split into two higher energy (eg) orbitals 
(dz
2, dx
2-y
2) and three lower energy (t2g) orbitals (dxy, dyz and dxz). Theoretically, the 
absorption of a photon equal to the energy difference between the higher and lower 
orbitals (o, Figure 1.21) can result in the promotion of an electron from the lower 
orbitals (t2g) to the higher (eg) orbitals.  
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In theory, the Laporte rule states transitions between states of equal parity, d ↔ d 
transitions are forbidden. However, experimentally the Laporte rule can be relaxed 
either due to the (a) centre of symmetry being temporarily destroyed due to the 
vibration of metal-to-ligand bonds in an octahedral complex possessing six identical 
ligands, or (b) the octahedral complex is not completely symmetric due to the 
presence of different ligands. However, these transitions are generally weak (ε ~ 
500 M-1 cm-1) and often masked by stronger transitions. 
 
1.6.2.2 Charge-transfer (CT) Transitions 
Charge-transfer transitions are allowed by both S and the Laporte selection rules. 
Being both orbital- and spin-allowed, results in intense charge-transfer transitions 
with high extinction coefficients (ε = 103 – 106 M-1 cm-1). If the ligand orbitals are 
filled and the metal-d orbitals are empty, charge transfer from the ligand to the metal 
(LMCT) can occur. Similarly, a metal in a low oxidation state (i.e. electron rich) 
with low lying ligand molecular orbitals can result in charge-transfer from the metal 
to the ligand (MLCT).  
 
1.6.2.3 Intraligand (IL) and Charge-Transfer to Solvent Transitions 
Transitions between ligands generally occur in complexes possessing ligands with 
multiple bond(s) such as pyridine. These transitions only involve the ligands and 
the central metal atom does not impose much effect on the transition. Intraligand 
charge-transfers (ILCT) are both orbital- and spin-allowed and possess high 
extinction coefficients (ε = 103 – 105 M-1 cm-1), similar to LMCT and MLCT 
transitions.  
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Charge-transfer to solvent (CTTS) transitions occur in complexes with either (a) 
low oxidation number or where (b) an increase in oxidation number without a 
change in the coordination sphere occurs. These transitions are allowed (ε = 10 – 
103 M-1 cm-1) but are dependent on the solvent reduction potential.  
 
Excited states are intermediate states and their energy can be dissipated through a 
variety of both radiative and non-radiative processes. These are referred to as 
deactivation pathways.  
 
1.6.2 Deactivation pathways of excited states 
The decay of excited states can occur through either photo-physical or photo-
chemical pathways. The Jablonski diagram accurately depicts the various photo-
physical deactivation pathways (Figure 1.22).109 The process of absorption occurs 
almost instantaneously on a time-scale of ca. 10-15 s. Both fluorescence and 
phosphorescence are emissive pathways. Fluorescence readily occurs between 
states of the same multiplicity (SnS0, where n is equal to an integer). However, 
phosphorescence occurs between two states of different multiplicity (e.g. T1S0), 
therefore S≠0 and possess longer life-times. Both internal conversion (IC) and 
intersystem crossing (ISC) are non-radiative type processes. ISC involves the 
molecule moving between levels with a change in multiplicity (S≠0), contrary to 
IC. 
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Figure 1.22 Jablonski diagram showing various deactivation pathways where S0 
refers to ground singlet state; Sn (n ≠ 0) refers to singlet excited state and Tn (n ≠ 
0) refers to triplet excited state (figure adapted from ref 109).  
 
Generally, processes whereby S = 0 are faster and those with S ≠0 are slower, 
i.e. lead to longer lived states (Table 1.2).  
 
Table 1.2 Time-scale of deactivation processes 
Process Time Scale (s) 
Absorption ~ 10-15 
Fluorescence ~ 10-9 
Phosphorescence ~ 10-3 to seconds 
ISC ~ 10-7 - 10-4 
IC (to lower excited state) ~ 10-12 
IC (to ground state) ~ 10-6 
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Additional, photo-chemical deactivation pathways exist, which compete with 
photo-physical pathways. Photo-chemical reactions are initiated at the excited state. 
The promotion of an electron to an excited state has potential to weaken certain 
bonds within the molecule. In general, photo-chemical reactions can be deduced 
from the electronic transitions present in the complex. Complexes possessing LF 
transitions typically undergo photo-isomerisation, photo-racemisation and photo-
solvation. In contrast, complexes exhibiting LMCT transitions photo-decompose 
through a photo-reduction process. Reduction of the metal centre and loss of 
ligand(s) are commonly observed during photo-reductions. In this thesis, photo-
redox pathways are observed and will be discussed in section 1.8.2. 
 
1.7 Phototherapy 
The use of light in the treatment of various diseases can be dated back to about three 
thousand years ago, used by both Egyptians and Chinese civilisations.110 
Phototherapy involves the use of light in combination with a chemical agent to 
induce a cytotoxic effect in the biological region of interest. The concept of 
phototherapy can be dated back to ca. 1900 from reports by Oscar Raab, effectively 
reporting on the cytotoxic effect of acridine in combination with light on 
infusoria.111  
 
1.7.1 Photodynamic therapy 
Studies performed by Dougherty led to the development of photodynamic therapy, 
PDT.112,113 PDT involves the administration of a non-toxic complex, a photo-
sensitiser (PS), into a patient’s bloodstream. After an incubation period (to allow 
sufficient accumulation of the PS into the target tissue) the PS is subject to 
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irradiation at a specific wavelength. Longer wavelengths of light (>600 nm) are 
used in PDT owing to its ability to penetrate into deeper tissues (Figure 1.23).114 
PDT is often used in cancer treatment115 but extends into treatment of both 
infectious diseases and disorders.116  
 
Figure 1.23 Percentage and depth penetration by various wavelengths of light 
(figure adapted from ref 114).  
 
Often, PS are porphyins consisting of four pyrrole rings fused together by methine 
bridges and possess an absorption in the region of 600-800 nm.117 The first 
generation photo-sensitiser synthesised by Dougherty, Photofrin® (Figure 1.24A), 
was approved clinically for the treatment of lung, esophageal and bladder cancer.118 
In contrast, Foscan® (Figure 1.24B), a second generation PS compound, has been 
clinically approved for head and neck cancer. Interestingly, this compound 
accumulates more specifically in the cancerous tissue and is irradiated with a 
slightly longer wavelength of light (652 nm) compared to Photofrin at 630 nm.119  
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Figure 1.24 Structures of the clinically approved photo-sensitisers Photofrin (30) 
and Foscan (31).  
 
1.7.1.1 Mechanism of PDT  
PDT has three essential requirements: (a) a photo-sensitiser, (b) light and (c) 
molecular oxygen (O2) necessary to induce a PDT effect in the cancerous tissue. 
The PS should have minimal dark toxicity in both human and animal models.115 
The process involves the irradiation of the PS in the ground (S0) state with a specific 
wavelength of light (generally matched to the absorption of the administered 
compound). Photon excitation promotes the PS into a single excited (S1) state. Once 
absorption occurs, the excited state can dissipate its energy through photo-physical 
pathways, as previously described (Figure 1.25).113,117 The longer lifetime (ca. µs – 
ms) of the triplet excited (T1) state compared to the singlet excited (S1) state 
suggests that the T1 excited state is involved in the photodynamic effect. The energy 
of the T1 state can be dissipated through phosphorescence (T1S0).  
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Figure 1.25 Absorption of light by the singlet ground state (S0), generating a singlet 
excited (S1) and the triplet excited (T1) states, the latter formed through intersystem 
crossing (ISC). Quenching of the T1 state by molecular oxygen (3O2) via type I () 
or type II () processes induces the PDT effect through the formation of various 
reactive oxygen species (figure adapted from ref 117).  
 
Quenching mechanisms for the T1 excited state have been reported to induce the 
observed PDT effect.120  Two quenching processes exist, type I and type II. The 
type I process involves either an electron or hydrogen transfer between the T1 state 
and a molecular substrate i.e. cell membrane, generating free radical species. These 
formed radical-based species interact with molecular oxygen (3O2) present in the 
cell leading to the formation of ROS. In contrast, a direct interaction between the 
T1 excited state and 3O2 occurs during type II. Through an energy transfer 
mechanism, singlet oxygen (1O2, 
1g) is generated from this interaction (Figure 
1.25). As mentioned earlier, 1O2 is a well-known cytotoxic species and is believed 
to be the main contributor to cell death from treatment via PDT. Both processes are 
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reported to proceed during PDT. The ratio of type I over type II is dependent on the 
concentration of the substrate, molecular oxygen and the administered 
photosensitiser.121  
 
PDT remains a highly used cancer therapy treatment as opposed to surgery due to 
its non-invasive nature. Additionally, the formation of 1O2 has been attributed as the 
main cytotoxic species inducing the PDT effect. Formed at the site of irradiation, 
1O2 has a short life-time and more importantly possesses a very short diffusion 
distance of ca. 0.02 µm.122 Thereby, healthy nearby cells remain undamaged.  
 
However, numerous disadvantages are associated with current PDT therapy. Firstly, 
the requirement of molecular oxygen inside the cell is a limiting factor of PDT 
treatment, due to the common hypoxic (3O2-deficient) environment of cancerous 
tissue.123 Secondly, despite the reported non-invasive nature, the long clearance 
times (4-8 weeks) of the PS from the patient’s body limit the patient’s exposure to 
daylight up to periods of a couple of months.117 Finally, resistance mechanisms 
similar to those previously reported for conventional chemotherapy and 
radiotherapy treatments have emerged.124 PDT resistance has been reported to be 
dependent on both the concentration of the PS and the light dose administered.125 
Antioxidant enzymes have been reported to inactivate the toxic reactive oxygen 
species (●OH, O2
●- and 1O2) during first stage PDT treatment.
125 Another mode of 
resistance has been noted through heat shock proteins (HSPs) which possess the 
ability to prevent unwanted protein aggregation and stabilise unfolded proteins, 
resulting in the repair of the damage induced by PDT.126 Therefore, another mode 
of cancer therapy is needed to overcome current resistance mechanisms.  
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1.8 Photo-chemotherapy 
Photo-activation of a chemotherapeutic (PACT) differs from conventional PDT as 
the administered complex remains non-toxic until photo-activation with visible 
light without the requirement of molecular oxygen (type III mechanism). As 
mentioned, PtIV complexes are kinetically inert making them ideal candidates as 
photo-activatable platinum prodrugs.  
 
1.8.1 Photo-activatable PtIV diiodo complexes 
Similar to PDT, longer wavelengths of light (> 600 nm) are preferred for PACT, 
for deep penetration into the cancerous tissue. The wavelength of activation for 
inorganic complexes can be determined from the exhibited electronic transitions. 
The first photo-activatable PtIV-diiodo complexes were synthesised in the Bednarski 
laboratory. All these PtIV complexes possessed an ethylene-diammine ligand as the 
non-leaving group, opposed to the ammine ligands present in cis-platin. This was 
specifically chosen to avoid photo-isomerisation and render the resultant complex 
more stable. Kratochwil investigated the absorption bands of cis,trans-
[Pt(en)(Cl)2(X)2] complexes, (where en = ethylenediammine and X = Cl, Br, I). The 
complex cis,trans-[Pt(en)(Cl)2(I)2] (32, Figure 1.26) with the least electronegative 
atom absorbed energy at the longest wavelength.127 Therefore, the choice of ligands 
coordinated to the PtIV centre can directly promote activation at longer 
wavelengths.128 Despite activation at longer wavelengths, complex 32 exhibited an 
equivalent dark and light cytotoxicity, attributed to its high reduction potential of 
ca. 75 E/mV. This large reduction potential rationalised its facile reduction by 
biological reducing agents (e.g. GSH) to the active PtII species.129 
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To increase the dark stability, the chlorido ligands where substituted by hydroxido-
based ligands. The resultant complexes (33-35, Figure 1.26) exhibited lower 
reduction potentials and possessed a LMCT band at ca. 400 nm.  
           
Figure 1.26 Structures of early photo-activatable PtIV-diiodo complexes.  
 
Nuclear magnetic resonance (NMR) studies revealed the reduction of the PtIV-
diiodo complexes (32, 33 and 35) by both glutathione (GSH) and N-acetyl-cysteine 
(NAC).130 Complex 34, the most potent complex, displayed ca. 65% DNA 
platination after 6 h, in contrast to cis-platin, which induced ca. 90% DNA 
platination after an equivalent time period.  
 
The abundance of biological reducing agents throughout the body (refer to Figure 
1.11), suggested reduction of PtIV to PtII was not specific to tumour cells. Therefore, 
effective PtIV photo-activatable prodrugs should exhibit dark-stability in the 
presence of biological reducing agents. Consequently, alternative ligands to iodides 
were investigated.  
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1.8.2 Photo-activatable PtIV diazido complexes 
Transition metal complexes possessing azido ligands have been reported to be light 
sensitive, regardless of the transition metal centre. Vogler was the first to report on 
the photo-chemical nature of platinum diazido complexes. Photo-irradiation of 
trans-[Pt(CN)4(N3)2]
2- at 300 nm UVA gave rise to the loss of two azide ligands, in 
the form of azidyl (N3) radicals. This proceeded through a simultaneous two one-
electron reduction of the PtIV centre without formation of a PtIII intermediate 
species,131 as shown below.  
             
The formation of the N3 radicals were confirmed by electron paramagnetic 
resonance (EPR). This technique is specific for the characterisation of paramagnetic 
species and will be discussed in more detail in Chapter III. Moreover, irradiation 
of cis-[Pt(PPh3)2(N3)2] led to the formation of hexazabenzene (N6) and [Pt(PPh3)2]2. 
Bubbles were observed in the irradiated solution, attributed to the decomposition of 
N6 into nitrogen gas.
132 Interestingly, [Pt(N3)6]
2-, initially synthesised and 
characterised by Beck et al. was photo-irradiated by Volger et al. with ca. 314 nm 
UVA and reported to undergo a two photon (four-electron) reduction via a PtII 
intermediate generating Pt0 , as shown below. The formation of a black precipitate 
upon additional irradiation confirmed the generation of Pt0.133   
      
The development of second-generation photo-activatable platinum(IV) complexes 
was paved by the work performed by Bednarski and Vogler and the concept of PDT. 
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Both cis (36) and trans (37) – photo-activatable diammine platinum(IV) complexes 
were investigated (Figure 1.27).134,135  Complexes 36 and 37 exhibited dark stability 
in the presence of intracellular reducing agents, as monitored by NMR 
spectroscopy.136,137 Irradiation of complexes 36 and 37 at 365 nm UVA led to the 
observation of gas bubbles, presumed to be nitrogen gas.138 Both complexes 
displayed IC50 values (50% inhibitory concentration) similar to both cis and trans-
platin. Interestingly, photo-irradiation of 37 in the presence of dimethyl-sulfide 
(DMS) led to the formation of a new carbon-to-carbon bond.139 Furthermore, in a 
separate study performed by Farrer et al., trans-diam(m)ine diazido PtIV complexes 
were determined to possess a greater photo-cytotoxic activity than their cis-isomers. 
The difference in activity was proposed to be due to the trans-based complexes 
targeting different cellular components or inducing different DNA lesions.140 
Despite the dark stability of 36 and 37 and their ability to induce a photo-cytotoxic 
effect in HaCaT human keratinocytes cells, these complexes were limited to photo-
activation at 365 nm UVA.  
 
         
Figure 1.27 Structures of platinum(IV) diammine diazido complexes synthesised 
in the Sadler group.  
 
Ways to lower the energy of the LMCT band of the PtIV diazido complexes involved 
the initial replacement of the ammine (NH3) group by a π-acceptor pyridine ligand. 
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Unfortunately, 38 (Figure 1.28) did not exhibit a LMCT band at lower energy (ca. 
289 nm). Nevertheless, substitution of the pyridine ligand (38) for the ammine 
(NH3, 37) ligand decreased the IC50 value from ca. 99.2 µM to 1.9 µM in A2780 
ovarian cancer cells. The stark difference in the photo-cytotoxicity values was 
attributed to the formation of alternative PtII-DNA adducts by 38.  
 
           
Figure 1.28 Structures of mono-pyridine (38); mono-piperidine (39) and bis-
pyridine (40) platinum(IV) diazido complexes. 
 
Photo-irradiation of 38 at 365 nm UVA in the presence of 5-guanosine 
monophosphate (5-GMP, model for nucleobase guanine) identified binding to the 
N7 of 5-GMP and generated both trans mono-[Pt(N3)(NH3)(py)(GMP)]+ and bis-
[Pt(NH3)(py)(GMP)2]
2+ adducts141 (Figure 1.29). The formation of these different 
platinated-DNA adducts suggested that 38 induced its photo-cytotoxic effect 
through a novel mechanism of action. The formation of such a complex suggested 
a method of overcoming current resistance mechanisms of platinum anticancer 
complexes.  
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Figure 1.29 Structures of (A) mono- and (B) bis-guanine species formed from the 
photo-activation of complex 38 in the presence of 5'guanosine monophosphate (5'-
GMP) (figures from ref 141) 
 
Recently, Westendorf reported on 38 photo-irradiated in vivo. Photo-irradiation of 
38 with UVA in mice bearing xenografted OE19 esophageal carcinoma gave rise 
to anti-tumour activity. The induction of the observed photo-cytotoxic effect was 
reported not to proceed through an apoptosis pathway (similar to cis-platin), but 
through an autophagic pathway.142 Autophagy is an additional cell death 
mechanism, extensively reviewed by He et al..143  
 
Moreover, the pharmacological activity of 38 was compared with an analogue 
possessing a piperidine ligand (39, Figure 1.28). Despite the piperidine being more 
basic and more lipophilic, both complexes displayed similar photo-cytotoxic 
profiles with minor differences in selectivity.144  
 
This work led to the replacement of the second ammine ligand to a pyridine ligand, 
generating the complex trans,trans,trans-[Pt(OH)2(N3)2(py)2] (complex 40, Figure 
1.28). This was the first photo-activatable platinum(IV) diazido anticancer complex 
to be activated with UVA, blue and green light. Complex 40 exhibited a LMCT 
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band at ca. 294 nm, which decreased upon irradiation, attributed to the loss of the 
coordinated azide ligands.145  
 
Complex 40 has demonstrated its photo-cytotoxic activity in a number of cancer 
cell lines. It was an order of magnitude more potent than cis-platin in HaCaT human 
keratinocyte cell line. Photo-irradiation of complex 40 in the presence of 5-GMP 
led to the observation of both gas bubbles attributed to nitrogen gas and various 
photo-products. These photo-products were characterised by 195Pt NMR 
spectroscopy. An initial minor species, [Pt(N3)(py)2(GMP)]
+ (41) was detected at -
2212 ppm. An additional species at -2288 ppm was detected and assigned as the 
bis-guanine species, [Pt(py)2(GMP)2]
2+ (42). A third species at ca. 874 ppm was 
assigned to [Pt(OH)2(py)2(GMP)]
 (43), the oxidised form of species 41.145      
          
Figure 1.30 Structures of platinated DNA adducts formed from the photo-
irradiation of complex 40 (figures adapted from ref 145). 
 
Recently, Pracharova et al. demonstrated that photo-irradiated 40 efficiently stalled 
RNA polymerase II to a greater extent than cis-platin. They deduced that 
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transcription inhibition has potential to initiate various downstream cellular effects, 
which may contribute to the photo-cytotoxic effect of 40.146  
 
To date, complex 40 is the most potent platinum(IV) diazido photo-activatable 
anticancer complex. However, questions remain regarding its photo-decomposition 
pathways and the nature of additional photo-products. As mentioned above, gas 
bubbles were observed from the photo-irradiation of 40. These were suggested to 
be due to N2 gas from the dimerisation of two azidyl (
●N3) radicals (Figure 1.31A). 
However, potential formation of hydrogen peroxide (H2O2) and singlet oxygen via 
hydroxyl radicals (●OH) could also account for the observed gas (Figure 1.31B). 
Formation of RNS and/or ROS have potential to contribute to the photo-
cytotoxicity of 40 (Figure 1.31C). 
 
As can be seen from Figure 1.31, all potential radical species are either ROS/RNS 
related species. These species are notoriously known for their oxidative damage 
ability as mentioned in section 1.1. Moreover, due their short life-times of ca. < 10-
9 s direct detection by EPR spectroscopy is not feasible. Consequently, EPR spin 
trapping is commonly used for their detection and characterisation. The concept of 
spin trapping EPR will be described in detail in Chapter III.    
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Figure 1.31 Photo-irradiation of complex 40 leading to the reduction of PtIV to PtII 
via two one-electron donations from (A) two azide; (B) two hydroxyl; (C) one azide 
and one hydroxyl ligands. 
 
Recently, photo-activation of trans,trans,trans-[Pt(N3)2(OH)2(py)(MA)] (44, MA = 
methylamine) identified the formation of singlet oxygen (1O2) in additional to Pt-N 
nitrene intermediates.147,148 Therefore, the photo-chemical reactions of PtIV diazido 
complexes have potential to generate numerous photo-products which can 
contribute the overall photo-cytotoxic effect.  
                
Figure 1.32 Structure of trans,trans,trans-[Pt(N3)2(OH)2(py)(MA)]. 
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1.8.3 Photo-activatable anti-tumour transition metal complexes 
FDA-approved carboplatin was recently photo-irradiated at 365 nm and reported to 
be ca. ten-fold more active in A2780 ovarian cancer cells than non-irradiated 
carboplatin.149 Mitra et al. reported on two distorted square-planar ferrocenyl PtII 
complexes with dark stability (IC50 =  60 µM) which upon photo-irradiation with 
visible light (400-700 nm) induced a photo-cytotoxic effect with IC50 values of ca. 
9.8 µM (45) and 12.0 µM (46) in HaCaT immortalised human skin keratinocytes 
cells. These ferrocenyl PtII complexes induced their photo-cytotoxicity via the PDT 
effect.150  
 
The concept of light-activated anticancer complexes has also been extended to other 
transition metals. In the Chakravarty group, glucose-appended photo-cytotoxic 
iron(III) complexes with phenolate ligands (47) demonstrated anticancer activity in 
HeLa cervical cancer cells with IC50 values of ca. 10 µM and 20 µM upon photo-
activation with visible (400-700 nm) and red light (600-720 nm), respectively. 
Furthermore, selective uptake of an iron(III) tetradentate phenolate complex with a 
biotin functional group selectively accumulated in HepG2 hepatocellular cancer 
cells inducing a photo-cytotoxic effect via ROS production.151 The Chakravarty 
group have also synthesised photo-activatable copper(II)152 and vanadium(IV)153 
anti-tumour complexes. Additionally, the Sadler group noted the photo-cytotoxicity 
for a family of ruthenium(II) arene-based anticancer complexes (48) irradiated with 
both UVA and white light.154 
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Figure 1.33 Structures of alternative photo-activatable complexes synthesised in 
the Chakravarty (45-47) and Sadler (48) groups (structures adapted from ref 150, 
151 and 154).  
 
Additionally, Kastl et al. reported on the photo-cytotoxicity of a rhenium(I) indolato 
complex (49), inactive in the dark with an EC50 value of ca. 100 µM. However, 
irradiation at 505 nm resulted in an EC50 value of ca. 0.1 µM, in HeLa cervical 
cancer cells.155 Structure activity relationships (SARs) identified the most potent 
complex possessed an σ-accepting fluorine ligand on the pyridine moiety (50) with 
an EC50 value of ca. 0.3 µM upon irradiation with red light.
156 
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Figure 1.34 Structures of photo-activatable rhenium(I) pyrido-carbazole (49 and 
50) and iridium (III) complex (51) with a dual mechanism of action synthesised in 
the Meggers group.  
 
Interestingly, both Chakravarty and Meggers groups devised anti-tumour 
complexes possessing dual mechanisms of action. Prasad et al. reported on a 
oxidovanadium(IV) complex possessing a anthracenyl fluorophore and dipeptide 
(Gly-Gly-OMe) moiety.157 This oxidovanadium(IV) complex is photo-cytotoxic 
upon irradiation and has the ability to specifically target the mitochondria of cancer 
cells and induce apoptosis via ROS. In a similar manner, Kastl et al. reported on the 
first photo-activatable iridium complex (51) with visible (λ = 450 nm) light 
inducing apoptosis in HeLa cervical cancer cells. Simultaneously, 51 exerted a 
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light-independent anti-angiogenicity through inhibition of the protein kinases, 
VEGFR3.158  
 
Finally, photo-activation of transition metal complexes has also been pursued for 
the release of carbon monoxide (CO). Similar to nitric oxide (NO) and hydrogen 
disulphide (H2S), carbon monoxide (CO) plays an important role in numerous 
physiological processes. 159The ability of CO to induce a cyto-protective effect 
particularly against oxidative stress has rendered it a possible therapeutic. In recent 
years, a more targeted approach for delivery of CO to the target site has been 
explored through the carbon monoxide releasing molecules (CORMs) via photo-
irradiation. Motterlini first reported on the concept of a photo-irradiated CORM 
from a manganese decacarbonyl based complex (52).160 Release of CO upon 
irradiation allows both spatial and temporal control on the release of CO. Numerous 
[M(CO)y] based complexes have been synthesised (53-55, Figure 1.35).161-163 
 
Recently, Pfeiffer et al. reported on the synthesis of various [Mn(CO)3(tpm)]
+ 
(where tpm = tris(pyrazlyl)methane) with a conjugated peptide. These complexes 
were stable in the dark and only illustrated CO release upon photo-irradiation at 365 
nm (UVA).164 They are currently being investigated for the selectively in cancerous 
cells. Moreover, [Mn(CO)3(tpm)]
+  loaded in a nano-diamond, a new form of nano-
carbon, has been shown to be stable in the dark causing no change in the myoglobin 
assay, and offers a more targeted delivery approach for the release of CO.165  
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Figure 1.35 Structures of various PhotoCORMs including first photo-irradiated 
manganese decacarbonyl molecule synthesised by Motterlini (52); new iron(II) 
dicarbonyl-thiolate-ethylamine complex (53); tungsten(0) pentacarbonyl 
synthesised in the Weserhausen (54) and a manganese(I) tricarbonyl complex 
synthesised in the Schatzschneider group (55).   
 
However, limitations of this current line of therapy are due to the majority of 
PhotoCORMs activated with short wavelengths of light, typically 300-370 nm. The 
future of PhotoCORMs involves lowering their energy to wavelengths of ca. 600 
nm, nearer to the therapeutic window.166 These latest studies suggest the wide utility 
of photo-chemotherapy using transition metal complexes and their potential in the 
treatment in a variety of cancer types.  
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1.9 Aims of thesis 
The main objectives of this thesis were as follows.  
1. To identify radical species generated from the photo-activation of 
platinum(IV) diazido anticancer complexes using spin trapping electron 
paramagnetic resonance (EPR) spectroscopy.  
 
2. To vary the nitrone spin trap, solvent, wavelength of activation and source 
of radiation to establish an optimum spin trapping EPR system for photo-
activatable platinum(IV) diazido anticancer complexes. 
 
3. Establish the consequence of photo-activation of a platinum(IV) diazido 
complex in the presence of various amino acids and antioxidants and 
identify the potential reactivity of the formed radical(s).  
 
4. To determine the effect of sulfur-containing molecules on the photo-
irradiation of a photo-activatable platinum(IV) diazido complex. 
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This chapter describes the main materials, instrumentation and experimental 
procedures used throughout this Thesis. Specific experimental methods will be 
detailed appropriately in the proceeding Chapters.  
 
2.1 Experimental 
 
2.1.1 Materials  
 
Complex 40, trans,trans,trans-[Pt(N3)2(OH)2(py)2] and 
15N-40 were synthesised 
and characterised as described below. K2[PtCl4] (99%) was obtained from Precious 
Metals Online, pyridine, ammonium chloride and 1,4 dioxane were purchased from 
Fischer Scientific. Na14N3 (99%), 4-hydroxy-2,2,6,6-tetramethyl-piperidine-1-oxyl 
(Tempol EPR standard), deuterium oxide (D2O), H2O2 (30 % v/v), phosphate 
buffered saline (PBS) tablets were purchased from Sigma Aldrich. Silver nitrate 
(AgNO3) from Fluka, d6-acetone from Goss Scientific, and Na
15N3 (with one 
terminal nitrogen 100% 15N labelled) from Cambridge Isotope Laboratories. EPR 
inner quartz tubes (1.2 mm O.D), outer quartz tubes (2.0 mm O.D) and high 
precision amber NMR tubes were purchased from Wilmad Labglass. Nitrone spin 
trap 5,5-dimethyl-pyrroline-N-oxide (DMPO) was purchased from Enzo Life 
Sciences obtained in the highest purity (≥ 99 %) and used without any further 
purification. HPLC Hamilton syringe 500 µL was purchased from Hamilton Ltd. 
ICP platinum standard was obtained from Inorganic Ventures.  
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2.2 Synthesis and characterisation of trans,trans,trans-[Pt(N3)2(OH)2(py)2] 
 
 
! Caution metal azides are known as shock sensitive detonators and synthesis 
of such compounds were handled with care.  
 
2.2.1 Synthesis of trans-[Pt(py)2(Cl)2] 
 
K2PtCl4 (1 g, 2.4 mmol) in H2O (25 mL) was added to pyridine (2 ml, 24 mmol, 
10× excess) and the solution heated at 358 K changing colour from deep red – 
through orange, then white – until colourless and transparent (ca. 1 h 15 min). The 
solution was allowed to cool on ice and was filtered (IM). IM filtration using a 
membrane-bound filter was employed to remove any Pt0 from the reaction mixture. 
The solvent was removed by rotary evaporator. HCl (2 M, 25 mL) was added and 
the solution was heated at 348 K for 24 h to give a yellow suspension. This was 
allowed to cool on ice, filtered under suction and washed with cold minimal 
solvents (H2O, ethanol and ether) to give a pale yellow product (0.88 g, 2.08 mmol, 
86 %).  
 
trans-[Pt(py)2(Cl)2]: 
1H NMR (d6–acetone, 400 MHz): δ = 8.86 (dd, J1H1H = 5 Hz, 
J1H195Pt = 32 Hz, 4H, HO), 8.11 (t, J1H1H = 14 Hz, 2H, Hp), 7.66 ppm (dd, J1H1H = 13 
Hz, 4H, Hm) 
 
From here synthesis was performed under dim controlled lighting conditions.  
 
2.2.2 Synthesis of trans-[Pt(py)2(N3)2] 
 
Trans-[PtCl2(py)2] (0.4 g, 0.95 mmol) was suspended in H2O (68 mL), AgNO3 (0.32 
g, 1.9 mmol, 2 mol equiv) was added and the reaction stirred at 333 K overnight. 
The grey solution was filtered by celite to remove the silver chloride (AgCl) 
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precipitate. Then, the solution was filtered by IM filtration. NaN3 (0.62 g, 9.5 mmol, 
5 mol equiv) was added and the reaction was stirred at ambient temperature. After 
4 h additional NaN3 (5 mol equiv) was added, and the reaction mixture was stirred 
for another 4 h. The solution was placed on ice, suction-filtered and the yellow 
product washed with cold, minimal solvents (H2O, ethanol, ether) to give the crude 
product (0.37 g, 0.85 mmol, 90 %). The product was purified by crystallisation from 
pyridine (pre-heated to 313 K; in the ratio 0.34 g/12.9 mL), followed by filtration 
(IM), and cooling to 269 K. The yellow product was isolated by filtration, washed 
and dried under suction (51 %).  
 
Trans-[Pt(py)2(N3)2]: 
1H NMR (d6-acetone, 400 MHz): δ = 8.8 (d, J1H195Pt = 37 Hz, 
JHH = 6.7, 1.3 Hz, 4H, HO), 8.04 (dd, J1H1H = 7.7, 1.50 Hz, 2H, Hp), 7.6 ppm (dd, 
J1H1H = 6.60, 1.26 Hz, 4H, Hm). 
 
*Equivalent synthesis was repeated for 15N-40 using Na15N3 (where one terminal 
nitrogen was 100% 15N labelled).  
 
2.2.3 Synthesis of trans,trans,trans-[Pt(N3)2(OH)2(py)2] 
 
Trans-[Pt(N3)2(py)2] (0.094 g, 0.21 mmol) was suspended in H2O2 (7.5 mL, 30 %) 
and stirred at 318 K for 3 h to give a bright yellow solution. The solvent was 
removed by rotary evaporator (323 K) until ca. 3 mL remained (ca. 40 min). Ethanol 
(3.75 mL) was added and the solution filtered (IM). Ether (11.30 mL) was added, 
the solution briefly mixed and left to cool at room temperature and then at 277 K. 
The yellow crystals were filtered and washed with ice cold ether/ethanol (0.060 g, 
0.13 mmol, 59 %).  
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C10H12N8O2Pt (471.37, confirmed by ESI-MS): 
1H NMR (D2O, 400 MHz): δ = 8.76 
(dd, 3J1H195Pt = 27 Hz, 
3JHH = 6 Hz, 2H, HO), 8.24 (t, 
3J1H1H = 7 Hz, 1H, Hp), 7.8 
ppm (t, 3J1H1H = 7 Hz, 2H, Hm). 
195Pt NMR (D2O, 129 MHz): δ = 941 ppm.    
 
This synthesis was reported by Farrer1; however the procedure was scaled down. 
Herein, both trans,trans,trans-[Pt(N3)2(OH)2(py)2] and trans,trans,trans-
[Pt(15N3)2(OH)2(py)2] will be denoted as complex 40 and 
15N-40, respectively 
 
2.3 Instrumentation  
2.3.1 Electron Paramagnetic Resonance (EPR) spectroscopy2-4 
All EPR spectra were recorded at ambient temperature (ca. 291 K) on a Bruker 
EMX (X-band) continuous wave mode spectrometer. A cylindrical TM110 mode 
cavity (Bruker 4103TM) was used. This cavity is particularly useful for studies of 
aqueous or other solvents exhibiting high dielectric loss.5,6 Samples ca. 75-85 µL 
were transferred using a 500 µL Hamilton syringe needle to a spectrosil quartz tubes 
with inner diameter of 1.0 mm and outer diameter (O.D.) of 1.2 mm (Wilmad 
Labglass), sealed with T-Blu Tac® at one end (Figure 2.1A). This tube was placed 
inside a larger quartz tube (O.D. 2.0 mm) so that the sample could be accurately 
and reproducibly positioned inside the resonator (Figure 2.1B). These filled sample 
tubes were longer than the active length of the TM110 cavity and were chosen such 
that when the tube was filled with water the cavity could still be critically coupled. 
Samples were transported in aluminium foil to the EPR spectrometer site to prevent 
photo-activation of the platinum(IV) diazido complex by sunlight, prior to 
performing EPR measurements.     
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Figure 2.1 EPR tubes used in this work; (A) inner quartz EPR tubes with inset 
depicting the EPR tubes sealed with T-Blu Tac® at one end, and (B) larger 2.0 mm 
O.D outer quartz EPR tubes. 
 
Typical key EPR spectrometer settings were modulation amplitude 2.0 G, 
microwave power 0.63 mW, 1.0 ×104 receiver gain, conversion time 40.96 ms, time 
constant 81.92 ms, sweep width 200 G. An incremental sweep mode was used in 
this work to monitor the formation and decay of the formed spin adduct. A repeated 
number of 10 X-scans were obtained in the x-axis at a rate of 42 s/scan and 
resolution in Y of 6. However, scans were analysed up to resolution in Y of 4, as 
these were deemed biologically relevant given the total irradiation dose after this 
time was ca. 107.9 J cm-2, with 463 nm LED light source (64 mW cm-2).  
 
The LED light irradiation source was mounted between the EPR magnets, 
supported by a foam sponge (Figure 2.2), to maintain its position throughout the 
EPR sample measurements.  The distance from the tip of the irradiation light bulb 
to the EPR cavity was ca. 8.5 cm (Figure 2.2). In this work, this distance was 
maintained for all subsequent irradiations. The TM110 EPR cavity used is equipped 
with a grid on one side allowing optical access (approximately 50%) transmission. 
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The refractive index of quartz is approximately 1.55;7 hence at normal incidence 
approximately 5% of the incident light is reflected at an air quartz interface.  
                            
Figure 2.2 Setup of the X-band EPR cavity used in this work with mounted LED 
light source supported by a foam sponge at each side the EPR magnet. The distance 
from the LED light source bulb to the EPR sample cavity is ca. 8.5 cm.   
 
2.3.1.1 Quantification of spin adducts 
The free radical 4-hydroxy-2,2,6,6-tetramethyl-piperidine-1-oxyl (tempol, Figure 
2.3) was used to quantify the formed spin adducts, as previously reported.8,9 This 
free radical exhibits a triplet EPR spectrum (Figure 2.3), due to the unpaired 
electron coupling with the nitroxide nitrogen (14N) with a nuclear spin of I = 1.10  
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Figure 2.3 EPR spectrum together with the line diagram of the standard free radical, 
tempol.  
 
For quantitative EPR spectroscopy, recording the free radical as close to the 
experimental conditions of the system under study is essential.11,12 Solvents have 
been reported to have a direct effect on the nitrogen (aN) hyperfine splitting 
values.13,14 Consequently, the EPR spectrum of tempol was recorded in equivalent 
sample tubes, sample volume and temperature with varying solvent between H2O, 
PBS/D2O and cell culture medium RPMI-1640.  
 
The concentrations prepared for the standard calibration curves were 300, 200, 100, 
75, 50, 25, 12.5 and 5 µM. The EPR spectrum of each solution was recorded and 
after a baseline correction, double integration (DI) was performed using the Bruker 
WINEPR software programme,15 providing the area under the curve.12 In this thesis, 
EPR spin adduct spectra were quantified at 7 min intervals, where each interval 
represents an accumulation of 10 X-scans in the x-axis.  
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2.3.2 Nuclear Magnetic Resonance (NMR) spectroscopy16  
2.3.2.1 1H NMR  
In this thesis, 1H NMR spectra were recorded on a Bruker DPX-400 (1H, 399.10 
MHz), Bruker DRX-500 (1H, 500.13 MHz) or Bruker AV III-600 (1H, 600.13 MHz) 
spectrometers at ambient 298 K. Spectra were recorded with standard 1H NMR zg30 
pulse program and acquired with 32 transients into 65 k data points with a spectral 
width of 20 ppm. Irradiated samples were performed in a transparent glass vial and 
transferred to the NMR tube to record the NMR spectrum. Any formed precipitates 
were removed prior to recording NMR spectra. Spectra were processed with an 
exponential line-broadening of 0.5 with J values quoted in Hz. All 1H NMR spectra 
were internally calibrated to 1,4 dioxane (3.75 ppm in D2O),
17 unless otherwise 
stated.  
 
2.3.2.2 14N NMR18-20  
NMR spectra were recorded on a Bruker AV III-600 (14N, 43.36 MHz) instrument 
with a BBO probe. Due to the rapid quadrupolar relaxation of the 14N nucleus, an 
anti-ringing pulse sequence “aring” and the digitization mode in “baseopt” were 
used for improvement of baselines.21 Spectra were recorded with a pre-scan delay 
(DE) of 6.5 µs, with a relaxation delay (D1) of 0 s, with 8 k time domain with 32 k 
transients and spectral width of 100 ppm. Irradiated samples were performed in a 
transparent glass vial and any formed precipitates were removed prior to recording 
the NMR spectrum. Irradiated samples ca. 550 µL were transferred into the NMR 
tube to record the NMR spectrum. Data were processed with an exponential line 
broadening of 30 Hz unless otherwise stated. Similar to the external referencing 
previously reported by Farrer et al., in this work external referencing was carried 
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out with D2O solutions in a capillary tube, inserted into a 5 mm tube containing 
either 14NH4Cl (1.5 M) in 1 M HCl (δ = 0). The 14NH4Cl signal was found 360.13 
ppm (298 K) upfield of the standard 14N reference (neat MeNO2, D2O in a Shigemi 
tube), and this value can be used to convert literature shifts referenced to CH3NO2 
to the 14NH4Cl reference. Similarly, chemical shifts may be converted from MeNO2 
to NH3 referencing (the latter is common for biological NMR spectroscopy) by 
subtraction of 380.23 ppm.21,22  
 
2.3.3 UV-visible spectroscopy23  
UV-visible electronic absorption spectra were recorded on a Varian Cary 300 UV-
visible (V9.0) spectrophotometer in 1 cm path-length dark cuvettes purchased from 
Starna Scientific. Prior to sample measurement, cell alignment and a baseline 
correction were performed. Spectra were recorded with scan rate 600 nm/min, 200-
800 nm spectral width, 2.0 nm bandwidth and temperature controller set at ca. 25.2 
°C. Typical sample volume was ca. 650 µL. Irradiated samples were performed in 
a transparent glass vial and transferred to the cuvette to record the UV-visible 
spectrum.  
 
2.3.4 Irradiations  
The majority of irradiations were carried out using a blue light-emitting-diode 
(LED) source with a power outage measured at 64 mW cm-2 using an International 
Light Technologies Power meter (ILT1400-A) equipped with a SEL033 detector 
and either a UVA/TD filter (315-390 nm) for a flat response visible filter F/W (400-
1064 nm)for visible wavelengths. To confirm irradiation with 463 nm blue LED 
light source, the spectral output was measured (Figure A2.1). Continuous 
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irradiation implies the irradiation source was switched on during the entire time of 
the experiment, unless otherwise stated. Irradiation setup for NMR and UV-visible 
spectroscopy is depicted in Figure 2.4, where the distance of the LED light bulb to 
the centre of the sample was measured to ca. 8.5 cm, consistent with the EPR 
spectroscopy irradiation setup. Light doses were determined using the Equation 2.1, 
below. 
Figure 2.4 Irradiation setup used in this work for both NMR and UV-visible 
spectroscopy experiments from both (A) vertical and (B) horizontal viewpoints. 
The distance from the tip of the LED light bulb to the centre of the cuvette was ca. 
8.5 cm. This distance is equivalent to that used for EPR spectroscopy irradiations.  
 
  Dose (mJ cm-2) = Time (s) × Irradiance (mW cm-2) 
                1000 
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2.3.5 Mass Spectrometry 
2.3.5.1 Electrospray Ionisation Mass Spectrometry24 (ESI-MS)  
Electrospray ionisation mass spectrometry was performed on an Agilent 1630 
single quad ESI spectrometer with a mass range of 50 - 3,000 m/z. Due to 
components in PBS able to supress the electrospray signal,25 mass spectra samples 
were H2O only and irradiated with 463 nm (64 mW cm
-2). Solutions were not 
prepared in PBS due to components The stock solution under investigation was 
irradiated, prior to performing a 100-fold serial dilution, to produce a solution in 
the low micro-molar range, suitable for the mass spectrometer instrument. The 100-
fold diluted solution was transferred into a 2 ml amber mass spectroscopy vial. 
Typically 2 µL of the irradiated sample was injected into the machine. Samples 
were run in positive mode between the range of 50-500 m/z, and 500-1000 m/z. 
Automatic washes were pre-programmed by the computer software and one scan 
typically took 3 min 21 sec. Data were processed using the Bruker Daltonics 
software data analysis programme.  
 
2.3.5.2 Inductively Coupled Plasma Mass Spectrometry (ICP-MS)  
ICP-MS was performed to determine the platinum (195Pt isotope) content of cell 
sample solutions provided by Dr. Julie Woods. ICP-MS solutions were recorded 
with the assistance of Dr. Isolda Romero on Aligent Technology series 7500, a part 
of the Mass Spectrometry facility at Warwick University. All solutions were 
prepared in doubly deionised (DDI) water with 5% nitric acid (HNO3). The standard 
solutions were freshly prepared in DDI water with 5% HNO3. The concentrations 
prepared for the standard calibration curve were 500, 200, 100, 50, 10, 5, 1, 0.5 and 
0.2 ppb.  
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2.3.6 pH measurements 
pH values were determined using a Corning 240 pH meter equipped with a micro 
combination electrode calibrated with Aldrich buffer solutions of pH 4, and 7. For 
solutions in D2O, these are given as pH* values, pH meter readings without 
correction for effects of deuterium on glass electrode. The pH values of solutions 
were adjusted using 1 mM KOH and 1 mM NaCl.  
 
2.4 Deuterated phosphate buffered saline (PBS/D2O) solution 
The phosphate buffered solutions were prepared by dissolving a PBS tablet in H2O 
giving 0.01 M phosphate, 0.0027 M KCl, pH 7.4 at 298 K. Likewise a PBS/D2O 
buffer refers to the above prepared by dissolving the PBS tablet in D2O. A resultant 
PBS/D2O at pH* 7.4 was obtained, where pH* refers to pH meter reading without 
correction effects for deuterium on a glass electrode.  
 
 
2.5 Cell studies  
All cellular studies were performed in the laboratory of Dr. Julie Woods, 
Photobiology Unit, Ninewell’s Hospital, Dundee, UK.  
 
2.5.1 Cell maintenance  
Cell culture and other chemicals were obtained from Sigma-Aldrich Ltd (Poole, 
UK) unless otherwise stated. Disposable sterile cell culture plastics were obtained 
from Greiner Bio-One (Cambridge, UK). Cell lines were obtained from both the 
European Collection of Animal Cell Cultures, and the American Cell Culture 
Collection. HaCaT keratinocytes cells were donated to the Photobiology Laboratory 
by Professor N. E. Fusenig (Heidelberg, Germany). Cell lines were maintained in 
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culture medium containing 5-10% foetal bovine serum and other additives as 
specified by the supplier. Cells were free of mycoplasma and were maintained in 
antibiotic-free conditions in a humidified atmosphere of 5% CO2/95% air.   
 
2.5.2 Cell irradiation  
Visible light was delivered from a bank of 2 x 2 feet TL03 fluorescent tubes. 
Wavelengths shorter than 400 nm were blocked by filtering. The spectral output 
was centred at 420 nm and the irradiance measured with a Gigahertx Optik meter 
calibrated to the source using a spectroradiometer (Bentham, UK). Irradiances were 
measured through filters, and where appropriate, cell culture plate lids. Test 
compounds were prepared immediately before use in warm Earle’s balanced salt 
solution (EBSS) and sterile filtered, or in dimethyl sulfoxide. All procedures were 
carried out in a specially adapted photobiology laboratory with ambient light levels 
measured below 1 lux (Solatell, UK). 
 
2.5.3 Photo-toxicity  
The neutral red photo-toxicity test was performed to determine the photo-toxic 
index (PI). This assay is used to assess the cell viability, where uptake of neutral 
red indicates viable cells.26 Test compounds were treated as previously described,1 
briefly co-incubated with the cells for 60 min in the dark, before irradiation. The 
test compounds were in-situ during the irradiation with visible light (5 J cm-2). Two 
identical plates were prepared, one of which was irradiated while the second was 
covered in aluminium foil and sham irradiated. Cell viability was measured using 
the uptake of neutral red dye as an endpoint after 24 h. 
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2.5.4 Data Analysis  
 
The concentration of test compound required to inhibit neutral red dye retention by 
50% (IC50 value) was calculated from the log-transformed concentration-response 
curves, constrained to 100% at the maximal value (Prism, Graphpad). The photo-
toxicity index was calculated as previously described. The data represent the mean 
of at least two independent experiments performed in triplicate. 
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This chapter initially investigates the photo-generation of radical species from the 
photo-activation of platinum(IV) diazido anticancer complexes characterised by 
electron paramagnetic resonance (EPR) spectroscopy. Experimental conditions 
were varied to optimise spin trapping EPR. Finally, photo-activation of complex 
40 at longer wavelengths and using gamma-rays was investigated.  
 
3.1 Introduction 
3.1.1 Metal diazido complexes 
Photo-irradiation of trans,trans,trans-[Pt(OH)2(N3)2(py)2] (complex 40, py = 
pyridine) leads to a decrease in the intensity of the ligand-to-metal charge transfer 
(N3PtIV, LMCT) transition, previously assigned as the loss of the azide ligands.1 
Photo-activation studies of metal diazido complexes of the type 
[Mn+(N3)2(X)2(Y)2] (where M = Pd
II, PtII, SnII, AuIII, CoIII, FeIII and MoIV; X = 
OH/OR; Y = amine-based ligands) have reported on azidyl (N3) radical formation 
through one-electron reduction of the Mn+ centre,2-6 as shown below (Figure 3.1). 
 
Figure 3.1 One-electron reduction of the metal centre (Mn+) induced from the 
photo-irradiation of a metal-diazido complex.   
 
The observation of bubbles, proposed to be N2 gas, has been reported as evidence 
to support N3 radical formation, where N3 radical dimerisation was the suggested 
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mechanism for N2 formation.
7-9 Thermodynamically favourable (ΔH = -210 ± 6 
kcal mol-1), N3 radical dimerisation leading to N2 gas was suggested to proceed 
through an intermediate N6 species;
10   
 
where k1 and k2 are rate constants of 1.3 × 10
10 M-1 s-1 and 3.6 × 103 M-1 s-1, 
respectively and the N6 intermediate species possesses a half-life (t½) of ca. 200 
µs.11 Whilst detection of N2 gas may be postulated by the observation of bubbles 
or more accurately by gas chromatography, the formation of metal-nitrene 
intermediates may also account for the detection of N2 gas.
12 Additional loss of 
azide ligands can also proceed via direct solvent substitution through a non-redox 
photo-substitution pathway, typically characterised by the formation of free azide 
(N3).
8 Consequently, the most reliable method to establish N3 radical formation 
is by EPR spin trapping spectroscopy.  
 
Previous photo-irradiation studies of complex 40 in the presence of guanosine 5-
monophosphate (5-GMP, a model for the nucleobase guanine in DNA) identified 
both mono- and bi-functional PtII-GMP adducts suggesting the stepwise loss of the 
azide ligands.1,13,14 It was suggested that the formed N2 gas detected by 
14N NMR 
spectroscopy was due to N3 radical dimerisation.
15 The reduction of the PtIV to PtII 
metal centre of complex 40 has also been suggested to involve hydroxyl (OH) 
radical formation (Figure 3.2B).1 Interestingly, photo-irradiation of 
trans,trans,trans-[Pt(N3)2(OH)2(MA)(py)] (44, where MA = methylamine), an 
analogue of complex 40, has been reported to generate singlet oxygen (1O2) 
through OH radical dimerisation leading to the formation of hydrogen peroxide 
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(H2O2), which upon disproportionation generated both 
1O2 and H2O.
16 
Consequently, various different photo-activation pathways of platinum(IV) 
diazido complexes appear to exist.  
    
Figure 3.2 Photo-activation of complex 40 through two successive one electron 
reductions from (A) the azide (B) hydroxyl (C) one azide and one hydroxyl 
ligands, all in turn generating a PtII photo-species. 
 
A useful method to detect and characterise radical species is electron paramagnetic 
resonance (EPR) spectroscopy. In Chapter I, a brief description of the theory and 
characterisation of EPR spectra was given. This Chapter will focus on EPR spin 
trapping of radicals. Radical species possessing short life-times (ca. 109 s) such 
as ROS and RNS radicals,17 cannot be directly detected by EPR spectroscopy and 
are referred to as transient species. These transient species can undergo uni-
molecular (fragmentation) or bimolecular (addition) reactions prior to detection by 
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EPR spectroscopy. Consequently, EPR spin trapping spectroscopy, developed in 
the late 1960’s, is a more appropriate technique for their detection. 
 
3.1.2 Spin trapping Electron Paramagnetic Resonance  
3.1.2.1 Spin adduct formation 
Spin trapping EPR involves the use of a diamagnetic compound, commonly 
referred to as a spin trap (ST), typically a nitroso or nitrone compound. This ST 
covalently interacts with an unstable radical (R) leading to the generation of a 
longer lived radical species, referred to as a spin adduct (ST-R).18 
     
where k1 is the rate of the radical being trapped by the spin trap and varies 
dependent on the experimental conditions.19   
 
3.1.2.2 Choice of spin trap  
Both nitroso and nitrone spin traps are available for spin trapping EPR. They 
possess the ability to trap oxygen-, carbon-, nitrogen- and sulfur-based radicals. 
However, the information obtained about the composition of the trapped radical is 
directly dependent on the chosen spin trap. Nitroso spin traps, such as 2-methyl-2-
nitrosopropane (MNP), provide direct information on the trapped radical (Figure 
3.3A),20 in contrast, nitrone spin traps such as 5,5-dimethyl-1-pyrroline-N-oxide 
(DMPO) provide indirect information on the trapped radical (Figure 3.3B).21,22 In 
this instance, although the nitrogen hyperfine splitting is not as specific to the 
trapped radical, the presence of the β-hydrogen provides a wealth of information 
on the radical trapped. 
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Figure 3.3 Trapping of a radical (R) species by (A) nitroso and (B) nitrone spin 
traps, showing the position at which the R species covalently attaches in the 
resultant spin adduct.  
 
The photo-lability of MNP spin trap limited its use in this work. Irradiation of 
MNP with visible light leads to the formation of both nitric oxide and tert-butyl 
radicals, subsequently trapped by MNP, obscuring the radical species under 
investigation. Additionally, various EPR-active impurities have been identified 
from the reduction of nitroso spin traps.23 Consequently, nitrone spin (Figure 3.4) 
traps were selected for this work. 
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Figure 3.4 Structures of the nitrone spin traps used in this study; (2) 5,5-dimethyl-
pyrroline-N-oxide (DMPO); (3) -4-pyridyl-1-oxide-N-tert-butylnitrone (POBN) 
and (4), 5-diethoxyphosphoryl-5-methyl-1-pyrroline-N-oxide (DEPMPO). 
 
3.1.2.3 McConnell equation24 
Regardless of which nitrone spin trap is chosen, all generate nitroxide radicals 
(Figure 3.5A), from the covalent interaction with an unstable radical. Nitroxide 
radicals possess resonance structures (Figure 3.5).  
           
Figure 3.5 Resonance structures of nitroxide spin adduct. Radical is based on the 
(A) oxygen atom (16O, I =0), and (B) nitrogen atom (14N, I =1).  
 
As described in Chapter I, hyperfine coupling arises from the interaction of the 
unpaired electron spin with the nuclear spin of a magnetically-active nucleus, 
whose spin (I) is greater than zero (I ≠ 0). Depending on the position of the proton 
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coupling to the unpaired electron, the spin density in the 2pπ orbital can be 
calculated. The standard McConnell equation (Equation 3.1) determines an α-
proton coupling (Figure 3.6A), where QHCH is the proportionality constant (mT) 
and varies dependent on the atom.24   
                                                      aH = QHXρc                                 Eq 3.1 
However, in nitroxide spin adducts, a β-proton coupling is present (Figure 3.6B), 
which is dependent on the dihedral angle (θ) of the C-H bond w.r.t to the z axis. 
This dihedral angle (θ) can vary dependent on the orientation of trapped radical 
species (R).25 
                   
Figure 3.6 Illustrations of (A) α-proton and (B) β-proton coupling to the unpaired 
electron (). Where β-proton coupling is dependent on the dihedral angle θ and 
varies according to the trapped radical (R) (figure adapted from ref 21).  
 
Therefore, determining the spin density in spin systems such as nitroxide radicals, 
the standard McConnell equation has been modified to incorporate this dihedral 
angle parameter (Eq 3.2).       
                
                                              αHβ = QHCHρc(cos2θ)               Eq 3.2 
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However, in this thesis the spin density of obtained nitroxide radicals were 
accessed via density functional theory (DFT) calculations. Previous DFT 
calculations were performed on both the DMPO-O2
- and DEPMPO-O2
- spin 
adducts to investigate the dependence of the aβ-H value with the spin density on the 
nitrogen atom.25  
 
3.1.2.4 Decay of spin adducts 
The decomposition of spin adducts has been reported to proceed through a 
disproportionation pathway generating a nitrone and hydroxylamine species 
(Figure 3.7).22 This process requires a β-hydrogen and is retarded by the presence 
of bulky substituents at the C5-position in cyclic nitrone spin traps.21  
 
           
Figure 3.7 Decomposition pathway of a DMPO spin adduct forming a (A) nitrone 
and (B) hydroxylamine species in aqueous solution.  
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3.1.2.5 Azidyl and hydroxyl radicals  
The trapping of N3 radicals has been investigated using a variety of spin traps. In 
particular, the DMPO-N3 spin adduct has been well characterised.
2,26,27 The 
quartet-of-triplets EPR spectrum indicates 14N3 radicals, in contrast to the quartet-
of-doublets EPR spectrum reported for the 15N3 radicals, trapped by DMPO.
28 The 
resultant change in these EPR spectra is due to the change in their nuclear spin (I) 
of each isotope (14N, I = 1; 15N, I = ½).  
 
The trapping of the OH radical by DMPO generates a quartet EPR signal.29 
However, this EPR spectrum can also be detected from the spontaneous 
decomposition of unstable DMPO-R spin adducts.30 This has been distinguished 
by the addition of OH radical scavengers, such as ethanol (EtOH) or dimethyl-
sulfoxide (Me2SO). Interaction of the formed OH radicals with these radical 
scavengers leads to the formation of carbon-centred radicals, generating distinct 
EPR spectra.31,32 The 4-POBN (4, Figure 3.4) spin trap has been shown to be the 
most efficient spin trap for the detection of the -hydroxy-ethyl (CHCH3OH) 
radicals.33,34  
 
3.1.2.6 Wavelength of activation 
The choice of the irradiation source in photo-chemotherapy is important for 
achieving sufficient penetration into the tissue, where longer wavelengths of light 
(white, red and NIR) penetrate more deeply (refer to Figure 1.23, p 36).35,36 Photo-
activation of complex 40 with 463 nm and 517 nm light limits the potential 
application of complex 40 to thin-walled organ cancers such as bladder and 
oesophagus cancers.1 Therefore, activating complex 40 with alternative radiation 
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sources, such as gamma rays (widely used clinically) has potential to widen the 
types of tumours treatable by complex 40. The main aim of radiotherapy is to 
achieve cancer cell death with minimal damage to normal “healthy” tissue(s), 
through the use of high energy particles or waves such as X-rays, gamma-rays, 
electron beams or photons. Commonly used radiation sources are radioactive 
cobalt-60 (60Co) and cesium-137 (137Cs) isotopes. 137Cs emits gamma () rays of 
energy 0.66 MeV.37 Currently used in chemotherapy, cis-platin and carboplatin 
have been shown also to be efficient radiosensitisers. Their cytotoxicity is 
sometimes enhanced by activation with a radiation source compared to 
conventional treatment procedures.38,39 However, the activation of platinum(IV) 
diazido anticancer complexes with gamma-rays has not been previously reported.  
 
In this Chapter, the detection of radical species from the photo-activation of 
complex 40 was investigated through the use of spin trapping (EPR) spectroscopy, 
using a variety of nitrone spin traps. Successful trapping of N3 radicals led to 
varying experimental conditions to best mimic a biological environment. The spin 
trapping of azidyl radicals was extended to other photo-activatable platinum(IV) 
diazido anticancer complexes. Finally, spin trapping studies of photo-activated 
complex 40 with longer wavelengths of light (green and yellow LED light sources) 
and a gamma-ray irradiation source were investigated.  
 
3.2 Experimental 
Below are the experimental sample preparation and instrumentation set up specific 
to this Chapter. More details regarding instrumentation and the irradiation setup 
are described in Chapter II. 
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3.2.1 Materials  
 
Complex 40, trans,trans,trans-[Pt(N3)2(OH)2(py)2] and 
15N-40 were synthesised 
and characterised as described in Chapter II. Trans,trans,trans-[Pt 
N3)2(OH)2(MA)(py)] (complex 44, MA = methylamine) was provided by Dr. Yao 
Zhao40 and  trans,trans,trans-[Pt(N3)2(OH)(SAD)(py)2] (complex 56, SAD = 
succinate), trans,trans,trans-[Pt(N3)2(OH)(ethyl-methyl-SAD)(py)2] (complex 
57) and trans,trans,trans-[Pt(N3)2(OH)(N-MI)(py)2] (complex 58, N-MI = N-
methylisatoate) were provided by Dr. Evyenia Shaili.41 Nitrone spin traps -4-
pyridyl-1-oxide-N-tert-butylnitrone (4-POBN) and 5-diethoxyphosphoryl-5-
methyl-1-pyrroline-N-oxide (DEPMPO) were purchased from Enzo Life Sciences, 
obtained in the highest purity (≥ 99 %) and used without any further purification. 
The fully prepared cell culture medium RPMI-1640 (without L-glutamine) was 
purchased from PAA Laboratories Gmbh.  
 
3.2.2 Instrumentation  
 
3.2.2.1 X-band Electron Paramagnetic Resonance  
All EPR spectra were recorded on a 9.5 GHz X-band EPR spectrometer at ambient 
temperature (ca. 291 K). More specific details regarding EPR acquisition and spin 
adduct quantification are described in Chapter II.  
 
3.2.2.2 Irradiation Sources 
The majority of irradiations were performed using a blue LED light source ( = 
463 nm, 64 mW cm-2) commonly denoted herein as “463 nm” unless otherwise 
stated; the spectral output is shown in Figure A2.1. Additional irradiations 
involving green LED light source ( = 517 nm, 33 mW cm-2) and yellow LED 
light source ( = 593 nm, 17 mW cm-2) were used with spectral outputs shown in 
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Figure A3.1 and Figure A3.2, respectively. More specific details regarding 
irradiation setup, times and light power intensity measurements are described in 
Chapter II.  
 
3.2.2.3 Gamma-ray irradiations 
Gamma-ray irradiations were performed by Dr. Rebecca Carter at the Gray 
Institute in Oxford. Plates were irradiated using a 137Cs irradiator (dose rate 1.81 
Gy min-1) at room temperature.  
 
3.2.3 Sample preparation  
3.2.3.1 Varying solvent 
Solutions of complex 40 and spin trap were both prepared in deuterated phosphate 
buffer (PBS/D2O) and Roswell Memorial Park Institute medium (RPMI-1640), the 
latter to represent a more physiologically relevant environment. The phosphate-
buffered saline (PBS) solution was prepared in D2O as opposed to H2O. D2O was 
chosen essentially for direct comparison purposes between EPR and NMR 
spectroscopic data (in subsequent Chapters IV-IV).  
 
3.2.3.2 UV-visible spectroscopy 
The UV-visible spectrum of a solution of complex 40 (50 µM) prepared in 
PBS/D2O was recorded in the dark and after 5 min, 15 min, 30 min and 60 min 
irradiation with both 463 nm and 517 nm light. UV-visible instrumentation and 
irradiation setup were as described in Chapter II.  
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3.2.3.3 Gamma ray samples 
Complex 40 was transported from Warwick University to the Gray Institute in 
Oxford in an amber Eppendorf tube and wrapped in aluminium foil to prevent 
photo-activation from sunlight. Spin traps were stored under dry ice in an 
appropriate container and sealed to maintain the spin traps viability during transit. 
An aqueous stock solution of complex 40 (5 mM) in the presence of spin trap (10 
mM) was prepared immediately prior to performing the experiment. An aliquot of 
the stock solution (ca. 1 mL) was transferred on a plastic cell plate and placed 
inside the irradiation source. The selected irradiation doses, some of therapeutic 
relevance were delivered by specific placement of the cell plate containing the 
solution on the appropriate shelf and positioned near the gamma-ray source. After 
irradiation, the solution was transferred to a transparent vial, covered with 
aluminium foil to reduce additional light exposure. It was transported back to 
Warwick University where EPR analysis was undertaken, ca. 1.5 h after the initial 
irradiation was performed.  
 
3.2.4 Density functional theory (DFT) calculations 
Density functional theory calculations were performed by Miss Nichola Smith. 
Geometry optimisations were performed using Gaussian0342 in the gas phase using 
Becke’s three-parameter hybrid functional43 with Lee-Yang-Parr’s gradient-
corrected correlation functional (B3LYP).44 The split valence 6-31G** basis set 
was applied to all atoms. Electrostatic potential surfaces (EPS) were calculated and 
mapped on electron density (isovalue 0.001) of the molecules. The selected spin 
density maps for the spin adducts, DMPO-N3, DEPMPO-N3 and 4-POBN-N3 are 
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provided where green indicates a decrease in spin density, while dark blue 
indicates an increase.  
 
3.3 Results 
 
3.3.1 Dark and irradiated controls 
The spin traps used in this work (Figure 3.4) were purchased with the highest 
degree of purity (> 99 %). However, some commercially available spin traps 
contain hydroxylamines, which, under oxidising conditions, can generate EPR 
spectra obscuring the radical species under investigation.17 To investigate the 
presence of background EPR signals from the different spin traps used in this 
work, both dark and irradiated controls of the spin traps were performed.  
 
No EPR signals were detected from either the dark or after 30 min irradiation with 
463 nm (blue), 517 nm (green) and 593 nm (yellow) LED light for all of the spin 
traps DMPO (2, Figure 3.4), 4-POBN (3, Figure 3.4) and DEPMPO (4, Figure 3.4) 
in H2O, deuterated phosphate buffer (PBS/D2O) and in cell culture medium 
(Figure A3.3). The stability of these spin traps rendered them suitable for the 
potential detection of radicals generated from the photo-irradiation of complex 40.  
 
Furthermore, solutions of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (complex 40) 
were prepared in all three solvents and did not display an EPR spectrum in either 
the dark or upon irradiation. Additionally, the dark EPR spectrum of complex 40 
in the presence of spin traps (2-4) in all three solvents did not display an EPR 
signal (Figure A3.4), confirming no radical detection from complex 40 in the dark.  
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The cyclic nitrone spin trap, DMPO is the most commonly used spin trap in both 
in vitro45 and in vivo46 studies. Therefore, primary photo-activation of complex 40 
was performed in the presence of this spin trap.  
 
3.3.2 EPR spectroscopy with 5,5-dimethyl-pyrroline-N-oxide (DMPO) 
3.3.2.1 Azidyl radical trapping  
A solution of complex 40 (4 mM) in the presence of DMPO (8 mM, 2 mol equiv) 
was prepared in H2O at pH 7.4 and irradiated at 463 nm. An EPR signal was 
observed after 42 s (2.7 J cm-2) irradiation at 463 nm (Figure 3.8A). After 7 min 
irradiation, this EPR signal became more pronounced in its intensity in the ratio of 
1:1:1:2:2:2:2:2:2:1:1:1 (Figure 3.8B) and was assigned to a quartet of triplets EPR 
spectrum. An equivalent EPR spectrum was generated after performing a 
simulation (Figure 3.8B) using the experimentally determined hyperfine coupling 
constants. The observed hyperfine coupling values were similar to previously 
reported values for the DMPO-14N3 spin adduct (Table 3.1).
28 Therefore, this 
spectrum is assigned to the DMPO-14N3 spin adduct.  Differences between the 
experimental and previously reported hyperfine coupling constants values will be 
discussed in section 3.4.2.   
 
To confirm that the ●N3 radicals arose from the platinum(IV)-bound azide, the 
experiment was repeated with 15N-complex 40, prepared from azide labelled with 
15N at one of the terminal nitrogen atoms ([15N=N=N]−). The coupling of the 
unpaired electron to the 15N possessing a spin of I=½, is expected to alter the 
resultant EPR spectrum.    
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Figure 3.8 EPR spectra together with the line diagram of the DMPO-N3 spin 
adduct formed from a solution of complex 40 (4 mM) in the presence of DMPO 
(8 mM, 2 mol equiv) at pH 7.4 after (A) 42 s; (B) 7 min irradiation at 463 nm and 
(C) a simulation using experimental values as depicted in Table 3.1, together with 
the structure of the DMPO-14N3 spin adduct.  
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Table 3.1 Hyperfine coupling constants and g-factor determined for the DMPO-
N3 spin adduct shown in Figure 3.8 with literature values for the DMPO-
14N3 spin 
adduct (in brackets).   
DMPO-14N3 aNNO / (G) aH / (G) a14N  / (G) g-factor 
Experimentala 14.76 ± 0.02 14.49 ± 0.04 3.15 ± 0.02 2.011 ± 0.0004 
Publishedb (14.8) (14.2) (3.1) -c 
 adata represent means ± standard deviation of three independent experiments; bref 
28; cnot determined. 
 
3.3.2.2 Confirmation of ●N3 radical formation 
A solution containing 15N-40 (4 mM, 50% labelled at Nα position) in the presence 
of 2 mol equiv DMPO was prepared in H2O at pH 7.4 and irradiated at 463 nm, 
which generated the spectrum shown in Figure 3.9A. This spectrum contains a 
quartet of doublets28 superimposed with peaks from residual DMPO-14N3 spin 
adduct due to 50% 14N at the Nα position, as evidenced through the presence of the 
central (−) lines. These central lines assigned to DMPO-14N3  spin adduct were 
confirmed, from the parallel alignment of both the DMPO-14N3 and DMPO-
15N3 
line diagrams (Figure 3.9). The presence of the DMPO-14N3 spin adduct, meant 
that not all hyperfine splitting values were accurately resolved, in particular the 
a15Nα splitting. The remaining hyperfine coupling constants for the DMPO-
15N3 
spin adduct were determined and were similar to previously reported hyperfine 
splitting values28 (Table 3.2). The ratio between a15N / a14N was ca. 1.6, was similar 
to the gyromagnetic ratios of 15N/14N = 1.40. The minor difference is attributed 
to the crude determination of the a15Nα value due to the presence of the DMPO-
14N3 spin adduct.  
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Figure 3.9 EPR spectra together with the line diagrams of both the DMPO-14N3 
and DMPO-15N3 spin adducts generated from the (A) photo-irradiation of an 
aqueous solution of 15N-40 (4 mM) in the presence of DMPO (8 mM) at pH 7.4 
with 463 nm light for 7 min and, (B) simulation generated using experimental 
values depicted in Table 3.2, together with the structure of the DMPO-15N3 spin 
adduct. Contribution of the DMPO-14N3 (−) spin adduct due to only one terminal 
end of coordinated azide ligand being 15N labelled.  
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Table 3.2 Hyperfine coupling constants and g-factor determined from Figure 3.9 
with literature values for the DMPO-15N3 spin adduct (in brackets). 
DMPO-15N3 aNNO / (G) aH / (G) a15N  / (G) g-factor 
Experimentala 14.72 ± 0.1 14.5 ± 0.00 5.26 ± 0.01 1.934 ± 0.105 
Publishedb (14.8) (14.7) (4.5) -c 
 adata represent means ± standard deviation of two independent experiments; bref 
28; cnot determined. 
 
Similar to the DMPO-14N3 spin adduct, differences between the experimental and 
previously reported hyperfine coupling constants values will be discussed in 
section 3.4.2.   
 
3.3.2.3 Quantification of the DMPO-N3 spin adduct 
Successful trapping and characterisation of the N3 radicals, led to monitoring the 
formation and photo-decomposition of the DMPO-N3 spin adduct after 21 min 
irradiation at 463 nm. EPR signals were quantified at 7 min intervals over a total 
irradiation period of 21 min (80.7 J cm-2). Quantification of the EPR spectra was 
performed as described as Chapter II. The photo-irradiation of complex 40 in the 
presence of spin trap DMPO was monitored over a series of concentrations, 
maintaining the spin trap in excess. Irradiating a 9 mM solution complex 40 with 
DMPO (18 mM, 2 mol equiv) at 463 nm for 14 min led to ca. 237 M of formed 
DMPO-14N3 spin adduct (Figure 3.10). Lowering the concentration of complex 40 
to 5 mM led to a maximum concentration of DMPO-N3 spin adduct of ca. 369 M 
after 14 min irradiation with 463 nm light (ca. 1.5-fold higher compared to the spin 
adduct formed from the photo-irradiation of complex 40 at 9 mM). 
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Figure 3.10 Quantification of the DMPO-N3 spin adduct formed from the photo-
irradiation at 463 nm after 7 min, 14 min and 21 min intervals from a solution 
containing complex 40 (different concentrations, see legend) in the presence of 
DMPO (2 mol equiv relative to complex 40) prepared in H2O at pH 7.4. No spin 
adduct was observed in the dark (0 min). Error bars represent standard error of 
three independent experiments.  
 
This reduced N3 radical trapping by DMPO at higher concentrations of complex 
40, is likely to be due to azidyl radical dimerisation (2k = 9 × 109 M-1 s-1).11 Despite 
varying the concentration of complex 40, the photo-decomposition profile of the 
DMPO-N3 spin adduct remained consistent with the maximum trapping after 14 
min irradiation (Figure 3.10).  
 
Due to the position of the EPR tube in the EPR spectrometer cavity, it was not 
possible to observe in situ formation of bubbles, previously assigned to the 
formation of dinitrogen gas (N2). However, upon removal of the quartz tube from 
the EPR cavity, bubbles were observed. 
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Primarily, solutions in water were studied to ascertain the formation of the N3 
radicals from the photo-irradiation of complex 40. Next N3 radical formation 
generated from the photo-irradiation of complex 40 under more physiologically 
relevant conditions was investigated.  
 
3.3.2.4 DMPO-N3 formation in phosphate buffered saline solution 
A solution of complex 40 (5 mM) and DMPO (2 mol equiv) were prepared in 
PBS/H2O at pH 7.4 and irradiated at 463 nm for 21 min. The amount of formed 
DMPO-N3 spin adduct appeared to be unaffected by the PBS components, 0.01 M 
phosphate and 0.0027 M KCl (Figure A3.5). Next, a solution of complex 40 (4 
mM) in the presence of DMPO (2 mol equiv, 8 mM) prepared in PBS/D2O at pH* 
7.4 (where pH* is the pH meter reading in D2O, refer to Chapter II) was irradiated 
with 463 nm light, which led to the formation of the quartet-of-triplets EPR 
spectrum, as previously observed in water. Interestingly, the amount of the 
DMPO-N3 spin adduct formed was ca. two-fold higher in PBS/D2O (Figure 3.11). 
This increase is possibly due to the deuterated (D2O) solvent.  
 
The increase in the DMPO-N3 spin adduct in PBS/D2O (ca. 20% higher per mol 
of complex 40 compared to water) was also observed from the photo-irradiation 
of complex 40 at both 1 mM and 0.6 mM concentrations prepared in PBS/D2O at 
pH* 7.4. Next, the trapping of the N3 radicals in RPMI-1640 cell culture medium 
was investigated.  
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Figure 3.11 Quantification of the DMPO-N3 spin adduct formed from the photo-
irradiation at 463 nm after 7 min, 14 min and 21 min intervals from a solution 
containing complex 40 (different concentrations, see legend) and DMPO (2 mol 
equiv relative to complex 40) prepared in PBS/D2O at pH* 7.4. No EPR signal 
was observed in the dark (0 min). Error bars represent the standard error of three 
independent experiments.  
3.3.2.5 DMPO-N3 formation in cell culture medium  
A solution of complex 40 (5 mM) with DMPO (2 mol equiv) prepared in RPMI-
1640 was irradiated at 463 nm for 21 min. The quantity of the DMPO-N3 spin 
adduct generated after 14 min irradiation was ca. two and four-fold lower, 
compared to the DMPO-N3 spin adduct formed in water and PBS/D2O, 
respectively, summarised in Figure 3.12. This reduction in the DMPO-N3 spin 
adduct in RPMI-1640 may to be due to both the viscosity change and the presence 
of various components in the cell culture medium (Figure A3.6). Despite this 
reduced trapping, this result illustrated the release of the azide ligands from photo-
irradiated complex 40 in cell culture medium.  
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Figure 3.12 Quantification of the DMPO-N3 spin adduct formed from the photo-
irradiation at 463 nm after 7 min, 14 min and 21 min intervals from a solution 
containing complex 40 (5 mM) and DMPO (2 mol equiv) prepared in () H2O () 
PBS/D2O and () RPMI-1640. No EPR signal was observed in the dark (0 min). 
Error bars represent standard error of three independent experiments. 
These results illustrate the effect of changing from H2O and PBS/D2O to a medium 
can directly influence the amount of N3 radicals trapped by DMPO. Next, the 
generation of N3 radicals from the photo-activation of related platinum(IV) 
diazido anticancer complexes was investigated.  
3.3.3 Related platinum(IV) diazido complexes 
3.3.3.1 Modified equatorial ligand  
Spin trapping EPR spectroscopy of photo-activatable platinum(IV) diazido 
anticancer complexes with varying ligands in both the equatorial and axial 
positions compared to complex 40 (Figure 3.13) was performed. Initial work was 
performed on a solution of trans,trans,trans-[Pt(N3)2(OH)2(MA)(py)] (4 mM, 
complex 44, Figure 3.13) in the presence of DMPO (2 mol equiv) prepared in 
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water at pH 7.4 irradiated with 450 nm light (10 mW cm-2) at a distance of ca. 30 
cm from the EPR sample cavity. An identical EPR spectrum to the previously 
assigned DMPO-N3 spin adduct was obtained (Figure 3.8A).  
   
Figure 3.13 Photo-activatable platinum(IV) diazido complexes with various 
ligands in the axial (complex 44) and equatorial (complexes 56-58) positions.  
Therefore, it appeared that the replacement of the equatorial pyridine ligand for 
methylamine (MA) did not affect the release of the azide ligand in azidyl radical 
form from the photo-irradiation of complex 44.  
3.3.3.2 Modified axial ligands 
The release of azidyl radicals from complexes 56-58 (Figure 3.13) was also 
investigated. Two of these complexes possess carboxylate functional groups 
(complexes 56 and 57) and the third complex possesses an N-methylisatoate group 
(complex 58). Both carboxylate compounds 56 and 57 were soluble in phosphate 
buffered saline (PBS) solution. However, complex 58 was soluble only in 
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dimethyl-formamide (DMF). Therefore, two separate investigations were 
performed.  
Initially, the yield of the DMPO-N3 spin adduct formed from photo-irradiation of 
complex 40 with 517 nm light was compared with the photo-irradiation of 
complexes 56 and 57. From these results, it was observed that complex 40 does 
not generate N3 radicals from photo-irradiation with 517 nm light in PBS/H2O. 
However, both carboxylate complexes generated the DMPO-N3 spin adduct 
(Figure 3.14). 
     
 Figure 3.14 Quantification of the DMPO-N3 spin adduct formed from the photo-
irradiation of 2 mM () complex 57; () complex 56; () complex 40 and DMPO 
(4 mM, 2 mol equiv) prepared in PBS/H2O at pH 7.4 at 517 nm. No EPR signal 
observed in the dark (0 min) or from photo-irradiated complex 40. Refer to Figure 
3.2 and Figure 3.13 for structures of complexes 40 and 56 & 57, respectively. 
To compare complexes 40 and 56-58, under equivalent experimental conditions, 
the solvent was changed to aid the dissolution of complex 58. As a result, 2 mM 
solutions of complexes 40 and 56-58 were prepared in DMF/H2O (75%/25%, v/v) 
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in the presence of DMPO (4 mM, 2 mol equiv) and irradiated at 517 nm. 
Interestingly, all complexes (including complex 40) generated the DMPO-N3 spin 
adduct (Figure 3.8A). The detection of the DMPO-N3 spin adduct from complex 
40, under these experimental conditions, suggested photo-activation of 
platinum(IV) diazido anticancer complexes are directly dependent on the 
irradiation environment. As can be seen from Figure 3.15, a slight reduction in the 
DMPO-N3 spin adduct formed from the photo-irradiation of complex 58 is 
observed. This reduction will be discussed in more detail in Chapter IV.  
                         
Figure 3.15 Quantification of the DMPO-N3 spin adduct formed from the photo-
irradiation of 2 mM () complex 56 () complex 57 () complex 40 and () 
complex 58 in the presence of DMPO (2 mol equiv, 4 mM) prepared in DMF/H2O 
(75%/25%, v/v) at 517 nm. No EPR signal observed in the dark (0 min). Refer to 
Figure 3.2 and Figure 3.13 for structures of complexes 40 and 56-58, respectively.   
In summary, the trapping of N3 radicals using the nitrone spin trap, DMPO was 
successfully demonstrated. The release of the azide ligand in azidyl radical form 
was not limited to complex 40, but extended to other photo-activatable 
platinum(IV) diazido anticancer complexes, possessing varied axial and equatorial 
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ligands. Next, spin trap analogues of DMPO were examined for their ability to trap 
N3 radicals and/or additional radical-based species formed from the photo-
irradiation of complex 40.  
3.3.4 Alternative nitrone spin traps 
3.3.4.1 -4-Pyridyl-1-oxide-N-tert-butylnitrone (4-POBN) 
A solution of complex 40 (5 mM) with 4-POBN (2 mol equiv, 10 mM) prepared 
in water at pH 7.4 was irradiated with 463 nm light for 28 min. This led to the 
formation of a triplet-of-quartets EPR signal (Figure 3.16A). This EPR 
spectroscopic signal exhibited similar hyperfine coupling constants to previously 
published data of the 4-POBN-N3 spin adduct (Table 3.3).
47 Consequently, this 
spin adduct is assigned to the 4-POBN-N3 spin adduct. Minor variations between 
the experimental and previously reported hyperfine coupling constants values will 
be discussed in section 3.4.2.   
 
In this EPR spectrum, the two central lines of the quartet in the overall triplet of 
quartets were unresolved, appearing as shoulders (Figure 3.16A). This  has been 
attributed to a sterically induced alternation between the dihedral angle between 
the -hydrogen, -carbon, nitrone nitrogen plane with the plane defined by the -
carbon, nitrone nitrogen and its p-orbitals as reported by Walter et al..48  
 
The amount of the 4-POBN-N3 spin adduct formed from the photo-irradiation of 
complex 40 (5 mM) in the presence of 4-POBN (2 mol equiv, 10 mM) was ca. 
four-fold lower than the DMPO-N3 spin adduct (refer to Figure 3.17).  
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Figure 3.16 EPR spectra together with line diagram of the 4-POBN-N3 spin adduct 
formed from (A) a solution of complex 40 (5 mM) and 4-POBN (2 mol equiv) 
prepared in water at pH 7.4 irradiated at 463 nm for 7 min and (B) simulation 
performed using experimental values depicted in Table 3.3, together with structure 
of the 4-POBN-N3 spin adduct.  
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Table 3.3 Hyperfine coupling constants and g-factor determined from Figure 3.16 
with literature values for the 4-POBN-14N3 spin adduct (in brackets). 
4-POBN-N3 aNNO / (G) aH / (G) a14N  / (G) g-factor 
Experimentala 14.66 ± 0.01 1.92 ± 0.10 2.06 ± 0.08 2.0119 ± 0.0003 
Publishedb (14.68) (1.95) (1.95) -c 
 adata represent means ± standard deviation of two independent experiments; bref 
47; cnot determined. 
 
Changing the solvent from water to PBS/D2O, led to a two-fold higher formation 
of the 4-POBN-N3 spin adduct (Figure 3.17), which gradually decayed after 21 
min irradiation at 463 nm. This increase in spin adduct formation was similar to 
that observed in the presence of DMPO, which suggests that PBS/D2O induces an 
equivalent effect regardless of the spin trap present in solution.  
 
The primary use of 4-POBN in this work, was to determine the release of OH 
radicals from the photo-irradiation of complex 40. However, the 4-POBN-OH spin 
adduct has a short life-time of ca. < 1 min.49 A useful method for OH radical 
detection is from the reaction of the OH radicals with ethanol, which forms a 
unique carbon-centred radical. Therefore, the addition of ethanol (EtOH) to the 
system was investigated as an indirect method to confirm the presence of OH 
radicals.  
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Figure 3.17 Quantification of the 4-POBN-N3 spin adduct formed from the photo-
irradiation at 463 nm after 7 min, 14 min and 21 min intervals from a solution of 
complex 40 (5 mM) with 4-POBN (2 mol equiv, 10 mM) prepared in () H2O and 
() PBS/D2O. No spin adduct was observed in the dark (0 min). Error bars shown 
represent standard error of three independent experiments.  
 
3.3.4.2 Addition of ethanol  
Pou et al. reported on the optimum concentrations of both 4-POBN and EtOH for 
the detection of the OH radical.34 Ideally working with 4-POBN (10 mM) in 
conjunction with EtOH concentration ranging from 17 – 170 mM were optimum 
for the indirect detection of the OH radicals. Therefore, a solution containing 
complex 40 (2.5 mM) and 4-POBN (4 mol equiv, 10 mM) prepared in water at pH 
7.4 was irradiated at 463 nm for 14 min in both the absence and presence of EtOH 
(17 mM). 
 
A similar amount of 4-POBN-N3 spin adduct was formed in both the absence and 
presence of ethanol (Figure 3.18), but no new EPR signals were detected in the 
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presence of ethanol. In view of these results, this spin trap was not investigated 
further in the photo-irradiation studies of complex 40.  
   
Figure 3.18 Quantification of the 4-POBN-N3 spin adduct formed after 7 min and 
14 min intervals from the photo-irradiation at 463 nm of a solution containing 
complex 40 (2.5 mM) with 4-POBN (10 mM) prepared in water at pH 7.4 in () 
the absence and () presence of ethanol (17 mM). No EPR signal was observed in 
the dark (0 min). Error bars represent the standard error of three independent 
experiments.  
 
3.3.4.3 Phosphorus nitrone spin trap 
A solution of complex 40 (5 mM) in the presence of DEPMPO (4, Figure 3.4, 2 
mol equiv) prepared in water at pH 7.4 was irradiated at 463 nm for 21 min. A 
more complex EPR spectrum was generated (Figure 3.19A) compared to 
previously observed spin adducts, studied in this work. The additional lines are 
attributed to the unpaired electron coupling to the magnetically active, phosphorus 
atom (31P, I = ½). The generated EPR spectrum is assigned to the DEPMPO-N3 
spin adduct, in agreement with previously published data of the DEPMPO-N3 spin 
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adduct (Figure 3.19B).50 Differences between the experimental and previously 
reported hyperfine coupling constants values will be discussed in section 3.4.2.   
                                
Figure 3.19 EPR spectra together with the line diagram of the DEPMPO-N3 spin 
adduct generated from the (A) a solution of complex 40 (5 mM) and DEPMPO (10 
mM) prepared in water at pH 7.4 irradiated at 463 nm for 7 min and (B) simulation 
using experimental values depicted in Table 3.4, together with the structure of the 
DEPMPO-N3 spin adduct.  
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Table 3.4 Hyperfine coupling constants and g-factor determined from Figure 3.19 
with literature values for the DEPMPO-14N3 spin adduct (in brackets). 
DEPMPO-N3 aNNO / (G) aH / (G) aP/ (G) aN / (G) g-value 
Experimentala 13.82 ± 0.05 13.76 ± 0.13 45.94 ± 0.09 2.93 ± 0.06 2.013 ± 0.0003 
Publishedb (13.93) (12.39) (46.05) (2.80) -c 
 adata represent means ± standard deviation of two independent experiments; bref 
50; cnot determined. 
 
The DEPMPO-N3 spin adduct generated was ca. three-fold higher than the DMPO-
N3 spin adduct formed, under similar experimental conditions (Figure 3.20).        
             
Figure 3.20 Quantification (µM) and % trapping per mol of complex 40 for both 
() DMPO-N3 and () DEPMPO-N3 spin adducts generated from the photo-
irradiation of a solution of complex 40 (5 mM) and spin trap (2 mol equiv) with 
463 nm light after 7 min, 14 min and 21 min prepared in H2O at pH 7.4. No EPR 
signal was observed in the dark (0 min). Error bars represent the standard error of 
three independent experiments.  
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The DEPMPO-N3 spin adduct was observed at a concentration of ca. 580 M after 
2 h irradiation with 463 nm light. This illustrated the persistency of the DEPMPO-
N3 spin adduct in contrast to both DMPO-N3 and 4-POBN-N3 spin adducts, which 
photo-decomposed within ca. 1 h after irradiation with 463 nm light. 
Consequently, the DEPMPO spin trap proved to be the most efficient in the 
trapping of the N3 radicals, generated from the photo-irradiation of complex 40. 
 
The efficiency of the phosphorus spin trap for trapping N3 radicals (17% higher 
per mol of complex 40 compared to DMPO) prompted investigation of N3 radical 
trapping by DEPMPO at more biologically-relevant conditions. Individual 
solutions of complex 40 (0.8 mM and 0.4 mM) in the presence of DEPMPO (2 
mol equiv relative to complex 40) were prepared in water at pH 7.4 and irradiated 
at 463 nm light for 21 min (Figure 3.21). Photo-irradiation of complex 40 (0.8 
mM) with DEPMPO (1.6 mM) led to the trapping of ca. 24% per mol of complex 
40, equivalent to that observed from the photo-irradiation of complex 40 (5 mM). 
The yield of the DEPMPO-N3 spin adduct was ca. two-fold lower from the 
irradiation of a 0.4 mM solution of complex 40. Interestingly, an equivalent ca. 
14% per mol of complex 40 was obtained after 21 min irradiation from solutions 
containing 0.8 mM and 0.4 mM complex 40. After 21 min irradiation, the 
DEPMPO-N3 spin adduct formed in both solutions gradually decayed.  
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Figure 3.21 Quantification (µM) and % trapping per mol of complex 40 of the 
DEPMPO-N3 spin adduct formed from irradiation at 463 nm after 7 min, 14 min 
and 21 min from solutions containing complex 40 () 0.8 mM and () 0.4 mM in 
the presence of DEPMPO (2 mol equiv relative to complex 40) prepared in H2O 
at pH 7.4. No EPR signals observed in the dark (0 min). Error bars represent the 
standard error of three independent experiments.  
 
Moreover, a solution containing complex 40 (100 µM) and DEPMPO (2 mol 
equiv) prepared in H2O at pH 7.4 was irradiated at 463 nm light for 21 min, which 
led to the detection of the DEPMPO-N3 spin adduct (Figure 3.22). Whilst under 
these conditions, owing to high signal-to-noise (S/N) ratio not all lines of the 
DEPMPO-N3 spin adduct were clearly visible. Consequently a crude 
quantification the DEPMPO-N3 spin adduct of ca. 2.0 ± 0.3 µM was determined. 
This result did suggest the potential use of this spin trap for in cellulo studies, due 
to its ability to trap the N3 radical at low micro-molar concentrations of complex 
40. Next, the formation of the DMPO-N3 and DEPMPO-N3 spin adducts was 
investigated from the photo-irradiation of complex 40 with longer wavelengths of 
light.  
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Figure 3.22 EPR spectra together with the line diagram of the DEPMPO-N3 spin 
adduct generated from (A) the photo-irradiation of an aqueous solution of complex 
40 (100 M) and DEPMPO (200 M) with 463 nm light after 21 min and, (B) 
simulation generated as per Figure 3.19 with the structure of the DEPMPO-N3 spin 
adduct.  
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Table 3.5 Summary of spin adducts detected in this Chapter. 
EPR spectra Spin Adduct H2O PBS 
(D2O) 
RPMI 463 nm 
 
517 nm 
                        Figure 3.8 
 
Quartet-of-triplets 
 
DMPO-14N3  
 
     
                      Figure 3.9 
 
Quartet-of-doublets 
 
DMPO-15N3  
 
 
     
                      Figure 3.16 
 
Triplet-of-quartets 
 
4-POBN-N3  
 
 
     
                      Figure 3.19 
 
Octet-of-triplets 
 
DEPMPO-N3 
 
 
     
, spin adduct detected; , experiment not performed. 
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3.3.5 Longer wavelength of activation  
Irradiating a solution of complex 40 (5 mM) with DMPO (2 mol equiv) in both 
protiated solvent and PBS/D2O buffer with green 517 nm light (33 mW cm
-2) for 
21 min did not produce any EPR signal. However, irradiating an equivalent 
solution of complex 40 with DMPO prepared in RPMI-1640 led to the detection 
of the quartet of triplets EPR spectrum (Figure 3.23).  
       
Figure 3.23 EPR spectra of the DMPO-N3 spin adduct formed from (A) a solution 
of complex 40 (5 mM) and DMPO (2 mol equiv) prepared in RPMI-1640 medium 
irradiated for 21 min at 517 nm and (B) simulation of DMPO-N3 (generated as 
Figure 3.8) to aid experimental peak assignment.  
The DMPO-N3 spin adduct formed from the photo-irradiation of complex 40 with 
517 nm light was ca. ten-fold lower in comparison to the DMPO-N3 spin adduct 
formed with 463 nm light, summarised in Figure 3.24A. Despite this reduction in 
the DMPO-N3 spin adduct formed, these results effectively demonstrate the release 
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of the N3 radicals from photo-irradiated complex 40 by green light in cell culture 
RPMI-1640 medium. 
 
Figure 3.24 Quantification of the (A) DMPO-N3 and (B) DEPMPO-N3 spin 
adduct formed from the photo-irradiation with either () 463 nm and () 517 nm 
light after 7 min and 14 min intervals from a solution containing complex 40 (5 
mM) with DMPO (2 mol equiv) prepared in (A) RPMI-1640 medium and (B) H2O. 
No EPR signal was observed in the dark (0 min). Error bars represent the standard 
error of three independent experiments.  
Photo-irradiation of complex 40 in the presence of DMPO at 593 nm (17 mW cm-
2) in H2O, PBS/D2O and RPMI-1640 was also performed. However, no EPR signal 
for the DMPO-N3 spin adduct was observed.  
Next, a solution of complex 40 (5 mM) with DEPMPO (2 mol equiv, 10 mM) was 
irradiated at 517 nm prepared in H2O at pH 7.4.  Despite the observation of the 
DEPMPO-N3 spin adduct EPR spectrum, the amount generated was 9- and 27-fold 
lower after 7 and 14 min, respectively, compared to the DEPMPO-N3 spin adduct 
formed from irradiation with 463 nm light (Figure 3.24B).  
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Photo-irradiation of complex 40 at 517 nm light, led to a reduction in the amount 
of both the DMPO-N3 and DEPMPO-N3 spin adducts. The N3PtIV ligand-metal-
charge-transfer (LMCT) transition present in complex 40, has been shown to 
decrease upon photo-irradiation, assigned to the loss of the azide ligands in azidyl 
radical form (Chapter I).1 Consequently, the decrease in the N3PtIV LMCT band 
of complex 40 photo-irradiated with both 463 nm (Figure 3.25A) and 517 nm 
(Figure 3.25B) light was monitored by UV-visible spectroscopy. It was determined 
that ca. 60% of complex 40 photo-decomposed after 60 min irradiation with 463 
nm light, compared to ca. 3% from irradiation with 517 nm light (Figure 3.25C). 
Therefore, photo-irradiation of complex 40 with 517 nm light leads to a reduction 
in azidyl radical formation, thereby rationalising the reduction in spin adduct 
formation.   
     
Figure 3.25 UV-visible spectra of complex 40 (50 µM) prepared in PBS/D2O at 
pH* 7.4 in the (–) dark and after (–) 5; (–) 15; (–) 30 and (–) 60 min irradiation 
with (A) 463 nm; (B) 517 nm light. Decrease () in the N3→PtIV LMCT band (C) 
extent of photo-decomposition in the N3PtIV LMCT transition.  
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3.3.6 Density Functional Theory (DFT) calculations 
The spin density in the formed spin adducts was determined from DFT 
calculations, performed by Miss Nichola Smith. The spin densities on atoms 
involved in the hyperfine coupling were the focus of this study. The spin density 
map of the DMPO-N3 spin adduct is shown in Figure 3.26A1 and displays the spin 
density on the O1, NNO, Hβ and N atoms (blue coloured orbitals). A similar spin 
density map is observed for the DEPMPO-N3 spin adduct (Figure 3.26A2). 
However, the DEPMPO-N3 spin adduct exhibits an additional spin density of ca. 
0.027 on the phosphorus atom. This additional spin density on the phosphorus 
atom is believed to account for the greater lifetime of the DEPMPO-N3 spin 
adduct. The spin densities are summarised in Table 3.6.  
 
Interestingly, the 4-POBN-N3 spin adduct exhibited a different spin density 
distribution, compared to both the DMPO-N3 and DEPMPO-N3 spin adducts 
(Figure 3.27). The spin density on the β-proton (Hβ) is about seven- and nine-fold 
lower, compared to the DMPO-N3 and DEPMPO-N3 spin adducts, respectively, 
(Table 3.6). Furthermore, the spin density on N atom (N3) of 4-POBN-N3 spin 
adduct was ca. eleven-fold lower in contrast to the N atom (N3) of the DMPO-N3 
spin adduct. Interestingly, the 4-POBN-N3 spin adduct exhibited spin density on 
other atoms present in the spin adduct, not involved in the hyperfine coupling 
(Figure 3.27A). These differences are believed to explain the reduced lifetime of 
4-POBN-N3 compared to the DMPO-N3 and DEPMPO-N3 spin adducts. The spin 
density on all atoms present in DMPO-N3, DEPMPO-N3 and 4-POBN-N3 are 
summarised in Tables A3.7-3.9.   
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Figure 3.26 Spin density maps together with 2D orientation of both (A1 and B1) 
DMPO-N3 and (A2 and B2) DEPMPO-N3 spin adducts. Green indicates a decrease 
in spin density, while dark blue indicates an increase values summarised in Table 
3.6. Spin densities were calculated by DFT as described in experimental section. 
Atom labels: red, oxygen; blue, nitrogen; orange, phosphorus, light grey, 
hydrogen; dark grey, carbon.  
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Table 3.6 Localisation of spin density in the DMPO-N3, DEPMPO-N3 and 4-
POBN-N3 spin adducts.  
Atom DMPO-N3  DEPMPO-N3  4-POBN-N3 
O1 0.5288 0.5153 0.5335 
aN2 0.4115 0.4226 0.4421 
Hβ 0.0126 0.0148 0.0017 
bN3 0.1356 0.0124 0.0115 
P3 - 0.0267 - 
arefers to nitroxide nitogen, NNO atom; brefers to -nitrogen of the trapped azidyl 
radical, N.  
 
 
Figure 3.27 Spin density map together with 2D orientation of the 4-POBN-N3 spin 
adduct. Green indicates a decrease in spin density, while dark blue indicates an 
increase. The values are summarised in Table 3.6. Spin densities were calculated 
by DFT as described in experimental section.  
 
3.3.7 Alternative radiation source 
Longer wavelengths of light are preferred therapeutically, owing to their deeper 
tissue penetration. Photo-activation of complex 40 has been limited to 517 nm 
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(green) light, with longer wavelengths of light not reported for the photo-activation 
of complex 40. In the clinic, combination of both chemotherapy and radiotherapy 
is commonly used. An investigation of the activation of complex 40 with a gamma-
ray source was therefore carried out.  
 
3.3.7.1 Gamma-ray irradiation in the presence of DMPO 
An aqueous stock solution of complex 40 (5 mM) with DMPO (10 mM) was 
prepared at pH 7.4 under dim lighting conditions. An aliquot (ca. 1 mL) was 
transferred onto a cell culture plate. The flat surface of the cell culture plate 
provided an optimum setup for exposure to the gamma-rays. Gamma irradiations 
were performed by Dr. Rebecca Carter. In an attempt to establish the photo-
activation of complex 40, various doses ranging from 2 – 100 Gy were chosen 
(Table 3.7).  
 
Table 3.7 Gamma (γ) radiation doses used in this work. 
γ-Dose / Gy Time of radiation / s 
1 10 
2 34 
4 68 
8 216 
100 7.42 min 
 
Irradiated samples were compared to both a dark control and the DMPO-N3 spin 
adduct formed with 463 nm light. No EPR signals were detected for samples 
radiated with 4, 8, 16 or 100 Gy. Interestingly, irradiation with 2 Gy gave rise to 
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an EPR signal (Figure 3.28). The low S/N ratio of this EPR spectrum meant that 
full characterisation and quantitative EPR spectroscopy could not be performed. 
This EPR signal did not resemble that of the quartet of triplets EPR signal assigned 
to the DMPO-N3 spin adduct. This suggested the possible trapping of an alternative 
radical species from irradiated complex 40 with gamma-rays. A crude estimation 
of the formed spin adduct was determined to be ca. 10 ± 0.4 µM. These results 
provided strong evidence for the activation of complex 40 with a 137Cs gamma-ray 
irradiation source.  
            
Figure 3.28 EPR spectra generated from (A) a solution of complex 40 (5 mM) 
with DMPO (2 mol equiv) prepared in water at pH 7.4 irradiated with 2 Gy dose 
of 137Cs gamma radiation source. Formed spin adduct was roughly quantified to 
ca. 10 ± 0.4 µM.  
 
3.3.7.2 Gamma-ray irradiation in the presence of DEPMPO 
Additional gamma-ray irradiation studies were performed with spin trap, 
DEPMPO, owing to its greater efficiency at N3 radical trapping, as previously 
observed in section 3.3.4. Solutions containing complex 40 (5 mM) and DEPMPO 
(10 mM, 2 mol equiv) were prepared in water at pH 7.4 and irradiated with varying 
doses of the 137Cs gamma-ray irradiation source (Figure 3.29). Irradiated solutions 
generated an EPR signal assignable to DEPMPO-N3 (Figure 3.29G), as previously 
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observed in Figure 3.19. The observation of the DEPMPO-N3 spin adduct from 
the irradiation of complex 40 (5 mM) with DEPMPO (2 mol equiv) with a 137Cs 
gamma source is the first report of the activation of complex 40 with gamma rays.  
 
Figure 3.29 EPR spectra generated from the gamma irradiation of complex 40 (5 
mM) with DEPMPO (2 mol equiv) with 137Cs gamma source with doses of (A) 1 
Gy; (B) 2 Gy; (C) 4 Gy; (D) 8 Gy; (E) 100 Gy and (F) simulation of DEPMPO-
N3 using experimentally-obtained parameters listed in Table 3.4. EPR signal 
assigned to the DEPMPO-N3 spin adduct, refer to Figure 3.19 for spin adduct 
formation.  
                                                       Chapter III: EPR Spin Trapping Studies 
 
131 
 
Table 3.8 Quantification of the DEPMPO-N3 spin adduct formed from gamma-
ray irradiation of complex 40 at varying doses.  
γ-Dose / (Gy) [DEPMPO-N3]a / M % Mol complex 40 
1 31.8 0.6 
2 18.0 0.4 
4 41.6 0.8 
8 45.1 0.9 
100 50.0 1.0 
aspin adduct formed from the gamma-ray irradiation of a solution of complex 40 
(5 mM) with DEPMPO (2 mol equiv) prepared in water at pH 7.4 recorded 1.5 h 
after initial irradiation.  
 
These results prompted the investigation of the cytotoxicity of complex 40 
irradiated with the 137Cs gamma-ray irradiation source. Complex 40 (up to 80 µM) 
incubated in DLD1 colorectal adenocarcinoma cell line did not exhibit any 
cytotoxic effect, either in the dark or after irradiation with the 137Cs gamma-ray 
source. This study has to be repeated to confirm this observation. However, this 
preliminary result suggests that despite the detection of the DEPMPO-N3 spin 
adduct, activated complex 40 is incapable of inducing a cytotoxic effect. 
Consequently, activation of complex 40 with a 137Cs gamma-ray irradiation source 
may activate the platinum(IV) diazido anticancer complex by an alternative 
pathway.  
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3.4 Discussion 
3.4.1 Efficiency and stability of formed spin adducts 
It was shown that the DEPMPO spin trap was more efficient at trapping N3 
radicals formed from the photo-irradiation of complex 40 with 463 nm light, 
compared to spin traps, DMPO and 4-POBN (summarised in Figure 3.30). This 
effect is thought to be due to the rate at which N3 radicals are trapped by each spin 
trap which is determined by their chemical composition.  
                 
Figure 3.30 Quantification of the spin trap-N3 spin adduct formed from the photo-
irradiation of complex 40 (5 mM) in the presence of spin trap (2 mol equiv, see 
legend) prepared in H2O at pH 7.4 with 463 nm light.   
 
3.4.1.1 DEPMPO 
Substituting a methyl group in DMPO for a diethoxy-phosphoryl group generating 
the DEPMPO spin trap has been previously reported to exhibit a faster rate for the 
trapping of the hydroxyl (OH) radical, kDEPMPO = 7.8 ×10
9 M-1 s-1 vs. kDMPO = 
3.4×109 M-1 s-1.51 This has been attributed to the electron-withdrawing effect of 
the diethoxy-phosphoryl group and it is believed that DEPMPO also possesses a 
faster rate than DMPO and 4-POBN for the trapping of the N3 radicals. This rate 
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is also thought to be faster than N3 radical dimerisation (2k = 9 × 10
9 M-1 s-1) 
rationalising the higher trapping of the N3 radicals.
28 Moreover, the DEPMPO-N3 
spin adduct was the most persistent spin adduct detected in this work. The 
increased stability is attributed to the presence of the diethoxy-phosphoryl group 
shielding the unpaired electron on the NO functional group, as reported previously 
for OH, OOH and O2
- radicals trapped by DEPMPO.52,53  
 
3.4.1.2 4-POBN  
The reduced trapping of the N3 radicals by 4-POBN is thought to be a result of 
steric hindrance due to the presence of both the 4-pyridyl and t-butyl groups 
present in 4-POBN, inhibiting the covalent bonding of the N3 radicals to the α-
carbon of the nitrone spin trap. As a result, azidyl radical dimerisation (2k = 9 × 
109 M-1 s-1)28 is suggested to proceed in preference to 4-POBN-N3 spin adduct 
formation. The use of 4-POBN has been commonly reported for spin trapping of 
oxygen- and carbon-centred radicals. Thus, it is thought that nitrogen-centred 
radicals, such as N3 radicals exhibit a lower affinity for spin trapping by 4-POBN.  
 
3.4.1.3 DMPO 
A rate constant of k = 1.6 × 109 M-1 s-1 for the trapping of N3 radicals by DMPO 
has been reported.54 This lower rate constant in comparison to N3 radical 
dimerisation indicates that DMPO does not trap all N3 radicals generated from the 
photo-irradiation of complex 40. However, the DMPO spin trap is more stable in 
solution compared to the phosphorus analogue. Therefore, this spin trap was still 
used throughout this study. Moreover, the stability of the formed DMPO-N3 spin 
adduct was enhanced by the β-methyl groups present on C5 of the nitrone spin 
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adduct. These bulky substituents delayed the decomposition the DMPO-N3 spin 
adduct.  
 
3.4.1.4 Spin density  
The DMPO-N3 spin adduct, exhibited similar spin densities on the nitroxide 
nitrogen (NNO), β-proton (Hβ) and -nitrogen of the trapped azidyl radical (N) 
atoms to that of the DEPMPO-N3 spin adduct. However, the DEPMPO-N3 spin 
adduct possessed additional spin density on the phosphorus atom. This extra spin 
density is believed to account for the longer lifetime of the DEPMPO-N3 spin 
adduct compared to the DMPO-N3 spin adduct. Interestingly, a difference in spin 
density distribution was obtained by DFT for the 4-POBN-N3 spin adduct 
compared to the DMPO-N3 and DEPMPO-N3 spin adducts. Lower spin densities 
were observed on the N and Hβ atoms present in 4-POBN-N3 spin adduct in 
contrast to both to the DMPO-N3 and DEPMPO-N3 spin adducts. Moreover, in 
contrast to both DMPO-N3 and DEPMPO-N3 spin adducts, where the majority of 
spin density was localised on atoms involved in the hyperfine coupling, in the 4-
POBN-N3 spin adduct, the spin density appeared to be distributed throughout the 
spin adduct molecule (Figure A3.9). 
 
Consequently, these observations are thought to account for the reduced lifetime 
of the 4-POBN-N3 spin adduct, compared to both DMPO-N3 and DEPMPO-N3 
spin adducts. These spin density distributions for each spin adduct are in agreement 
with the experimental data on DEPMPO-N3 > DMPO-N3 >4-POBN-N3, where 
DEPMPO-N3 is the longest lived spin adduct, under these experimental conditions. 
Complete spin density values are summarised in Figures A3.7 – A3.9. 
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Consequently, it appears spin density on the atoms involved in the hyperfine 
coupling can directly correlate with the lifetime of each respective spin adduct.  
 
3.4.2 Hyperfine coupling constants 
Increasing the solvent polarity has been correlated with the increase in both the 
aNNO and a
H
β values, which is attributed the spin adduct residing in resonance form 
B (refer to Figure 3.5).19,55 For example, Ozawa et al. detected the quartet EPR 
spectrum assigned to DMPO-OH spin adduct in acetonitrile possessing hyperfine 
couplings of aNNO = 14.10 G and a
H
β = 12.29 G.
56 In contrast, the equivalent quartet 
EPR spectrum was observed by Lai et al. in water, however the spin adduct 
possessed hyperfine couplings values of aNNO = a
H
β = 15.0 G.
57 Despite this 
difference of ca. 0.9 G and 2.7 G between the aNNO and a
H
β values, respectively, 
both studies concluded the trapping of the OH radicals by DMPO. Consequently, 
it would be expected that spin adducts recorded in the same solvent would exhibit 
identical hyperfine coupling constants. However, a variety of hyperfine coupling 
constants have been reported for the DMPO-N3 spin adduct recorded in water 
(Table 3.9).58-60 From these data, it is evident that the hyperfine splitting constants 
appear to be also influenced by the EPR spectrometer parameters such as 
modulation amplitude, microwave power and experimental conditions.61  
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Table 3.9 Comparison of the hyperfine coupling constants (G) from the DMPO-
N3 spin adduct formed in water under non-identical experimental conditions.  
Radical aNNO / G aHβ / G aNα / G Conditions Ref 
N3 14.9 14.9 3.0 HP,
a N3
− , light 60 
N3 14.5 14.5 3.1 MB,
b light 61 
N3 15.0 14.3 3.17 AP,
c N3
− , light 62 
ahorse-radish peroxidase; bmethylene blue; c antrapyrazole.  
 
Therefore, it appears no two independent EPR spin trapping studies will generate 
equivalent hyperfine coupling values, unless identical experimental conditions are 
used. Consequently, this rationalises the minor differences in hyperfine coupling 
constants determined in this thesis compared to previous literature.   
 
3.4.3 Solvent effects 
An equivalent formation of the DMPO-N3 spin adduct was detected in both (H2O) 
and PBS/H2O (Figure A3.5). Consequently, it appeared the PBS components 
(phosphate and potassium chloride) did not affect the trapping of the azidyl radical. 
However, changing from water to deuterated phosphate buffer led to an increase 
(ca. two-fold higher) in both the DMPO-N3 and 4-POBN-N3 spin adduct 
concentrations. An increasing yield in radical species in deuterated solvent has 
been previously reported, ca. 5% higher in deuterated solvent compared to aqueous 
solution.62,63  
 
Collectively, increasing radical yields and extended lifetimes are postulated to be 
due to the Brownian motion (diffusion) of the formed radicals. Previous literature 
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has described the higher tumbling rates of molecules in less viscous solvents.15 
Furthermore, Harbour et al. determined a three-fold increase in the DMPO-N3 spin 
adduct upon changing the solvent from H2O to D2O. Therefore, in this work it is 
proposed that changing from protiated (H2O) solvent (η = 0.8903 cP s at 25 ºC) to 
deuterated (η = 1.100 cP at 25 ºC) deuterated (D2O) solvent,64 is the reason for the 
concentration increase in the formed spin adducts.  
 
The reduction of the DMPO-N3 spin adduct generated in the cell culture medium 
RPMI-1640 may be at least partially attributed to its low viscosity (η = 0.7 cP at 
310 K).65 However, the N3 radicals are reactive towards a variety of amino acids, 
in particular L-tyrosine (L-Tyr) and L-tryptophan (L-Trp).62,66 RPMI-1640 
contains various components including amino acids (L-Tyr and L-Trp) (Figure 
A3.6). However, their concentrations in the cell culture medium are thought to be 
too low to induce reactivity with the formed N3 radicals. Nevertheless, other 
substituents in the cell culture medium may be strong azidyl radical quenchers at 
low concentrations. Owing to the array of substituents present in RPMI-1640, this 
effect was not investigated in greater depth.  
 
3.4.4 Irradiation sources 
3.4.4.1 Longer wavelength of activation 
Green (33 mW cm-2) LED light of 517 nm is ca. two-fold lower in power than the 
corresponding 463 nm blue (64 mW cm-2) LED light source. This lower power is 
envisaged to reduce the rate of photo-activation of complex 40. This was 
confirmed by monitoring the photo-decomposition of complex 40 with 517 nm 
light by UV-visible spectroscopy. The reduced decrease in the N3PtIV LMCT 
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band coincides with a reduction in N3 radical release, leading to a reduction in the 
amount of N3 radicals to be trapped by both DMPO and DEPMPO.  
 
Changing the wavelength of irradiation to 517 nm (green) light led only to the 
formation of the DMPO-N3 spin adduct in RPMI-1640 medium compared to water 
and PBS/D2O solvents. This was suggested to be due to the presence of the various 
substituents present in the cell culture medium. It is probable that one or more 
components in the cell culture medium enhance the light-dependent generation of 
N3 radicals. The reason why activation at the longer wavelength was successful 
only in the culture medium is not clear, although perhaps it could be related to the 
behaviour of very weak bands at longer wavelength found in density functional 
theory calculations.1 Longer wavelengths are of interest because of their deeper 
penetration into tissues, and both blue and green light are effective in activating 
related pyridyl/ammine PtIV complexes in cancer cells.1,67 
 
The trapping of the N3 radicals formed from the photo-irradiation of complex 40 
prepared in DMF/H2O (75% / 25% v/v) with 517 nm light is suggested to be due 
to both the higher solvent-mixture viscosity inducing a lower rate of molecular 
tumbling, subsequently leading to an increase in the amount of the N3 radicals 
trapped by DMPO.  
 
It was also established that the release of the azide ligands depends on the ligands 
coordinated to the platinum(IV) metal centre. As observed, the photo-irradiation 
with 517 nm LED light of complexes 56 and 57 (refer to Figure 3.13 for structures) 
prepared in PBS/H2O led to the trapping of the N3 radicals, in contrast to complex 
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40 photo-activated under similar conditions. Both of these carboxylate compounds 
exhibited an ability to be photo-activated with green light, suggesting equatorial 
ligand modification influence the wavelength of activation of platinum(IV) 
diazido complexes. This is in agreement with previous DFT calculations 
performed on complexes 56 and 57 which exhibited bands at longer wavelengths 
compared to complex 40.41 The trapping of the N3 radicals from photo-irradiated 
complexes 40, 44 and 57-59 suggested the release of the azide ligands in azidyl 
(N3) radical form is a common photo-decomposition pathway for platinum(IV) 
diazido complexes.  
 
3.4.4.2 Gamma ray irradiation 
Cis-platin was first reported to be a radio-sensitiser by Zák and Drobník.68 Second 
and third generation platinum anticancer complexes are also efficient radio-
sensitisers.69,70 However, this appears to be the first report on the activation of 
complex 40 with a gamma-ray irradiation source. Initial gamma-ray irradiation of 
complex 40 in the presence of spin trap, DMPO, did not generate EPR spectra 
suitable for full characterisation or qualitative analysis. It is most probably a decay 
product from the initial trapping of the N3 radicals by DMPO.  
 
Employing the phosphorus spin trap, DEPMPO was more efficient in allowing the 
resultant EPR spectra to be interpreted in terms of N3 radical trapping. The 
detection of the DEPMPO-N3 spin adduct suggests gamma-ray irradiation is 
effective in photo-activating complex 40. Two probable activation pathways of 
complex 40 with the 137Cs gamma-ray irradiation source have potential to occur. 
Firstly, the 137Cs gamma-ray irradiation source has potential to ionise the solvent, 
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H2O, leading to the generation of aqueous free radicals, hydrogen ion and low 
amounts of H2 and H2O2 (Equation 3.3). Previous studies by Khan reported on the 
one-electron reduction of trans-[PtIV(NH3)4(OH)2]
2+ by the aquated electron 
generated from pulse radiolysis, leading to the formation of a trans-
[PtIII(NH3)4(OH)2]
+ species. This platinum(III) species underwent additional 
reaction with the hydroxyl radicals generated from the pulse radiolysis of water, 
forming trans-[Pt(NH3)4(H2O)2]
3+.71 Additionally, free ammonia was also 
detected in these reactions.  
         
In this work, gamma-ray irradiations were performed in water, therefore ionisation 
of the solvent as shown in Equation 3.3 is possible. Through the hydrated electron, 
a one-electron reduction of the PtIV metal centre of complex 40 could occur, 
generating a platinum(III) intermediate. Although it is not fully understood, it is 
proposed the reactive nature of this platinum(III) transient species may result in 
the loss of the azide ligand in azidyl radical form, which is subsequently trapped 
by DEPMPO. Alternatively, the 137Cs, parent nuclide spontaneously decays via 
beta decay to the daughter nuclide, 137Ba and emits a β- particle, an antineutrino 
(ῡe) and Qβ- energy (Equation 3.4). The β- particle corresponds to an electron (e-), 
where its presence satisfies the energy conservation.72  
           
Therefore, the reduction of the PtIV metal centre may also be initiated from this 
electron in a similar pathway as described above. One-electron reduction of cis-
platin has also been reported with the hydrated electron, forming a platinum(I) type 
species.73 Free ammonia from trans-[PtIV(NH3)4(OH)2]
2+ was also detected in the 
                                                       Chapter III: EPR Spin Trapping Studies 
 
141 
 
study by Khan et al.. Therefore in this work, the lack of cytotoxicity in DLD-1 
cells from gamma-ray irradiated complex 40 may be due to the loss of coordinated 
pyridine. The loss of carrier ligands from platinum anticancer complexes has been 
associated with reduced cytotoxicity.74-76  
 
Interestingly, the detection of the DEPMPO-N3 spin adduct from complex 40 was 
obtained using clinically relevant gamma-ray irradiation doses. To date, the 
maximum dosage applied to patients is 45 Gy, given in aliquots of 1.8 – 2 Gy over 
a period of 5-8 weeks.37 However, despite the detection of the DEPMPO-N3 spin 
adduct, it should be noted that the 137Cs gamma-ray irradiation source emitting a 
photon with energy of ca. 662 keV is more destructive towards complex 40, 
compared to visible light with a power outage of ca. 64 mW cm-2. Therefore, the 
detection of the DEPMPO-N3 spin adduct has potential to be due to complete 
molecular fragmentation of complex 40 irradiated with 137Cs gamma-ray 
irradiation source. Additional UV-visible and NMR spectroscopy studies of 
complex 40 irradiated with gamma-rays are required to fully comprehend these 
preliminary results and elucidate the mechanism of action.   
 
3.5 Conclusion 
In this Chapter, photo-activation of complex 40 with blue light gave rise to the 
release of the azide ligand in azidyl (N3) radical form, which was detected by spin 
trapping EPR spectroscopy using a variety of nitrone spin traps namely: DMPO, 
4-POBN and DEPMPO. Varying the spin trap led to differences in efficiency and 
life-times of the resultant spin adducts. The phosphorus spin trap DEPMPO 
appeared to exhibit the fastest rate towards N3 radicals. In contrast, the spin trap, 
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4-POBN displayed the lowest level of N3 radical trapping, this was attributed to 
steric hindrance due to the presence of the 4-pyridyl and t-butyl groups present in 
4-POBN.  
 
The first generation cyclic nitrone spin trap, DMPO generated the quartet of 
triplets spectrum, indicative of DMPO-N3 spin adduct formation. However, with a 
known rate slower than N3 radical dimerisation, a portion of formed N3 radicals 
are believed to undergo radical dimerisation. The distribution of spin density on 
the atoms involved in the hyperfine coupling was correlated with the lifetime of 
the spin adducts under investigation.  
 
Interestingly, Brownian motion of the formed N3 radicals appears to account for 
the observed increase in the amount of spin adduct formed upon changing the 
solvent from PBS/H2O to PBS/D2O. In contrast, the reduction in the DMPO-N3 
spin adduct formed in RPMI-1640 was attributed to the various components in cell 
culture medium which have potential to behave as azidyl radical quenchers. 
Furthermore, the trapping of N3 radicals from related photo-activatable 
platinum(IV) diazido complexes, trans,trans,trans-[Pt(N3)2(OH)2(MA)(py)] (44, 
MA = methylamine), trans,trans,trans-[Pt(N3)2(OH)(SAD)(py)2] (56, SAD = 
succinate), trans,trans,trans-[Pt(N3)2(OH)(ethyl-methyl-SAD)(py)2] (57) and 
trans,trans,trans-[Pt(N3)2(OH)(N-MI)(py)2] (58, N-MI = N-methylisatoate) 
suggested the release of the azide ligand(s) as a common photo-decomposition 
pathway of platinum(IV) diazido complexes. Finally, it was shown that complex 
40 could be activated by gamma-rays from a 137Cs gamma radiation source at doses 
of therapeutic relevance.  
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In this Chapter, photo-irradiation of a family of platinum(IV) diazido anticancer 
complexes with visible light led to the trapping of the N3 radicals using a variety 
of spin traps. N3 radicals are regarded as reactive nitrogen species (RNS), which 
suggests their potential involvement in the photo-cytotoxic nature of platinum(IV) 
diazido anticancer complexes. These formed N3 radicals have potential to react 
with various amino acids, proteins and peptides, leading to a potential disruption 
in cell homeostasis inducing an acute phase cytotoxic effect. These results suggest 
platinum(IV) diazido complexes have the ability to exhibit a dual mechanism of 
action involving both an acute (radical based) and chronic (DNA platination at N7 
of guanine) phase.  
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This chapter investigates the potential biological target(s) of azidyl radicals in an 
attempt to elucidate their reactivity within cancer cells.  
 
4.1 Introduction  
 
Platinum(IV) diazido anticancer complexes such as trans,trans,trans-
[Pt(OH)2(N3)2(py)2] (complex 40) exert potent photo-cytotoxicity towards a 
number of cancer cell lines including parental (A2780) and cisplatin-resistant 
(A2780cis) ovarian carcinoma cells following irradiation with blue/green 
wavelengths of light, whilst being non-toxic in the dark.1 The mechanism of 
action of complex 40 and similar photo-activatable platinum(IV) diazido 
complexes (Figure 4.1) may involve a number of different pathways, including the 
platination of DNA nucleobases (such as guanine) which was discussed in 
Chapter I, and the formation of radical species, which was the subject of 
Chapter III.  
 
Similar to reactive oxygen species (ROS), reactive nitrogen species (RNS) are 
equally capable of inducing biochemical disorders including major tissue/cell 
damage.2,3 As shown in Chapter III, azidyl radicals (N3) were characterised by 
spin trapping EPR spectroscopy upon the photo-irradiation of complex 40 and 
related platinum(IV) diazido complexes. Once formed, these RNS are readily 
available to interact with near biological targets in cells. Prütz et al. reported the 
reactive nature of the N3 radicals towards aromatic functionalised amino acids in 
addition to noting their unreactive nature towards nucleic acid derivatives.4 
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Figure 4.1 Photo-activatable platinum(IV) diazido complexes studied in this 
work.  
 
Amino acids are involved in a variety of biochemical pathways. For example, L-
tyrosine (L-Tyr) possesses important roles in protein synthesis, including the 
production of neurotransmitters responsible for nerve cell communication and 
mood influence; it also acts as a precursor to melanin pigment.5 In contrast, L-
tryptophan (L-Trp) is transformed into various biomolecules including nicotinic 
acid (a vitamin), serotonin (a neuro-hormone) and indole acetic acid (a phyto-
hormone).6 Furthermore, L-Trp is a precursor for nicotine-aminde adenosine 
dinucleotide (NAD+), a coenzyme found in living cells, involved in redox 
reactions and cellular processes such as post-translational modifications of 
proteins.6,7  
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Previous reports on the reactivity of N3 radicals have been on the interaction with 
L-Trp, L-Tyr,8 N-methylindole (NMI), various styrenes and olefin derivatives.8 
Thermodynamically, the reaction between N3 radicals with L-Trp was reported to 
proceed via a hydrogen-atom abstraction process (Scheme 4.1A), leading to the 
formation of a neutral L-Trp radical and hydrazoic acid (HN3).
9 However, 
reacting near the diffusion-controlled limit, N3 radicals favour an electron-transfer 
mechanism (Scheme 4.1B).9 One-electron oxidation of L-Trp by N3 radicals 
generates both free azide (N3) and the corresponding amino acid radical cation 
(L-Trp+).  
Scheme 4.1 Azidyl radical reaction with L-Trp through (A) hydrogen atom 
abstraction and (B) electron transfer pathways with included pKa
 and Gibbs Free 
Energy (ΔG°) values shown. The rate constants for the forward (kn) and back 
directions (– kn) are depicted. 
 
L-Trp+ with a pKa of ca. 4.3, deprotonates within nanoseconds at pH > 5, leading 
to the formation of L-Trp and HN3. The hydrogen atom belonging to the NH 
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amine functional group of the indole ring is abstracted from L-Trp+.9 These one-
electron oxidation reactions of amino acids by N3 radicals have been reported in 
numerous instances with the formation of the corresponding amino acid 
radical.9,10 The redox couples (Trp+ / Trp) with a reported reduction potential (E) 
of ca. 1.24 ± 0.02 V,11 is a stronger oxidant than the redox couple (Tyr+ / Tyr) 
with a E value of 0.94 V.12 Moreover, at pH 7, redox potential values for the 
redox couples (Trp/Trp) and (Tyr/Tyr) have been reported to be ca. 0.94 V and > 
0.8 V, respectively.13 Despite the reduction potentials showing a marked pH 
dependence,14 the above reduction potentials are weaker than the redox couple 
(N3/ N3) with a E value of ca. 1.33 V. The reduction potentials for the redox 
couples, (Trp+/Trp), (Tyr+/Tyr), (Trp/Trp) and (Tyr/Tyr) together with the pKa 
values of 4.74 for HN3 suggest it is favourable for either L-Trp or L-Tyr to donate 
an electron to the N3 radicals. Therefore, potential reaction of N3 radicals with 
either amino acid has potential to subsequently render partial or complete 
inhibition in their biochemical pathways. This could result in an overall disruption 
of the cell homeostasis, possibly inducing a series of unwanted side effects, 
compromising cell viability. 
 
In this Chapter the reactivity of N3 radicals generated from the photo-activation 
of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (complex 40) towards various amino 
acids was investigated using various spectroscopic techniques including UV-
visible, EPR, 1H and 14N NMR spectroscopy. The reactivity of N3 radicals 
towards L-Trp led to a further investigation of their activity in A2780 ovarian 
cancer cells. Additionally, the reactive nature of N3 radicals generated from 
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trans,trans,trans-[Pt(N3)2(OH)(N-MI)(py)2] (complex 58, Figure 4.1) was also 
briefly investigated.  
 
4.2 Experimental  
Below are the experimental sample preparation and instrumentation set up specific 
to this Chapter. More details regarding instrumentation and the irradiation setup 
are described in Chapter II. 
 
*Note  
Unless otherwise stated all experiments were undertaken in deuterated phosphate 
buffered saline solution (PBS/D2O) at pH* 7.4. Deuterated solvent was selected to 
allow comparison between the various spectroscopic techniques used. The effect 
of D2O on the system was previously discussed in Chapter III. It was shown not 
to affect the photo-activation pathway of complex 40 but rather prolong the 
lifetime of the generated free radical in solution in comparison to protiated 
solvent. A similar effect to has been observed for 1O2 generated in D2O.
15  
 
4.2.1 Materials 
Complex 40 was synthesised and characterised as previously described in 
Chapter II. Trans,trans,trans-[Pt(N3)2(OH)(N-MI)(py)2] (complex 58, Figure 
4.1) was provided by Dr. Evyenia Shaili and was synthesised and characterised as 
previously described.16 L-tryptophan was purchased from Sigma Aldrich. L-
tyrosine was purchased from Acros Organics and glycine from BDH Ltd. A2780 
human ovarian carcinoma cells were obtained from the European Collection of 
Animal Cell Cultures (Porton Down, UK) and grown as 6 monolayers in RPMI-
1640 containing 10 % (v/v) foetal calf serum.  
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4.2.2 Sample preparation  
All solutions were freshly prepared prior to performing experiments.  
 
4.2.2.1 UV-visible spectroscopy  
The concentration of complex 40 was kept constant at 50 µM while varying the 
mol equiv. of the added amino acids, Gly, L-Tyr and L-Trp were prepared in 
PBS/D2O at pH* 7.4.  
 
4.2.2.2 Electron Paramagnetic Resonance (EPR) spectroscopy 
Solutions were prepared containing complex 40 (4 mM), DMPO (8 mM) in 
addition to amino acid (Gly, L-Tyr and L-Trp) present at a final concentration of 
either 0.5 mM or 1 mM prepared in PBS/D2O at pH* 7.4.  
 
4.2.2.3 Nuclear Magnetic Resonance Spectroscopy 
 1H NMR 
Complex 40 (4 mM), DMPO (8 mM) in both the absence and presence of L-Trp 
(2 mol equiv) were prepared in PBS/D2O at pH* 7.4. Dark stability was monitored 
at 0 h and 24 h time intervals.  
 
 14N NMR 
The 14N NMR resonance of L-Trp was monitored by preparing a solution of L-Trp 
(18 mM) in PBS/D2O at pH* 7.4. Additional solutions containing complex 40 (9 
mM) in both the absence and presence of L-Trp (2 mol equiv) were prepared in 
PBS/D2O at pH* 7.4. All 
14N NMR spectra were externally referenced to 14NH4Cl 
(1.5 M) in 1 M HCl (δ = 0).  
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4.2.3 Cell studies  
All biological experiments were carried out by Dr. Julie Woods (Photobiology 
Unit, Ninewells Hospital, Dundee UK). 
 
4.2.3.1 A2780 ovarian cancer cells 
Cell irradiations were performed with 420 nm (5 J cm-2) irradiation source, as 
described in Chapter II.  
 
4.2.3.2 Photo-toxicity 
A2780 cells were seeded at a density of 6-7 x 104 cells cm-2 in 96 well plates 24 h 
before the initiation of the experiment. The neutral red photo-toxicity test was 
performed as previously described.1 Cell viability was measured using the uptake 
of neutral red dye as an end point 24 h later. 
 
4.2.3.3 Data analysis  
Goodness-of-fit of dose response curves were determined from R2 values and the 
95% confidence interval of the IC50 value. The IC50 value was defined as the 
concentration of test compound required to inhibit dye uptake by the cells by 50% 
(Graph pad Prism v5). Exposures were performed in triplicate and experiments 
were repeated at least twice, as stated in the figure legends. 
 
4.3 Results 
4.3.1 UV-visible spectroscopy - Glycine 
Prior to irradiating in the presence of functionalised amino acids, the amino acid 
glycine (Gly, Figure 4.2) was studied. Glycine, the simplest amino acid, possesses 
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both amino and carboxylate groups, present in all amino acids. It was chosen to 
investigate a possible interaction between photo-activated complex 40 with Gly, 
either through formation of a PtII-Gly species or a reaction with the formed N3 
radicals with either the carboxylate or amino group (or both). Establishing an 
interaction between photo-activated complex 40 and Gly has potential to suggest 
photo-activated complex 40 would behave similarly towards all amino acids.  
           
Figure 4.2 Structures of amino acids studied in this work at physiological pH. 
 
As shown in Chapter III, the UV-visible spectrum of complex 40 in the dark 
displayed an absorption at 294 nm (Figure 4.3A) assigned as a ligand-to-metal 
charge transfer (N3PtIV, LMCT) transition.1 After 30 min irradiation at 463 nm, 
the decrease of ca. 40% in this LMCT band is attributed to the release of the azide 
ligands (Figure 4.3B). Consequently, the decrease in the intensity of the LMCT 
band was used to monitor the photo-decomposition of the platinum complex.  
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Figure 4.3 Absorption spectrum of complex 40 (50 M) prepared in PBS/D2O at 
pH* 7.4 in the (A) dark; N3→PtIV LMCT band at ca.  294 nm (294nm = 1.35104 
M-1 cm-1) and (B) after 30 min irradiation with 463 nm light,  shows a decrease 
in the LMCT band (294nm = 0.5104 M-1 cm-1).  
 
There is no absorption from Gly over the range shown (Figure 4.4A), as such, 
subsequent mol equiv additions of Gly to a solution of complex 40 (50 M) did 
not affect the absorption of the LMCT band of complex 40, in the dark (Figure 
4.4B). Irradiating complex 40 in both the absence and presence of Gly (0.5 and 4 
mol equiv) for 30 min with 463 nm light led to a decrease of ca. 40% in the 
LMCT band (Figure 4.4C). This equivalent photo-decomposition of complex 40 
in the presence of Gly (up to 4 mol equiv), suggests that Gly does not affect the 
photo-activation of complex 40.  
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Figure 4.4 Absorption spectrum of solutions of (A) glycine (50 M) prepared in 
PBS/D2O at pH* 7.4 in the dark and after 30 min irradiation with 463 nm light; 
and solutions of complex 40 (50 M) in the presence of Gly (0.5 and 4 mol equiv) 
prepared in PBS/D2O at pH* 7.4 in the (B) dark; (C) after 30 min irradiation with 
463 nm,  shows a decrease in the LMCT band.   
 
4.3.1.2 In the presence of aromatic amino acids. 
Next, aromatic amino acids L-Tyr and L-Trp were studied (Figure 4.2). Aromatic 
amino acids have an absorbance in the region of < 300 nm. L-Tyr and L-Trp 
exhibit maximum absorbance’s at ca. 274 nm and 278 nm, respectively, as 
reported by Fasman.17  
 
L-Tyr (50 M) prepared in PBS/D2O at pH* 7.4, was photo-stable exhibiting an 
extinction coefficient of ca. 1.8 104 M-1 cm-1 at ca. 274 nm, both before and after 
irradiation with 463 nm light (Figure 4.5A). Supplementing a solution of complex 
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40 (50 M) with L-Tyr (0.5 and 4 mol equiv) enhanced the absorbance in the dark 
(Figure 4.5B). This increase was attributable to the sum of both complex 40 and 
L-Tyr absorbance’s. Photo-irradiation of solutions containing complex 40 (50 
M) in the presence of L-Tyr (0.5 and 4 mol equiv) with 463 nm light for 30 min, 
led to a decrease of ca. 40% in the LMCT band, comparable to the photo-
decomposition of complex 40 alone (Figure 4.5C). From this result, it is 
reasonable to deduce that L-Tyr does not affect the photo-activation of complex 
40.  
 
Figure 4.5 Absorption spectra of (A) L-Tyr (50 µM) prepared in PBS/D2O at pH* 
7.4 in the dark and after 30 min irradiation with 463 nm light; and solutions 
containing complex 40 (50 M) in the presence of L-Tyr (0.5 and 4 mol equiv) 
prepared in PBS/D2O at pH* 7.4 in the (B) dark and (C) after irradiation at 463 
nm for 30 min,  shows a decrease in the LMCT band.   
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L-Trp exhibits two absorption bands due to both the →* (190 nm) and n→* 
(278 nm)17 transitions (Figure 4.6A). L-Trp was photo-stable towards irradiation 
at 463 nm light, displaying a constant absorption at ca. 278 nm (Figure 4.6A). 
Solutions containing complex 40 (50 M) and L-Trp (various mol equiv) were 
prepared in PBS/D2O at pH* 7.4. As can be seen from Figure 4.6B, successive 
additions of L-Trp led to an increase in the absorbance region of the N3→PtIV 
LMCT band absorption. This increase was attributable to the absorption by L-Trp.            
 
Figure 4.6 Absorption spectra of (A) L-Trp (50 µM) prepared in PBS/D2O at pH* 
7.4 in the dark and after 30 min irradiation with 463 nm light; and solutions 
containing complex 40 (50 M) in the presence of L-Trp (different mol equiv) 
prepared in PBS/D2O at pH* 7.4 in the (B) dark and (C) after irradiation at 463 
nm for 30 min,   shows a decrease in the LMCT band.   
 
                 Chapter IV: Reactivity of azidyl radicals 
 
162 
 
The N3→PtIV LMCT band of complex 40 decreased to a similar extent in both the 
absence and presence of L-Trp, attributable to an equivalent release of the azide 
ligands (Figure 4.6C). As a result, the UV-visible data suggest that photo-
irradiation of complex 40 in the presence of amino acids; Gly, L-Tyr and L-Trp 
proceeds through two one-electron donations from the azide ligands to the PtIV 
metal centre. N3 radicals are reported to undergo one-electron transfer reactions 
with amino acids. This possible interaction was investigated by performing spin 
trapping EPR spectroscopy.  
 
4.3.2 EPR spectroscopy 
The EPR spectrum of complex 40 in the presence of amino acids Gly, L-Tyr and 
L-Trp was recorded and did not produce any EPR signals in the dark (Figure 
A4.1). Therefore, photo-irradiation experiments were performed.  
 
Solutions of complex 40 (4 mM), DMPO (8 mM) were irradiated with 463 nm 
light prepared in PBS/D2O at pH* 7.4 in the presence of 0.5 mM and 1 mM Gly. 
A comparable concentration of the DMPO-N3 spin adduct was formed in both the 
absence and presence of Gly (Figure 4.7A). The quantity and decomposition of 
the DMPO-N3 spin adduct followed a similar trend despite the presence of Gly. 
 
Similarly, continuous irradiation for 28 min of complex 40 with 463 nm light in 
the presence of 0.5 mM and 1 mM L-Tyr did not induce any effect in the trapping 
of the azidyl radicals by DMPO (Figure 4.7B).  
 
                 Chapter IV: Reactivity of azidyl radicals 
 
163 
 
     
Figure 4.7 Quantification of the DMPO-N3 spin adduct formed after 7 min, 14 
min, 21 min and 28 min of irradiation at 463 nm of a solution containing complex 
40 (4 mM) with DMPO (8 mM) in the (), absence and presence of (), 0.5 mM; 
(), 1 mM (A) Gly and (B) L-Tyr prepared in PBS/D2O at pH* 7.4 at 291 K. No 
EPR spectrum was observed in the dark (0 min). Error bars represent the standard 
deviation from three independent experiments. 
 
The DMPO-N3 spin adduct exhibited a concentration maximum of ca. 360 M in 
both the absence and presence of Gly and L-Tyr after 7 min irradiation with 463 
nm light. These results suggest that under these conditions the N3 radicals are 
unreactive to either the carboxylate or the amino group(s) present in these amino 
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acids, which may extend across the range amino acids. Previous literature has 
reported on the inert nature of the N3 radicals towards phenylalanine, alanine and 
valine.18  
 
Irradiation of complex 40 (4 mM) and DMPO (8 mM) at 463 nm generates the 
DMPO-N3 spin adduct, quartet of triplets EPR spectrum (Figure 4.8A), previously 
characterised in Chapter III. However, in presence of 0.5 mM (Figure 4.8B) and 
1 mM (Figure 4.8C) L-Trp, a partial and complete suppression in the DMPO-N3 
spin adduct was observed, respectively.  
 
Interestingly, in the presence of 0.5 mM L-Trp, the DMPO-N3 spin adduct was 
suppressed by ca. 85%, determined after 7 min irradiation. This was reduced to ca. 
70% after 14 min irradiation. The effect of L-Trp on the trapping of the N3 
radicals produced from photo-irradiated complex 40 can be seen quantitatively in 
Figure 4.9.   
 
This result above differed from that observed for the photo-irradiation of complex 
40 in the presence of Gly or L-Tyr. Thus, these EPR data suggested a possible 
interaction of the N3 radicals with L-Trp. To further investigate this potential 
interaction, NMR spectroscopy was performed.  
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Figure 4.8 DMPO-N3 spin adduct EPR spectra formed from the photo-irradiation 
of complex 40 (4 mM) and DMPO (8 mM) in (A) absence; (B) in the presence of 
0.5 mM and (C) 1 mM L-Trp prepared in PBS/D2O at pH* 7.4 at 291 K with 463 
nm light after 7 min.  
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Figure 4.9 Quantification and percentage suppression of the DMPO-N3 spin 
adduct formed after 7 min, 14 min, 21 min and 28 min from irradiation with 463 
nm light of a solution containing complex 40 (4 mM) and DMPO (8 mM) in the 
() absence and presence of () 0.5 mM; () 1 mM L-Trp prepared in PBS/D2O 
at pH* 7.4 at 291 K. No EPR spectra were observed in the dark (0 min) in the 
absence or in the presence of 1 mM L-Trp. Error bars represent the standard 
deviation from three independent experiments.  
 
4.3.3 1H NMR spectroscopy  
4.3.3.1 Absence of L-Trp 
Prior to studying the photo-irradiation of complex 40 with L-Trp, the photo-
irradiation of complex 40 in the presence of the spin trap DMPO was initially 
studied. A solution containing complex 40 (4 mM) and DMPO (8 mM) was 
prepared in PBS/D2O at pH* 7.4. The 
1H NMR spectrum of the diamagnetic spin 
trap DMPO alone displayed four resonances (Figure 4.10), unaffected by 
irradiation with 463 nm light. Additionally, the 1H NMR resonances showed that 
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both complex 40 and DMPO were stable in the dark prior to photo-irradiation 
(Figure 4.11A).  
 
Figure 4.10 1H NMR spectrum of 5,5-dimethyl-1-pyrroline-N-oxide (DMPO, 5 
mM) in PBS/D2O at pH* 7.4 at 298K.  
 
Irradiation of complex 40 (4 mM) and DMPO (8 mM) with 463 nm light for 30 
min led the solution to lighten in colour and generate a yellow coloured precipitate 
(Figure 4.12). The precipitate was removed by centrifugation and filtration, prior 
to recording the 1H NMR spectrum. Bubbles thought to be due to N2 gas, from the 
dimerisation of the N3 radicals were observed, as previously reported.
1 The 
extracted precipitate could not be dissolved in a variety of either polar (water, 
ethanol, methanol) or non-polar (benzene, toluene) solvents.  
 
Photo-irradiation of complex 40 led to ca. 40% reduction in the pyridine proton 
resonances consistent with previous reports1 on the photo-decomposition of 
complex 40. Furthermore, new photo-generated peaks (e-i) were observed after 
30 min irradiation of complex 40 with 463 nm light (Figure 4.11B).  
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Figure 4.11 The aromatic region of the 1H NMR spectra from a solution of 
complex 40 (4 mM) and DMPO (8 mM) prepared in PBS/D2O buffer at pH* 7.4 
in (A) dark and (B) after 30 min irradiation with 463 nm light. Assignments: Pt-py 
peaks, (o/p/m); platinum photoproducts, (e'-i'). Inset (6× magnification) is an 
expansion of the 8.9 – 7.4 ppm region of the formed photo-products. Refer to 
Figure 4.13 for DMPO 1H NMR resonances.  
 
Figure 4.12 Precipitate from the photo-irradiation of complex 40 (4 mM) with 
DMPO (8 mM) with 463 nm light prepared in PBS/D2O at pH* 7.4. Magnified 
(4x) image of precipitate in the included inset.  
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The assignment of photo-generated peaks e-i (Figure 4.11B) was made by 
comparison of the Pt-py resonances of complex 40, PtII-py intermediates 
(intermediate complexes formed during the synthesis of complex 40) and free 
pyridine 1H NMR chemical shifts. It is postulated that the 1H resonances e, f and 
h are in close agreement with those belonging to a PtIV-py based species, 
whereas, g and i resonances are in closer agreement being assigned to the Hp and 
Hm resonances of a Pt
II-py based species, respectively (Table 4.1).  
 
None of the platinum photo-generated peaks (e-i) corresponded to that of free 
pyridine, suggesting all new peaks are likely to arise from coordinated pyridine. 
This is in agreement with previous reports on the photo-stability of the Pt-py 
bond, both before and after irradiation.1 
 
Table 4.4 Assignment of the platinum photo-products (e- i) shown in Figure 
4.11B.  
Photo-products  / ppm 1H Resonance 
e 8.73 HO (Pt
IV-py) 
f 8.25 –b (Pt
IV-py) 
g 8.01 Hp (Pt
II-py)  
h 7.77 –b (Pt
IV-py) 
i 7.56 Hm (Pt
II-py) 
bcomplete peak assignment not feasible.   
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The photo-irradiation of complex 40 (4 mM) in the presence of DMPO (8 mM) 
with 463 nm light was repeated in D2O. Equivalent photo-products (e-i) were 
identified (Figure A4.2), confirming that the presence of the chloride (0.0027 M) 
and phosphate (0.01 M) in the PBS buffer did not affect the photo-activation or 
photo-decomposition of complex 40. This is a similar chloride concentration as in 
the cell nucleus (ca. 4 mM), which suggests that an equivalent photo-
decomposition pathway of complex 40 could occur in cells.   
 
As shown in Chapter III (Figure 3.8, p 106), the DMPO-N3 spin adduct decayed 
with prolonged irradiation. The decomposition of spin adducts has been reported 
to proceed via a disproportionation reaction pathway, forming both a nitrone and 
hydroxylamine species (Figure 4.13), with the latter reported to be the main 
decomposition product.19-21  
          
Figure 4.13 Decomposition pathway of the DMPO-N3 spin adduct into either a 
DMPO-N3 (A) nitrone, or (B) hydroxylamine species, both NMR detectable. 
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Therefore, photo-products (a'-d'') formed from the photo-irradiation of complex 
40 (4 mM) with DMPO (8 mM) at 463 nm for 30 min prepared in PBS/D2O at 
pH* 7.4 (Figure 4.14), are believed to be related to the DMPO-N3 hydroxylamine 
species (Figure 4.13B). Assignments of the 1H NMR resonances of the photo-
products a' - d'' are summarised in Table 4.2, and are in close agreement with 
previous 1H NMR studies of a DMPO-SO3 hydroxylamine species.
22   
                
Figure 4.14 The 1H NMR spectra from a solution of complex 40 (4 mM) and 
DMPO (8 mM) prepared in PBS/D2O buffer at pH* 7.4 in (A) dark and (B) after 
irradiation at 463 nm for 30 min. Assignments: DMPO peaks, (a-d); DMPO-N3 
hydroxylamine peaks, (a'- d''). Inset (4) is an expansion of the 2.9 – 1.3 ppm 
region of the formed photo-products. Refer to Figure 4.11 for complex 40 region.  
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Table 4.2 Assignment of the photo-products (a- d) shown in Figure 4.14B to the 
DMPO-N3 hydroxylamine species.   
 / ppm Assignment DMPO-N3 Hydroxylamine 
2.872   C2H (a')  
 
2.406  C3HA (b') 
2.139  C3HB (b'') 
1.952  C4H2 (c') 
1.352  C6H3 (d') 
1.266  C7H3 (d'') 
 
Through 1H NMR integration, it was determined ca. 40% of complex 40 had 
photo-decomposed after 30 min irradiation with 463 nm light (Figure 4.11B), 
whilst the spin trap, DMPO photo-decomposed by ca. 12% (Figure 4.14B). This 
decrease in the 1H NMR resonances of DMPO is attributed to the transformation 
of diamagnetic DMPO into the paramagnetic DMPO-N3 spin adduct. It was 
determined via 1H NMR integration that ca. 0.74 mM of the DMPO-N3 
hydroxylamine species was present in solution. Integrals of both parental and 
photo-products generated in both Figures 4.11 and 4.14 are summarised in Table 
4.3. 
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Table 4.3 Quantification of the species observed in both Figures 4.11 and 4.14 
determined by 1H NMR integration.  
Species  Conc Start / (mM) Conc Afterb / (mM)  
Complex 40 (o/m/p) 4 2.4 
DMPO (a-d) 8 7.0 
Pt-photoproducts (e'-i') -a 0.6 
DMPO-N3 hydroxylamine (a'-d'') -a 0.7 
 apeaks not present in the dark; bsolutions irradiated for 30 min with 463 nm light 
and precipitate removed prior to recording the 1H NMR.  
 
4.3.3.2 In the presence of L-Trp 
The photo-stability of L-Trp was previously reported in section 4.3.1, however it 
was further confirmed via 1H NMR spectroscopy (Figure 4.15).  
 
Figure 4.15 1H NMR spectra of L-Trp (8 mM) prepared in PBS/D2O at pH* 7.4 
in (A) the dark and (B) after irradiation at 463 nm for 30 min. Assignments: L-Trp 
peaks, (J-V); internal reference 1,4 dioxane, ().  
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The 1H NMR resonances of complex 40 (4 mM) with DMPO (2 mol equiv) in the 
dark remained unchanged in the presence (Figure 4.16A) of L-Trp (2 mol equiv), 
indicating no dark interaction. The overlap between L-Trp (HK) and the DMPO 
spin trap (Ha) slightly obscured their 1H resonances (, Figure 4.16A). Irradiation 
of complex 40 (4 mM) with DMPO (8 mM) in the presence of L-Trp (2 mol 
equiv, 8 mM) at 463 nm led the solution to lighten in colour and generate a 
yellow-brown dark coloured precipitate (Figure 4.17). The precipitate was 
removed by centrifugation and filtration prior to recording the 1H NMR spectrum. 
The precipitate was insoluble in a variety of solvents, so solution-phase NMR 
spectroscopy was not feasible. Furthermore, bubbles were observed in the NMR 
tube consistent with previous reports on the radical dimerisation of two N3 
radicals forming N2 gas.
1  
 
Integrating the signals present in Figure 4.16 revealed that ca. 40% of complex 40 
had photo-decomposed after 30 min irradiation with 463 nm light, similar to that 
observed in the absence of L-Trp (Table 4.7). Furthermore, platinum photo-
products (e'-i') were observed in the presence of L-Trp (inset Figure 4.16B). 
Additionally, only in the presence of irradiated complex 40, was a decrease of ca. 
20% in the L-Trp peaks observed. Moreover, the 1H NMR resonances of spin trap 
DMPO remained consistent both before and after irradiation, with no detection of 
new peaks previously assigned to the DMPO-N3 hydroxylamine species. All 
species present in Figure 4.16 were quantified by 1H NMR integration and are 
summarised in Table 4.7.  
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Figure 4.16 1H NMR spectra of a solution of complex 40 (4 mM) and DMPO (8 
mM) in the presence of L-Trp (2 mol equiv, 8 mM) prepared in PBS/D2O buffer at 
pH* 7.4 in the (A) dark and (B) after 30 min irradiation with 463 nm light.  
Assignments: Pt-py peaks, (o/p/m); L-Trp peaks, (J-V); DMPO peaks, (a-d); Pt-
photo-products, (e'-i'); (), overlap of peaks from L-Trp (HK) and DMPO (Ha).  
 
 
Figure 4.17 Precipitate from the photo-irradiation of complex 40 (4 mM) and 
DMPO (8 mM) in the presence of L-Trp (2 mol equiv) with 463 nm light prepared 
in PBS/D2O at pH* 7.4. Magnified (4x) image of precipitate in the included inset.  
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Table 4.7 Quantification of the species observed in Figure 4.16 by 1H NMR 
integration.  
Peaks Assignment Conc Start/ (mM) Conc Afterb /(mM) 
Complex 40 (o/m/p) 4 2.4 
DMPO (a-d) 8 8 
L-Trp (J-V) 8 6.2 
Pt-photoproducts (e'-i') -a 0.6 
apeaks not present in the dark; bsolutions irradiated for 30 min and precipitate 
removed prior to recording the 1H NMR spectrum.  
 
The lack of detection of the 1H NMR resonances related to the DMPO-N3 
hydroxylamine species in the presence of L-Trp, further supports the potential 
reaction between photo-activated complex 40 and L-Trp. As described in section 
4.3.1, the interaction between N3 radicals and L-Trp has been reported to proceed 
via one-electron transfer generating both free azide (N3) and L-Trp
+, the latter 
readily deprotonates to L-Trp at pH 7.9 In an attempt to establish such an 
interaction between N3 radicals generated from photo-activated complex 40 with 
L-Trp, 14N NMR spectroscopy was performed. 
 
4.3.4 Free azide (N3) detection  
Due to the lower sensitivity (receptivity relative to 1H at 100 % = 1.01 10-3) and 
quadrupolar nature23 of the 14N nucleus, 14N NMR spectroscopy was performed at 
higher concentrations (ca. 2.25 fold higher mol equiv). The 14N NMR spectrum of 
L-Trp displayed a peak at 17.1 ppm (Figure 4.18A), assigned to the nitrogen (NH) 
atom present in the indole ring. The additional 14N NMR resonance for the α-
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amino (+NH3) group was not observed in the region shown. This was in agreement 
with previous 14N NMR spectroscopic reports on Gly, Glu (glutamic acid) and 
Arg (arginine) in which the α-amino group (+NH3) 14N NMR resonance was 
reported at ca.  > -300 ppm.24 Irradiation of L-Trp for 30 min with 463 nm light 
did not have any effect on its 14N NMR resonance (Figure 4.18B) consistent with 
its photo-stability.  
       
Figure 4.18 The 14N NMR spectra of L-Trp (18 mM) in PBS/D2O at pH* 7.4 in 
(A) the dark and (B) after 30 min irradiation with 463 nm light. The resonance at 
17.1 ppm is assigned to the amine (NH) group present in L-Trp. This resonance 
remains unchanged after irradiation confirming the photo-stability of L-Trp. The 
amino group present in the side chain of L-Trp is not observed in this range 
(+NH3, δ ~ -300 ppm).24  
 
Dark solutions containing complex 40 (9 mM) both in the presence (Figure 
4.19A) and absence (Figure 4.19B) of L-Trp (2 mol equiv, 18 mM) prepared in 
PBS/D2O at pH* 7.4, exhibited resonances related to the coordinated azide (Nβ 
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and Nγ) and pyridine (N) ligands of complex 40. In the presence of L-Trp, an 
additional resonance was observed at 15.7 ppm and is assigned to the nitrogen 
atom of the indole ring (NH) functional group.  
          
Figure 4.19 Dark 14N NMR spectra of complex 40 (9 mM) in (A) the presence 
and (B) absence of L-Trp (2 mol equiv, 18 mM) prepared in PBS/D2O at pH* 7.4. 
The peak for the terminal nitrogen atom of the coordinated azide (Nγ) is 
overlapped with the pyridine (N) at ca. 168.1 ppm. The appearance of the Nα peak 
of complex 40 (expected at ca. 60 ppm) is dependent on viscosity and temperature 
and is too broad to observe under the conditions used due to a strong 
inhomogeneity in the electric field at Nα.
25 Assignments:  = 288.9 (N2, 
atmospheric nitrogen gas), 227.5 (N, central N of coordinated azide), 15.7 (indole 
NH of L-Trp).  
 
The NH resonance of L-Trp was slightly upfield-shifted in the presence of 
complex 40 and is attributed to a weak interaction with the platinum(IV) diazido 
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complex. Irradiation of complex 40 (9 mM) in the presence of L-Trp (2 mol equiv, 
18 mM) with 463 nm light for 30 min resulted in the formation of a new peak 
(N) at 77.3 ppm (Figure 4.20A) assigned as the central nitrogen of free azide.  
     
Figure 4.20 14N NMR spectra of complex 40 (9 mM) irradiated at 463 nm for 30 
min in the (A) presence and (B) absence of L-Trp (2 mol equiv, 18 mM) prepared 
in PBS/D2O at pH* 7.4. The new 
14N NMR resonance at 77.3 ppm (N) is 
assigned to the central N of free azide. Overlap between the terminal nitrogen of 
N3 (N, δ = 228.2) with the central nitrogen of coordinated azide (Nβ, 228.7). 
Assignments:  = 288.9 (N2), 77.3 (N central nitrogen of N3) and as labelled in 
Figure 4.19.  
 
The overlap between the resonances for the terminal (N) nitrogen of free azide 
(˗N3) with the central nitrogen of coordinated azide, meant this peak alone was not 
indicative of the formation of free azide (˗N3). Comparison of the spectra in 
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Figures 4.19 and 4.20, observed a decrease in the 14N NMR resonances of both 
complex 40 and L-Trp. The NH resonance of L-Trp at ca. 15.7 ppm decreased in 
its intensity by ca. two-fold, only in the presence of irradiated complex 40. This 
decrease and the subsequent detection of N3ˉ supports the postulated one-electron 
transfer reaction between the N3 radicals generated from photo-irradiated 
complex 40 with L-Trp. N3
 is generally considered to be a species with toxicity 
comparable to that of cyanide.26 Therefore, photo-irradiation of complex 40 in the 
presence of L-Trp was thought to enhance the photo-cytotoxicity profile of 
complex 40. To examine this hypothesis, photo-irradiation studies in A2780 
ovarian cancer cells were undertaken.   
 
4.3.5 Cell studies 
4.3.5.1 Photo-irradiation in A2780 ovarian cancer cells  
Cell studies performed by Dr. Julie Woods showed that neither complex 40 alone 
nor complex 40 in the presence of L-Trp exhibited any effects on the cell growth 
in the dark under the experimental conditions used (, Figure 4.21). Similarly, 
blue light ( = 420 nm, 5 J cm-2) did not produce any observable effects towards 
A2780 ovarian cancer cells (cell viability of 115.7 ± 9.4%). However, it can be 
seen that co-incubation of complex 40 (42.5 M) in variable concentrations of L-
Trp (0 - 2 mM), reduced cell death following irradiation at 420 nm (, Figure 
4.21). This photo-protective effect enhanced with successive addition of L-Trp 
(62.5 µM – 500 µM). However, the extent of photo-protection appeared to reach a 
plateau at ca. 85%, in the presence of L-Trp (0.5 -2 mM).  
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Figure 4.21 Ability of photo-activated complex 40 (42.4 µM, n = 3 independent 
experiments) to reduce the cell viability in A2780 ovarian cancer cells in the 
presence of L-Trp (varied concentrations) in the () dark and () after irradiation 
at max = 420 nm (5 J cm-2). NC: negative control (no L-Trp or complex 40). Data 
represent means ± standard errors of the mean for three independent experiments 
performed in triplicate.  
 
Co-incubation of 0.5 mM L-Trp with a variable concentration of complex 40 (0-
105 M) reduced cell death (Figure 4.22), leading to a protection factor of ca. 7 
based on IC50 values (Table 4.8).  
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Figure 4.22 Ability of photo-activated complex 40 (varied concentration) to 
reduce the viability of A2780 human ovarian cancer cells () in the absence and 
() presence of 0.5 mM L-Trp at 420 nm (5 J cm−2). Data represent means ± 
standard errors of the mean for three independent experiments performed in 
triplicate.  
 
Table 4.8 Ability of photo-activated complex 40 to reduce the viability of A2780 
ovarian cancer cells in both the absence and presence of L-Trp (0.5 mM).  
 
Treatment IC50 /(M)a 95% interval /(M) Confidence R2 
No L-Trp 8.3 3.4-20.4 0.85 
+ 0.5 mM L-Trp 59.4 34.7-101.8 0.86 
 aIC50 = concentration of complex 40 that inhibited uptake of the neutral red dye 
by 50%. Data represent the mean of three independent experiments.  
 
Furthermore, the implication of this photo-protective effect was examined 
morphologically on A2780 ovarian cancer cells by Dr. Julie Woods using the 
neutral red uptake dye. The assay is based on the principle that it is absorbed only 
by viable cells.27 Interestingly, irradiation of complex 40 (42.4 M) in the 
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presence of 0.5 mM L-Trp at 420 nm led to the neutral red dye being taken up by 
the cells 24 h after exposure, indicating viability (Figure 4.23A), whereas few 
viable cells could be seen in the absence of L-Trp (Figure 4.23B). Surprisingly, 
photo-activation of complex 40 in the presence of L-Trp led to a photo-protective 
effect in A2780 ovarian cancer cells. Despite earlier spectroscopic methods 
detecting N3, its formation appeared not to induce a cytotoxic effect in A2780 
ovarian cancer cells. 
      
Figure 4.23 Microscopy image of both (A) viable and (B) non-viable A2780 
ovarian cancer cells. Images were obtained from A2780 cells treated with 
complex 40 (42.4 μM) in the (A) presence; (B) absence of 0.5 mM L-Trp 24 h 
after irradiation at 420 nm. The clearly visible intracellular red staining in the left-
hand image is neutral red dye (Leica DMIL microscope, 200 magnification).  
 
This photo-protection is postulated to be induced by the quenching of the N3 
radicals by L-Trp, but could also be due to a reduced Pt uptake of complex 40. 
Therefore, ICP-MS was performed to determine the amount of platinum 
accumulation from complex 40 in both the absence and presence of L-Trp.  
 
 
 
                 Chapter IV: Reactivity of azidyl radicals 
 
184 
 
4.3.5.2 Platinum accumulation in A2780 ovarian cancer cells  
Dark and irradiated cell samples containing complex 40 (42.4 µM) in the absence 
and presence of L-Trp in A2780 ovarian cancer cells were provided by Dr. Julie 
Woods. These cell samples for ICP-MS were prepared as described in Chapter II 
for the detection of 195Pt metal. As can be seen from Figure 4.24, in both the dark 
and irradiated samples, the accumulation of Pt from complex 40 was equivalent in 
both the (A) absence and (B) presence of 0.5 mM L-Trp.  
 
           
Figure 4.24 ICP-MS of platinum accumulation in A2780 ovarian cancer cells 
treated with complex 40 (42.4 µM) in the absence (purple bars) and presence 
(green colour) of L-Trp (0.5 mM) in A2780 ovarian cancer cells. Accumulation 
was determined for cell samples in the dark (A and C) and after irradiation (B and 
D) at 420 nm. Error bars represent ± standard error of the mean for two 
independent experiments performed in duplicate.  
 
This confirms that the photo-protective effect of complex 40 in the presence of L-
Trp is not due to a reduced uptake of complex 40 in the presence of L-Trp, 
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suggesting the photo-protective effect is due to the quenching process of the N3 
radicals by L-Trp.  
 
4.3.6 Azidyl radical quenching for a related PtIV diazido complex 
As shown in Chapter III, the trapping of the N3 radicals was not limited to 
photo-irradiated complex 40 but extended across a range of platinum(IV) diazido 
complexes (Figure 4.1). Interestingly, photo-irradiation of trans,trans,trans-
[Pt(N3)2(OH)(N-MI)(py)2] (58, N-MI = methylisatoate 2 mM, Figure 4.1) in the 
presence of DMPO (4 mM) with 517 nm light generated the lowest yield of the 
DMPO-N3 spin adduct compared to complexes 56 and 57 (Figure 4.1). This 
reduction in the DMPO-N3 was suggested to be due to the presence of the 
methylisatoate (N-MI) ligand. Azidyl radicals have been reported to be reactive 
towards N-methylindole and various olefins,8 suggesting potential reactivity with 
the N-MI ligand. The quenching ability of N-MI ligand towards the N3 radicals 
was investigated through the photo-irradiation of complex 40 (2 mM, 75% DMF/ 
25% H2O), DMPO (2 mol equiv) in the presence and absence of N-MI (1 and 2 
mol equiv) with 463 nm light for 35 min. No DMPO-N3 spin adduct was formed 
in the presence of N-MI (Figure 4.25), confirming its ability to quench the formed 
N3 radicals.  
 
The photolysis of N-methylisatoate has been previously reported to undergo 
photo-chemical decarboxylation leading to formation of aniline via hydrogen 
atom abstraction from the solvent.28 Recent studies have determined a lower 
photo-cytotoxic activity of complex 58 (Figure 4.1) in A2780 ovarian cancer cells. 
This was attributed the quenching of the N3 radicals by N-MI.
16 This further 
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supports the hypothesis that the photo-cytotoxic nature of platinum(IV) diazido 
complexes involves a radical-based mechanism.  
 
Figure 4.25 Quantification of the DMPO-N3 spin adduct generated from the 
photo-irradiation of complex 40 (2 mM) in the absence () and presence 1 mol 
equiv (); 2 mol equiv () N-methylisatoate (N-MI) with 463 nm light for 35 min 
prepared in 75% DMF/ 25% H2O.  
 
4.4 Discussion 
4.4.1 Reactivity of the azidyl radicals  
The unreactive nature of the N3 radicals generated by pulse radiolysis towards 
aliphatic amino acids has been previously reported.18 Therefore, in this work, the 
equivalent formation of the DMPO-N3 spin adduct in both the absence and 
presence of Gly was an expected result. In contrast, previous studies have reported 
on the oxidation of L-Tyr by N3 radicals generated by pulse radiolysis,
4,10,18 
where the rate of reaction was dependent on the pH of solution (Figure 4.26). Rate 
constants for pathway A of k1 = 1.0 × 10
8 M-1 s-1 and pathway B of k2 = 3.6  109 
M-1 s-1 have been reported for the oxidation of L-Tyr by the N3 radicals, at 
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different pH values (Figure 4.26). The trapping of N3 radicals by DMPO has been 
reported to proceed with a rate constant of ca. k = 1.6 × 109 M-1 s-1.29 In this work, 
a competition for reaction of the N3 radicals with DMPO and L-Tyr is believed to 
exist in solution.  
 
Figure 4.26 Oxidation of L-tyrosine by the N3 radicals formed from pulse 
radiolysis at pH (A) 6.5 and (B) 11.8, where k1 and k2 are the forward and -k1 and 
-k2 are the backward rate constants of each respective reaction. (Figure based on 
ref 15).  
 
In this work, photo-irradiation of complex 40 in the presence of L-Tyr led to an 
increase in pH* from ca. 7.4 to ca. 8.2. Despite this pH* increase, the reaction of 
N3 radicals with L-Tyr is believed to be slower than trapping of N3 radicals by 
DMPO. This rationalises the equivalent formation of the DMPO-N3 spin adduct in 
both the absence and presence of L-Tyr.  
 
4.4.2 In vitro effect of L-Trp on irradiated complex 40 
Photo-irradiation of complex 40 in both the absence of L-Trp led to the 
observation of a yellow coloured precipitate (refer to Figures 4.12). Similar 
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formation of precipitates have been reported by Ronconi30 and Mackay31 from the 
photo-irradiation of platinum(IV) diazido complexes, 36 and 37 (Chapter I). 
Consequently, the formed precipitate in this work, is thought to be multinuclear 
oxygen-bridged PtII species.31 The observation of the platinum photo-products (e'' 
– i'') in both the absence and presence of L-Trp supported an equivalent photo-
decomposition pathway of complex 40 occurred in the presence of L-Trp.  
 
The dark-brown colour of the formed precipitate (refer to Figure 4.17) in the 
presence of L-Trp is attributed to a possible L-Trp polymer-type species. Previous 
literature has reported on the polymerisation of aromatic compounds including, 
pyrroles,32-35 aniline,36 and indoles.37,38 Additionally, numerous spectroscopic and 
theoretical studies have reported on the polymerisation of unsubstituted indoles 
generating poly-indoles through radical cation intermediates.37 Consequently, the 
L-Trp+ radicals formed from the oxidation of L-Trp by the N3 radicals are 
suggested to react with unreacted L-Trp, through an electron transfer pathway, 
leading to the formation of a poly-tryptophan species. Solar et al. reported on the 
bio-molecular reaction of L-Trp+ radicals, providing additional evidence to 
support the formation of L-Trp polymer-type species.9 A decrease in the L-Trp 1H 
NMR resonances supports the potential formation of L-Trp polymer species. 
Moreover, previous literature has reported on the formation of dark coloured 
precipitates attributed to poly-pyrroles.33  This further supports the idea that the 
observed dark brown colour is due to an L-Trp polymer species. Therefore, the 
precipitate formed in the presence of L-Trp, is likely to contain both a 
multinuclear oxygen-bridged PtII species.31 Solution-phase analysis of the 
extracted precipitates was unsuccessful due to their insolubility in a variety of 
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solvents. Irradiation of complex 40 (≤ 100 M) in either the absence or presence 
of L-Trp did not lead to the formation of these precipitates. Additionally, previous 
photo-irradiation studies of complex 40 (15 M) have shown that cell death is 
induced in A2780 ovarian carcinoma cells.1 This suggests that these precipitates 
are not a factor contributing to the photo-cytotoxicity of complex 40 but a direct 
consequent of photo-irradiating platinum(IV) diazido complexes at milli-molar 
(mM) concentrations. 
 
4.4.3 Azidyl radical quenching  
In the absence of L-Trp, photo-irradiation of complex 40 with DMPO led to the 
detection the DMPO-N3 spin adduct and the corresponding DMPO-N3 
hydroxylamine species by EPR and NMR spectroscopy, respectively. Potapenko 
et al. identified a large upfield shift from ca. 7.2 ppm to ca. 4.1 ppm characteristic 
of a break in the N=CH double bond at the C2 position of spin trap, DMPO.22 The 
new 1H NMR resonance, a', at ca. 2.87 ppm (refer to Figure 4.14B) is assigned to 
the Ha' resonance of the DMPO-N3 hydroxylamine species (refer to Figure 
4.14B). Additionally, covalent attachment of the N3 radical leads to the non-
equivalence of the protons at the C3 position of the DMPO-N3 hydroxylamine 
species, generating two 1H NMR resonances at 2.14 ppm (b') and 1.94 ppm (b''). 
The change in the 1H NMR resonance “c” at ca. 2.73 ppm from a triplet to a 
multiplet at ca. 1.94 ppm, further supports the formation of diasterotopic protons 
at C3 in the hydroxylamine DMPO-N3 species. Additionally, the splitting of the 
singlet at 1.38 ppm into two signals  = 1.35 (d') and 1.27 (d'') suggests non-
equivalence of the methyl groups upon the N3 radical covalently bonding to the 
DMPO spin trap. 
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However, in the presence of L-Trp, the partial and complete suppression of the 
DMPO-N3 spin adduct detected by EPR spectroscopy was a primary indicator of 
N3 radical quenching by L-Trp. Moreover, the lack of 
1H NMR resonances 
attributable to the DMPO-N3 hydroxylamine species in the presence of L-Trp, 
further supported the quenching of the N3 radicals. The reactivity between the N3 
radicals with L-Trp was established through the detection of free azide (N3) 
which proceeded through a one-electron transfer process. This observation is in 
agreement with Solar et al., who identified that reaction of N3 radicals with 
indole-related compounds favours a one-electron transfer pathway as opposed to 
an hydrogen atom abstraction pathway.9  
 
The reaction of N3 radicals with L-Trp at neutral pH 7 has been previously 
reported to possess a higher rate constant18 of 4.1 109 M-1 s-1 in comparison to L-
Tyr (1.0 × 108 M-1 s-1 at pH 6.5). This faster rate compared to trapping of N3 
radicals by DMPO (k = 1.6 × 109 M-1 s-1)29 rationalises the reduced formation of 
DMPO-N3 spin adduct in the presence of L-Trp. The majority of N3 radical 
reactions have been reported to occur at L-Trp residues in proteins such as - 
lactoglobulin, pepsin, trypsin and yeast alcohol dehydrogenase (yADH).4,18  
 
The reduction of the DMPO-N3 spin adduct from the irradiation of 
trans,trans,trans-[Pt(N3)2(OH)(N-MI)(py)2] (complex 58, Figure 4.1) at 517 nm 
was established as being due to the photo-release of the equatorial N-
methylisatoate (N-MI) ligand (refer to Figure 4.25). This released equatorial 
ligand has been recently reported to react with the N3 radicals, prior to reaction 
with spin trap, DMPO.16 The nature of this reaction is currently unknown, but is 
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predicted to proceed through an electron transfer pathway at the NH moiety of the 
N-MI ligand. The quenching of the N3 radicals by the N-MI ligand present in 
complex 58, has potential to induce an in-situ photo-protective effect in cellulo.  
 
It should be noted that determining a possible target of the N3 radicals in vitro 
does not necessarily render this the primary biological target of N3 radicals 
generated in vivo. Radicals generated in an intracellular environment are 
surrounded by an array of amino acids, proteins, peptides, lipids, DNA and 
vitamins. Nevertheless, these initial results suggest that indoles and derivatives 
thereof are favourable targets for N3 radicals generated from photo-irradiated 
platinum(IV) diazido complexes. 
 
4.4.4 Photo-protection in A2780 ovarian cancer cells 
4.4.4.1 Free azide 
The presence of L-Trp induced a photo-protective effect in A2780 ovarian cancer 
cells despite the formation of N3. Azide is considered to be a toxic species, 
similar to cyanide which binds to Fe3+ of cytochrome oxidase leading to enzyme 
inhibition26 but also binds to cytochrome bo, a quinol oxidase from Escherichia 
coli.39 Furthermore, numerous publications have reported on azide induced 
poisoning in recent years.40,41 The toxicity of azide has been directly correlated 
with the administered dose. Burger et al.42 reported on the survival of a patient 
who ingested 150 mg of sodium azide, compared to the documented fatalities 
upon ingestion of 0.7 - 2.0 g of sodium azide.43,44 Therefore, in this work it is 
believed the concentration of N3
 formed, is below the toxic level to induce a 
cytotoxic effect.   
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Moreover, detection of N3 suggests the formation of both L-TrpH
+ and Trp  
radicals. Mediated by amino acid radicals, electron transfer (ET) is paramount to a 
myriad of biological processes including enzyme cytochrome c peroxidase, DNA 
photolyase and galactose oxidase.45 L-Trp radicals are involved in both electron 
transfer and catalytic processes.46 L-Trp radicals formed in di-peptides of L-Trp 
and L-Tyr have been reported to undergo a fast intra-molecular process (k = 6  
104 M-1 s-1) either through hydrogen-atom abstraction or electron-transfer resulting 
in the same overall effect.4 Furthermore, increasing the distance between the L-
Trp and L-Tyr residues lowers the intra-molecular rate constant but not its 
efficiency. Electron transfer processes in ribo-nucleotide reductase (RNR) have 
been reported to occur at distances >35Å.47 However, with the driving force of 
these reactions being dependent on the protonation of the L-Trp radical, it is 
important to determine whether the radical is in its cation or neutral form. 
Previous studies have characterised the neutral L-Trp radical,46-49 with only a few 
publications50-52 reporting the detection of the cationic L-Trp radical, compared 
to other spectroscopic techniques capable of detecting both species.10,49,53,54  
 
4.4.4.2 Amino acid radicals 
Recent in vitro studies have shown that trans,trans,trans-[Pt(N3)2(OH)2(NH3)py] 
(complex 38, Figure 4.27) induced autophagy in A2780 ovarian cancer cells.55 
Cell death can be induced either through apoptosis,56 autophagic57 or necrosis58 
pathways. Morphological changes in cancer cells have characterised the induction 
of apoptosis typically through cellular shrinkage, nuclear chromatin condensation 
and nuclear fragmentation.59 The widely used anticancer agent cis-platin has been 
reported to induce apoptosis.60 Previous cellular studies of photo-activated 
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complex 40 reported on its inability to induce either fragmented or condensed 
nuclei, both commonly associated with apoptosis.1 Additionally, the structural 
similarly between complex 40 and 38, suggests autophagy as a possible cell death 
mechanism of photo-activated complex 40.  
        
Figure 4.27 Photo-activatable complex, trans,trans,trans-Pt(N3)2(OH)2(NH3)py] 
shown to induce autophagy in A2780 ovarian cancer cells.55  
 
In contrast, cell death by autophagy is typically determined by increased cellular 
levels of various autophagic proteins including a protein light chain 3 (LC3-II), 
p62 and beclin-1 (Bec-1).57 Decreased expression levels of Bec-1 have been 
reported in ovarian cancers.61 Consequently, LC3-II is typically used for 
establishing the induction of the autophagic pathway in ovarian cancers. The 
formation of LC3-II has been previously reported. Briefly, essential for 
autophagy, is the cleavage of the microtubule-associate protein (MAP) light chain 
3 (LC3) by a cysteine protease (Atg4) generating cytosolic LC3-I, which is then 
converted to LC3-II by Atg7.62 The structure of LC3-I determined by Kouno et al. 
was reported to be composed of four α-helices and a central β-sheet, where three 
histidine and four tyrosine residues were identified in the H1 helix of LC3-I.63  
 
The photo-protective effect observed in this work is proposed to be due to the 
quenching of the N3 radicals by L-Trp, in turn leading to the formation of free 
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azide and the L-Trp radical. This formed L-Trp radical has potential to undergo 
an inter-molecular process with one of four tyrosine residues present in LC3-I, 
postulated to be through an electron transfer process due to the packing of the L-
Tyr resides in LC3-I.63 Consequently, this is envisaged to disrupt the conversion 
of LC3-1 to LC3-II effectively inhibiting the process of autophagy and inducing a 
photo-protective effect. In the absence of L-Trp, cell death was observed. 
Interestingly, ovarian cancer cells are reported to have depleted levels of L-
Trp.64,65 Consequently, treatment of cancers with depleted serum levels of L-Trp 
have the potential to enhance the photo-cytotoxicity of complex 40. Moreover, the 
extent of the photo-cytotoxicity of complex 40 has potential to be controlled in the 
presence of L-Trp.  
 
4.5 Conclusion 
In this Chapter, the reactivity of azidyl radicals (N3) generated from the photo-
irradiation of complex 40 towards a variety of amino acids was studied. The N3 
radicals were unreactive towards glycine. This was consistent with earlier studies 
on the unreactive nature of N3 radicals, generated by pulse radiolysis, towards 
aliphatic amino acids.18 Previous literature has reported on the pH dependent 
oxidation of L-tyrosine by the N3 radicals, which is favoured at more alkaline pH. 
Interestingly, in this work N3 radicals were unreactive towards L-tyrosine. This 
was attributed to a slower rate of N3 radical reactivity with L-tyrosine, compared 
to that of spin trap, DMPO. In the presence of L-tryptophan the trapping of the N3 
radicals by DMPO suppressed. The extent of N3 radical quenching was enhanced 
with successive addition of L- tryptophan (0.5 – 1 mM).  
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1H NMR spectroscopy in the absence of L- tryptophan identified various platinum 
photo-products and 1H NMR resonances assigned to the DMPO-N3 
hydroxylamine species, a photo-decomposition species of the paramagnetic 
DMPO-N3 spin adduct. Equivalent platinum photo-products were observed from 
the photo-irradiation of complex 40 in the presence of L-tryptophan. However, the 
1H NMR resonances related to the DMPO-N3 hydroxylamine species were not 
detected. This was in agreement with EPR spectroscopic data on the suppression 
of the DMPO-N3 spin adduct. Through the use of 
14N NMR spectroscopy, this 
quenching process was attributed to the oxidation of L-Trp tryptophan by the N3 
radicals through a one-electron transfer pathway, generating free azide (N3) and 
L-Trp (undetected). Free azide was not observed from the photo-irradiation of 
complex 40 alone, this further supported the one-electron transfer process.  
  
The known cytotoxic nature of N3 suggested that an increase in the photo-
cytotoxicity of complex 40 in the presence of L-tryptophan would be observed. 
However, a photo-protective effect was established from the photo-irradiation of 
complex 40 in the presence of L- tryptophan. Consequently, the formation of N3
 
appears to be below the concentration level required to induce a cytotoxic effect. 
Detection of N3
 from the one-electron transfer between the N3 radicals with L-
tryptophan, also suggested the formation of the L-Trp (undetected). The 
formation of the L-Trp radical has potential to interact with the autophagic 
protein, LC3-I through an electron-transfer process, at one of the L-tyrosine 
residues present in the H1 α-helix of LC3-I. Consequently, this could augment the 
suggested autophagic pathway of photo-activated complex 40. These data suggest 
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that the photo-toxicity induced by complex 40 involves both acute (radical) and 
chronic (DNA platination) based mechanisms.  
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The objective of this work was to establish the effect of melatonin on the photo-
irradiation of a platinum(IV) diazido anticancer complex. Melatonin is a metabolite 
from the biodegradation of the amino acid, L-tryptophan (L-Trp). In Chapter IV, 
the azidyl radical was quenched by L-Trp through a one-electron transfer pathway. 
Melatonin possesses a methoxy group on the indole ring. It was interesting to 
investigate whether this functional group would alter the photochemistry of photo-
irradiated complex 40.  
 
5.1 Introduction 
Oxygen is essential for most aerobic living organisms. As mentioned in Chapter I, 
through oxidative stress, numerous reactive oxygen species (ROS) including singlet 
oxygen (1O2), the superoxide (O2
-) and the hydroxyl (OH) radicals have been 
reported to be generated.1 ROS are known to interact with cell membranes, proteins, 
lipids and DNA inducing a cascade of unwanted side effects.2,3 The OH radical 
with a high reduction potential (E = 2.31 V)4 is regarded as the most aggressive 
reactive oxygen-based radical, reacting immediately upon formation with nearby 
target molecules5 due to its maximum diffusion radius of ca. 3 Å.6 Various aerobic 
redox processes generate both hydrogen peroxide (H2O2) and the superoxide (O2
-) 
radical.7 Interestingly, the Fenton reaction, simplified in Equation 5.1 has been 
involved in the in vivo generation of OH radicals,8 but its formation can also 
involve highly active copper(II) and iron(II) species.9 Lloyd et al. confirmed using 
17-labelled hydrogen peroxide and molecular oxygen that the OH radicals were 
generated from the hydrogen peroxide and did not exchange with the oxygen in the 
aqueous solvent.10  
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Due to the short lifetime (ca. 10-9 s) of OH radicals, direct detection is not feasible. 
Therefore, the detection of OH radicals has been primarily achieved through the 
use of EPR spin trapping.11-14 The most widely used spin trap, DMPO has been 
reported to trap the OH radical and generate a quartet EPR spectrum (Figure 5.1), 
indicative on the formation of the DMPO-OH spin adduct.15  
                   
Figure 5.1 EPR spectrum (from ref 11) from the trapping of the hydroxyl (OH) 
radical with spin trap, DMPO and (B) molecular structure of DMPO-OH spin 
adduct giving rise to the quartet EPR spectrum. 
 
However, this quartet EPR spectrum has potential to be generated from the 
decomposition of DMPO-OOH spin adduct.16 Therefore, the addition of OH 
radical quenchers, such as dimethyl-sulfoxide (DMSO)17 or ethanol,18 have been 
used to confirm OH radical generation. Reaction of the OH radicals with DMSO 
and EtOH generate methyl and α-hydroxyl-ethyl radicals, respectively (Figure 5.2). 
These carbon-centred radicals subsequently trapped by DMPO give rise to unique 
EPR spectra.  
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Figure 5.2 Reaction pathway of the hydroxyl (OH) radical with (A) DMSO or (B) 
ethanol. Both lead to unique DMPO-R spin adducts (figure adapted from ref 17 and 
18).  
 
Melatonin, N-acetyl-5-methoxytryptamine (Figure 5.3), is a hormone commonly 
found in plants and animals. In mammals, it is synthesised in the pineal gland.  
             
Figure 5.3 Structure of N-acetyl-5-methoxytryptamine (melatonin, MLT) at pH 7.4 
together with pKa values.
19 
 
A simplified stepwise formation of melatonin is depicted in Figure 5.4. Melatonin 
is synthesised from serotonin through two enzymatic processes, described in more 
detail by Cardinali et al.20  
                                   Chapter V: Photo-irradiation in the presence of melatonin 
 
205 
 
 
Figure 5.4 Stepwise synthesis of melatonin originating from the amino acid L-
tryptophan involving two enzymes serotonin N-acetyltransferase (SNAT) and 
hydroxylindole-O-methyl-transferase (HIOMT) (figure adapted from ref 20).  
 
Regarded as an important biological compound, melatonin is involved in a series of 
membrane-bound receptor-mediated processes including the regulation of retinal 
function, circadian rhythms and reproduction cycles.21,22 In 2003, it was approved 
as a dietary supplement by the FDA23 and is commonly used for the treatment of 
insomnia20 and jet lag.24 The intracellular concentration of melatonin has been 
reported to be dependent on the tissue/organ.25 The plasma concentration of 
melatonin has been reported to be in the nanomolar (nM) range.26 Melatonin has 
many functions,27 it is well known for its anti-oxidant properties in reducing both 
oxidative cellular and molecular damage.28 Over the last two decades, the ability of 
melatonin to scavenge the most reactive oxygen radical, the hydroxyl (OH) radical, 
has been the subject of numerous reports.29-31  
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Tan et al. attributed the reduction in the DMPO-OH spin adduct to the quenching 
of the OH radicals by melatonin.32 Ebelt et al. reported on the dose-dependent 
scavenging ability of melatonin towards the OH radicals, determined through the 
use of the phosphorus-based spin trap, DEPMPO (Figure 5.5).33 The electron-rich 
indoleamine ring present in melatonin functions as an electron-donating group.      
 
          
Figure 5.5 Structure of spin trap, 5-(Diethoxyphosphoryl)-5-methyl-1-pyrroline-N-
oxide (DEPMPO).  
 
This quenching ability of melatonin has been reported to proceed through a one-
electron oxidation pathway generating a melatoninyl cation radical (MLT+) and a 
hydroxide ion (OH).22 Numerous spectroscopic data have indirectly confirmed the 
formation of the MLT+ radical,30,31,34 whereas to date no direct EPR data have been 
reported (A, Figure 5.6). Similar to L-Trp+ at neutral pH,35 the MLT+ radical cation 
has been reported to undergo rapid deprotonation generating a neutral MLT radical 
species and H2O (B, Figure 5.6).
36 Moreover, the addition of the OH radicals to the 
indole ring present in melatonin has also been reported.37 Furthermore, a novel 
metabolite, 3-hydroxy-melatonin, was reported by Tan et al. from the interaction of 
the OH radicals with melatonin.38 Consequently, from these previous reports it 
appears the metabolites from the interaction of the OH radicals with melatonin are 
dependent on the reaction conditions.  
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Figure 5.6 Scavenging ability of melatonin (MLT) towards the hydroxyl (OH) 
radical generating both a melatoninyl (MLT+) cation and a neutral melatonyl 
(MLT) radical species.  
 
Various other studies have reported on the quenching ability of MLT towards the 
alkoxyl (RO) and hydroxyl (OH) radicals using pulse radiolysis and flash 
photolysis techniques.39-41 Interestingly, melatonin inhibited oxidative damage 
induced by 5-aminolevulinic acid (ALA) in male hamster Harderian glands.42 ALA 
is a metabolic precursor of the photosensitiser, protoporhyrin(IX). Irradiation at the 
appropriate wavelength induces a cytotoxic effect due to singlet oxygen (1O2) 
formation43 via a PDT based mechanism44 (Chapter I). Interestingly, melatonin 
does not exhibit a quenching ability towards the superoxide (O2
-) radical.45 
 
Melatonin also exhibits a scavenging ability towards reactive nitrogen species 
(RNS) such as nitric oxide (NO)46, peroxynitrite anion (ONOO¯)47 and azidyl (N3) 
radicals. Roberts et al. reported on the reaction between the azidyl radicals (N3) 
and melatonin possessing a second order rate constant (k = 0.98 1010 M-1 s-1)37 
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slightly faster to that of N3 reaction with L-Trp (k = 0.41 1010 M-1 s-1)35 and other 
indole derivatives.48,49 Oxidation of melatonin by the N3 radicals has been 
postulated to proceed through a similar reaction pathway to that of N3 radical 
reaction with L-Trp.37   
 
Melatonin also possesses anti-tumour activity in various types of cancers.50 Certain 
cancers, such as breast cancer, are more sensitive towards low (nM) concentrations 
of melatonin,51 whereas colon cancer is responsive towards high (mM) 
concentrations of melatonin.52 Similarly, a ca. 12% decrease in the cell viability was 
observed in Chinese ovarian (CHO) cells treated with melatonin (2-3 mM), 
although lower concentrations (μM) did not induce a cytotoxic effect.53 The 
efficiency of various chemotherapeutic agents is enhanced upon administration 
with melatonin both in vitro54,55 and in vivo.56 To date no serious side-effects have 
been reported from patients treated with melatonin,57,58 compared to other 
chemotherapeutics.59 Melatonin was shown to induce its anti-tumour activity in 
colorectal cancer cells through both apoptosis and autophagy,60 programmed cell 
death pathways mediated by various melatonin receptors.61  
 
In addition to its antioxidant properties, through absorptive stripping voltammetry 
an electrochemical technique, melatonin has been shown to form complexes with 
various metal ions including iron(III), zinc(II), sodium(I), calcium(II), lithium(I), 
arsenic(III), aluminium(III), copper(II), nickel(II) and mercury(II).62,63 These 
interactions of melatonin with various metal ions have been reported to be of 
biological importance, either altering or inhibiting the mechanism of action of the 
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metal ion.64 However, neither of these studies identified the metal binding site(s) in 
melatonin.  
 
In this Chapter, photo-irradiation of trans,trans,trans-[Pt(N3)2(OH)2(py)2] 
(complex 40) in the presence of melatonin was investigated. The anti-tumour 
activity of melatonin has potential to enhance the efficiency of platinum(IV) diazido 
chemotherapeutic drugs. However, the antioxidant and metal-binding effects of 
melatonin have the ability to alter the mechanism of action of 40.  
 
5.2 Experimental 
Below are the experimental sample preparation and instrumentation set up specific 
to this Chapter. More details regarding instrumentation and the irradiation setup are 
described in Chapter II. 
 
5.2.1 Materials  
Trans,trans,trans-[Pt(N3)2(OH)2(py)2] (complex 40) was synthesised as described 
in Chapter II. Melatonin (MLT) was purchased from Sigma Aldrich and stored at 
–20 C. Absolute ethanol (HPLC grade) was purchased from Fischer Scientific.  
 
5.2.2 Sample preparation 
5.2.2.1 UV-visible spectroscopy 
Individual deuterated phosphate buffered solutions of melatonin (50, 100 and 200 
µM) were prepared to assess its photo-stability towards irradiation at 463 nm 
(Spectral output, Figure A2.1). Separate solutions of complex 40 (50 µM) in the 
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presence of melatonin (2.5, 6.25, 50, 100 and 200 µM) were prepared in PBS/D2O 
at pH* 7.4.  
 
5.2.2.2 EPR spectroscopy 
Solutions of complex 40 (different concentrations) containing excess spin trap, 
DMPO (2 mol equiv relative to complex 40) were prepared in PBS/D2O at pH* 7.4 
in both the absence and presence of melatonin (different concentrations). 
Additional, spin trapping studies were investigated the both absence and presence 
of ethanol. Finally, solutions of complex 40 (4 mM) with spin trap, DEPMPO (8 
mM, 2 mol equiv) in both the absence and presence of melatonin (0.5 mM) were 
prepared in PBS/D2O were at pH* 7.4.  
 
5.2.2.3 NMR spectroscopy   
 1H NMR 
A solution of melatonin (5 mM) was prepared in PBS/D2O at pH* 7.4 to assess its 
photo-stability. Additional, solutions containing complex 40 (9 mM) with 
melatonin (9 mM, 1 mol equiv) were prepared in PBS/D2O at pH* 7.4.  
 
 13C-DEPT135 NMR  
Solutions containing complex 40 (9 mM) with melatonin (9 mM, 1 mol equiv) were 
prepared in PBS/D2O at pH* 7.4.  
 
 14N NMR 
Similar solutions were prepared for 14N NMR, but at higher concentrations (ca. 6 
mM) due to the lower sensitivity of the 14N nucleus compared to the 1H nucleus 
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(receptivity relative to 1H at 100 % = 1.01 10-3). 1H and 14N NMR spectroscopy 
were performed as described in detail in Chapter II.  
 
 COSY NMR  
[1H, 1H] COSY NMR was recorded on a Bruker DPX-400 MHz (1H, 399.10 MHz) 
spectrometer at room temperature. Spectra were recorded with standard COSY 
NMR cosygpqf pulse program and acquired with 32 transients into 65 k data points 
with a spectral width of 10 ppm. The solution recorded was equivalent to that 
prepared for 1H NMR analysis. The advantage of COSY is that it determines a 
correlation between two and three-bonded coupled protons.  
 
5.2.3 Irradiations 
All irradiations were performed using a blue LED light source ( = 463 nm, 64 mW 
cm-2), spectral output (Figure A2.1) unless otherwise stated. In this Chapter, 
irradiations were performed in both continuous and semi-continuous mode. 
Information regarding continuous mode is detailed in Chapter II. Semi-continuous 
irradiation refers to samples irradiated for a set time period (e.g. 14 min) after which 
the irradiation source is switched off whilst the recording of the EPR spectrum 
remained continuous throughout. EPR parameters and irradiation setup are as 
described in Chapter II.  
 
5.3 Results 
5.3.1 Photo-stability of melatonin  
Melatonin exhibits a broad absorbance extending from ca. 240 to 310 nm, with a 
maximum absorbance at ca. 278 nm (Figure 5.7), attributed to a ππ* transition.65 
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The determined molar absorption coefficient of ca. 5.6 103 M-1.s-1, is in agreement 
with ε values reported by He et al.66 Melatonin (different concentrations) remained 
stable in solution after 30 min irradiation at 463 nm (Figure 5.7). A mass adduct 
with m/z of 233.1285 was detected both before and after irradiation and assigned to 
[melatonin+H]+ (Figure 5.8).  
       
Figure 5.7 UV-visible spectra of solutions of melatonin (50 µM, 100 µM and 200 
µM as labelled) prepared in PBS/D2O at pH* 7.4 in the (solid line) dark and (dashed 
line) after irradiation at 463 nm for 30 min. 
 
  
Figure 5.8 HR-MS of melatonin prepared in H2O solvent irradiated at 463 nm for 
30 min. Mass adduct at m/z of ca. 233.1285 is assigned to [melatonin+H]+, in 
agreement with calculated m/z of 233.1212.  
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Furthermore, the photo-stability of melatonin was also monitored by 1H NMR 
spectroscopy. The 1H NMR spectrum of melatonin (5 mM) prepared in PBS/D2O 
remained unchanged after irradiation at 463 nm light for 30 min. The photo-stability 
of melatonin rendered it a suitable molecule for studying its effect on the photo-
activation of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (40).  
 
             
Figure 5.9 1H NMR spectra showing photo-stability of melatonin (5 mM) prepared 
in PBS/D2O at pH* 7.4 in (A) the dark and (B) after irradiation at 463 nm for 30 
min. Where  refers to the resonance from the internal reference, 1,4-dioxane.  
 
5.3.2 Irradiation of complex 40 in the presence of melatonin  
Solutions of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (40, 50 µM) in the absence and 
presence of melatonin (different concentrations) were prepared in PBS/D2O at pH* 
7.4. In the absence of melatonin, the N3→PtIV LMCT band at 294 nm, photo-
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decomposed by ca. 40% after irradiation at 463 nm for 30 min (Figure 5.10A). 
Solutions containing complex 40 (50 µM) and melatonin (≥ 50 µM) prepared in 
PBS/D2O at pH* 7.4, were dominated by the absorbance from melatonin at ca. 278 
nm, in the dark. This absorption at ca. 278 nm masked the N3→PtIV LMCT band 
from complex 40 at ca. 294 nm. Therefore, to observe the LMCT band in solutions 
containing complex 40 and melatonin (≥ 50 µM), the absorbance of melatonin over 
the range of 240 – 410 nm was subtracted. It was determined that an equivalent 
photo-decomposition of ca. 40% in the N3→PtIV LMCT band occurred (B-F, Figure 
5.10).  
 
The formation of an isosbestic point (a') at ca. 330 nm (inset E40 and F40, Figure 
5.10), was determined to be dependent on the dose of melatonin. The formation of 
the isosbestic point only in the presence of melatonin suggests an alternative photo-
decomposition pathway of complex 40 occurs in the presence of melatonin. 
 
The equivalent decrease in the N3→PtIV LMCT band despite the presence of 
melatonin, suggested an equivalent release of azide ligand. The structural similarity 
between L-Trp and melatonin, suggests the quenching of the N3 radicals by 
melatonin. Furthermore, previous studies have reported on the oxidation of 
melatonin by the N3 radicals.
37 This quenching mechanism was investigated by 
performing EPR spectroscopy. 
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Figure 5.10 UV-visible spectra of complex 40 (50 µM) in the (–) dark and after (–
) 15 min; and (–) 30 min irradiation at 463 nm in (A) absence and presence of (B) 
2.5 µM; (C) 6.25 µM; (D) 50 µM; (E) 100 µM and (F) 200 µM melatonin (MLT) 
prepared in PBS/D2O at pH* 7.4. A decrease () of ca. 40% in the N3→PtIV LMCT 
band at ca. 294 nm was observed in all spectra (A-G). Insets (E40 and F40) show 
isosbestic point (a') at ca. 330 nm.  
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5.3.3 Radical scavenging ability of melatonin 
Solutions containing complex 40 (4 mM) and DMPO (8 mM) in both the absence 
and presence of melatonin (100 µM, 200 µM and 500 µM) were prepared in 
PBS/D2O at pH* 7.4. No EPR spectroscopic signals were observed in the dark 
(Figure A5.1). In the absence of melatonin, photo-irradiation with 463 nm light for 
7 min led to the quartet of triplets EPR spectrum (Figure 5.11A), previously 
assigned to the DMPO-N3 spin adduct (Chapter III). Under similar experimental 
conditions but in the presence of melatonin, either partial (Figure 5.11B and C) or 
complete (Figure 5.11D) suppression in the DMPO-N3 spin adduct was observed, 
dependent on the concentration of melatonin.  
 
         
Figure 5.11 EPR spectra generated from a solution containing complex 40 (4 mM) 
and DMPO (8 mM) in (A) absence and presence of (B) 0.1 mM; (C) 0.2 mM and 
(D) 0.5 mM melatonin (MLT) prepared in PBS/D2O at pH* 7.4 irradiated at 463 
nm for 7 min. 
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Despite the complete suppression in spectrum D (Figure 5.11), prolonged 
irradiation (> 14 min) led to both an increase in the intensity and formation of a 
different EPR signal (Figure 5.12). These generated EPR signals were not in 
agreement with the quartet of triplets DMPO-N3 spin adduct (Figure 5.11A). The 
marked intensity of the red lines (Figure 5.12C-G) suggests possible 
superimposition of two nitrone DMPO spin adducts.  
 
As can be deduced from the line diagrams in Figure 5.12F, it appears the centre 
lines of the DMPO-N3 (R1) spin adduct are overlapped with a quartet EPR spectrum 
from a second DMPO-X (R2, X = secondary radical species generated from 
irradiated complex 40) spin adduct, rationalising the pronounced intensity of the 
red lines. Moreover, from this assignment the black lines are attributed to the 
DMPO-N3 (R1) spin adduct only.  
 
As shown in Chapter III (Figure 3.2, p 86), photo-irradiation of complex 40 has 
potential to lead to the generation of both reactive oxygen and nitrogen species 
(ROS/RNS). Moreover, Ronconi et al. observed that experimental conditions can 
greatly affect both the photo-activation and photo-decomposition of platinum(IV) 
diazido complexes.67 The presence of residual DMPO-N3 (R1) spin adduct 
appeared to obscure the observation of DMPO-X (R2) spin adduct. Harbour et al 
determined the DMPO-N3 spin adduct decays to half its intensity within ca. 2 s after 
the light source is switched off.68 Therefore, in an attempt to observe R2 only, semi-
continuous irradiation mode was used. In this mode, the solution under 
investigation was irradiated for 14 min at 463 nm, after which the light source was 
switched off whilst the EPR spectrum was continuously recorded.  
                                   Chapter V: Photo-irradiation in the presence of melatonin 
 
218 
 
 
Figure 5.12 EPR spectra generated from the photo-irradiation of complex 40 (4 
mM) with DMPO (8 mM) in the presence of melatonin (0.5 mM) prepared in 
PBS/D2O at pH* 7.4 continuously irradiated for (A) 14 min; (B) 21 min; (C) 28 
min; (D) 35 min; (E) 42 min and (F) 49 min at 463 nm. The pronounced intensity 
of the red lines is assigned to the superimposition of both the DMPO-N3 (R1) and 
DMPO-X (R2) spin adducts, deduced from the parallel alignment of the R1 and R2 
line diagrams as shown in spectrum F, where X refers to second radical species.  
 
5.3.3.1 Semi-continuous irradiation  
A solution of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (40, 4 mM) and DMPO (8 mM) 
in the presence of melatonin (0.5 mM) was prepared in PBS/D2O at pH* 7.4 and 
irradiated for 14 min at 463 nm, after which the irradiation source was switched off. 
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Only in the presence of melatonin was a quartet EPR spectrum generated (R2, 
Figure 5.13).  
              
Figure 5.13 EPR spectra generated from (A) a solution of complex 40 (4 mM) and 
DMPO (8 mM) in the presence of melatonin (0.5 mM) irradiated for 14 min at 463 
nm, after which the light source was switched off (semi-continuous irradiation 
mode) prepared in PBS/D2O at pH* 7.4 and (B) a simulation using experimental 
values as depicted in Table 5.1 together with the line diagram of the DMPO-OH 
spin adduct.  
 
Previous studies have attributed the quartet EPR spectrum in the ratio of 1:2:2:1 to 
the trapping of the hydroxyl (OH) radical by DMPO. The experimentally measured 
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hyperfine coupling constants and g-factor of the unknown DMPO-X (R2) spin 
adduct are similar to those previously reported values for the DMPO-OH spin 
adduct (Table 5.1),18 this led R2 to be assigned to the DMPO-OH spin adduct.  
 
Table 5.1 Hyperfine coupling constants and g-factor determined for the DMPO-
OH spin adduct as shown in Figure 5.13 with literature values (in brackets).   
DMPO-OH aNNO / (G) aHβ / (G) g-value 
Experimentala 
Publishedb 
14.96 ± 0.04 
(14.9) 
14.90 ± 0.03 
(14.9) 
2.0133 ± 0.0012 
-c 
adata represent means ± the standard deviation of three independent experiments; 
bfrom ref 20; cnot determined. 
 
However, the formation of a quartet EPR spectrum has also been reported to form 
from the decomposition of the DMPO-OOH spin adduct.15 To confirm the 
formation of the OH radicals, the experiment was repeated with substitution of 
DMPO by spin trap DEPMPO (Figure 5.5). In the absence of melatonin, only the 
DEPMPO-N3 spin adduct (R3, Figure 5.14A) was observed, previously 
characterised in Chapter III. No EPR signal consistent with the trapping of the 
OH radicals by DEPMPO was observed. Rather, a gradual photo-decomposition 
of R3 was observed (Figure 5.14B). 
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Figure 5.14 (A) EPR spectrum of the DEPMPO-N3 spin adduct generated from a 
solution containing complex 40 (4 mM) with DEPMPO (8 mM) in the absence of 
melatonin prepared in PBS/D2O at pH* 7.4 irradiated for 14 min at 463 nm (semi-
continuous irradiation mode) and (B) quantification of DEPMPO-N3 spin adduct 
obtained in semi-continuous irradiation mode over a total of 54 min, where  and 
 refer to irradiation source switched off and on, respectively.  
 
However, in the presence of melatonin (0.5 mM) a new 8-lined EPR spectrum (R4) 
was observed (Figure 5.15). This EPR spectrum possessed hyperfine coupling 
constants (Table 5.2) in agreement with values reported by Paciolla et al. for the 
DEPMPO-OH spin adduct.69 This led to the assignment of R4 as the DEPMPO-OH 
spin adduct.  
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Figure 5.15 EPR spectra generated from (A) a solution containing complex 40 (4 
mM) and DEPMPO (8 mM) in the presence of melatonin (0.5 mM) irradiated for 
14 min at 463 nm (semi-continuous irradiation mode) prepared in PBS/D2O at pH* 
7.4 and (B) simulation using experimental values as depicted in Table 5.3 together 
with the line diagram of the DEPMPO-OH spin adduct.  
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Table 5.3 Hyperfine coupling constants and g-factor determined for the DEPMPO-
OH spin adduct as shown in Figure 5.15 with literature values (in brackets).   
DEPMPO-OH aNNO / (G) aHβ / (G) aP /(G) g-value 
Experimentala 
Publishedb 
13.84 ± 0.03 
(13.98)  
13.68 ± 0.11  
(13.26) 
47.48 ± 0.02 
(47.18) 
2.0209 ± 0.0098  
(-)c 
adata represent means ± the standard deviation of three independent experiments;  
bfrom ref 75; cnot determined.   
 
The minor variations in hyperfine coupling values are attributed to the different 
experimental conditions, as previously discussed in Chapter III (section 3.4.2). 
Frejaville et al reported on the detection of the DEPMPO-OH with hyperfine 
coupling constants of 14.1 G, 13.2 G and 47.3 G for the aNNO, a
H and aP, 
respectively.70 Consequently, it appears hyperfine coupling constants within this 
range and detection of the 8-lined EPR spectrum as shown in Figure 5.15A, can be 
attributed to the DEPMPO-OH spin adduct.  
 
The detection of the DEPMPO-OH spin adduct confirmed the formation of the ●OH 
radicals from irradiated complex 40 in the presence of melatonin. This supported 
that the quartet EPR signal observed (Figure 5.13) was due to the trapping of the 
●OH radicals by DMPO. The detection of the α-hydroxyl-ethyl radical (●EtOH) as 
shown in Figure 5.2 is another method to confirm ●OH radical formation. As 
described in Chapter III, the spin trap 4-POBN is the most efficient spin trap in 
the detection of the α-hydroxyl-ethyl radical.71,72 However, due to a dark reaction 
between 4-POBN with melatonin, this spin trap was unsuitable. Consequently, the 
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detection of the α-hydroxyl-ethyl radical was investigated using the spin trap 
DMPO.  
 
5.3.4 Detection of the α-hydroxyl-ethyl radical 
In the absence of ethanol (EtOH), the red lines (−, Figure 5.16) were quantified to 
ca. 9.7 µM from the photo-irradiation of a solution of complex 40 (4 mM), DMPO 
(8 mM) and melatonin (0.5 mM) at 463 nm. Addition of EtOH (1.2 mM) led to ca. 
a four-fold reduction in the red lines, quantified to ca. 2.1 µM (---, Figure 5.16). 
The black lines in both the absence and presence of ethanol retained their intensity. 
This supports the earlier suggestion that these outer lines belong to DMPO-N3 (R1) 
and do not contribute to the R2 spin adduct.  
               
Figure 5.16 EPR spectra generated from the continuous photo-irradiation of 
complex 40 (4 mM), DMPO (8 mM) and melatonin (0.5 mM) in (−) absence and (-
---) presence of ethanol (1.2 mM) with 463 nm after 35 min prepared in PBS/D2O 
at pH* 7.4 together with line diagrams of R1 and R2. 
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The presence of residual DMPO-N3 (R1) spin adduct appears to prevent the 
observation of the potential DMPO-EtOH (R5) spin adduct. Therefore, semi-
continuous irradiation was used to observe R5. Only upon the addition of ethanol 
(1.2 mM) were new EPR signals observed (−, Figure 5.17A). These new peaks 
exhibited similar hyperfine couplings to those previously reported for the DMPO-
EtOH (R5) spin adduct (Table 5.4).72 Consequently, these new peaks were 
assignable to the DMPO-EtOH spin adduct.  
                       
Figure 5.17 EPR spectra generated from (A) a solution of complex 40 (4 mM), 
DMPO (8 mM) and melatonin (0.5 mM) in the presence of ethanol (1.2 mM) 
irradiated for 14 min at 463 nm (semi-continuous irradiation mode) prepared in 
PBS/D2O at pH* 7.4 and (B) a simulation using experimental values as depicted in 
Table 5.4 together with the line diagram of the DMPO-EtOH spin adduct. Blue 
peaks in A refer to the DMPO-EtOH spin adduct. 
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Table 5.4 Hyperfine coupling constants and g-factor determined for the DMPO-
EtOH spin adduct as shown in Figure 5.17 with literature values (in brackets).   
DMPO-EtOH aNNO  / (G) aHβ  / (G) g-value 
Experimentala 14.24 ± 0.05 22.75 ± 0.06 2.0106 ± 0.0002  
Publishedb (15.8) (22.0) (-)c 
adata represent means ± the standard deviation of three independent experiments;  
bfrom ref 78; c not determined.  
 
As discussed in Chapter III (section 3.4.2), the hyperfine coupling values are 
dependent on the solvent and EPR spectrometer parameter settings.73 Consequently, 
unless recorded under identical experimental conditions, differences between 
experimental and previously reported values are possible.  
 
Ethanol was also added to the DEPMPO system, however no additional EPR signals 
were observed. Previous studies have reported on the trapping of the methanol 
radical formed from the interaction between formed OH radicals and methanol. 
This could suggest the DEPMPO spin trap exhibits a low rate for the α-hydroxy-
ethyl radical.70,74 From this section, five spin adducts shown in Table 5.5, were 
observed. Three of these spin adducts (R2, R4 and R5) are observed only in the 
presence of melatonin. This suggests melatonin contributes to their formation. 
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Table 5.5 Summary of spin adducts detected in this section 
EPR spectra Adduct EPR spectra Adduct 
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5.3.5 Quantification of the DMPO-N3 (R1) spin adduct  
Irradiation of complex 40 (4 mM) and DMPO (8 mM) with 463 nm light for 14 min 
led to ca. 378 µM formation of the DMPO-N3 (R1) spin adduct (Chapter III). In 
the presence of melatonin (0.1 mM) a decrease of ca. 180- and 11-fold in the 
DMPO-N3 (R1) spin adduct after 7 and 14 min continuous irradiation, respectively, 
with 463 nm light was observed. Interestingly, it appears a similar quenching effect 
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on R1 was observed in the presence of 0.2 mM melatonin. Consequently, this 
suggests lower concentrations of melatonin (< 0.5 mM) exhibit similar quenching 
effects on R1. However, increasing to the concentration of melatonin to 0.5 mM led 
to a complete suppression in the R1 spin adduct after 14 min irradiation at 463 nm 
(Table 5.6).  
 
Table 5.6 Quantification of R1 formed from the photo-irradiation of complex 40 (4 
mM), DMPO (8 mM) in the absence and presence of melatonin (varied 
concentration) prepared in PBS/D2O at pH* 7.4 
[Melatonin] / (mM) [R1]a / (µM) [R1]b / (µM) 
No MLT 378.3 ± 0.8  339.3 ± 1.0 
0.1 2.1 ± 0.7 30.1 ± 0.4 
0.2 1.6 ± 0.9 24.3 ± 1.2 
0.5 -c - c 
R1 refers to the DMPO-N3 spin adduct after a7 min; b14 min irradiation at 463 nm 
(64 mW cm-2); data represent means ± the standard error of three independent 
experiments cno spin adduct formation.   
 
Prolonged irradiation (> 21 min) at 463 nm of the solution containing complex 40 
(4 mM), DMPO (8 mM) and melatonin (0.5 mM) prepared in PBS/D2O at pH* 7.4 
led to a successive increase in the EPR signal. The resultant R1 and R2 spin adducts 
were quantified at 7 min intervals up to a total of 54 min continuous irradiation at 
463 nm (Figure 5.19). Suppression of R1 by melatonin appeared to be less potent 
with prolonged irradiation leading to an increase in its concentration. However, the 
level of R1 remained 21-fold lower than the R1 formed in the absence of melatonin. 
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Figure 5.19 Quantification of both the R1 and R2 spin adducts formed from a 
solution containing complex 40 (4 mM), DMPO (8 mM) in the absence () and 
presence ( and ) of melatonin (0.5 mM) continuously irradiated at 463 nm for 
54 min prepared in PBS/D2O at pH* 7.4. In the presence of melatonin no EPR 
spectrum is observed until after 21 min irradiation. Spin adduct concentrations 
determined at 7 min intervals. Refer to Figure 5.18 for structure of R1 and R2.  
 
Hydroxyl (●OH) radicals are regarded as the most aggressive ROS due to their 
ability to induce DNA, protein and lipid damage.75 The formation of ●OH radicals 
has potential to enhance the photo-cytotoxicity of complex 40. Therefore, EPR spin 
trapping of complex 40 in the presence of melatonin was performed under more 
physiologically relevant conditions, to determine ●OH radical formation.  
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5.3.6 Physiological concentrations  
A solution of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (40, 300 M) with DMPO (600 
M) prepared in PBS/D2O at pH* 7.4 was irradiated at 463 nm. In the absence of 
melatonin, R1 (DMPO-N3) was generated at ca. 31.5 M (spectrum A, Figure 5.20). 
A dose dependent suppression in R1 was observed upon addition of melatonin 
(spectra B-D, Figure 5.20).     
 
Figure 5.20 EPR spectra generated from the continuous photo-irradiation of 
complex 40 (300 µM) and DMPO (600 µM) with 463 nm light after 28 min 
prepared in PBS/D2O at pH* 7.4 in (A) absence and presence of (B) 25 µM; (C) 50 
µM; (D) 60 µM melatonin (MLT) together with the line diagrams of both R1 and 
R2. Complete suppression of R1 in the presence of 60 µM melatonin.  
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In the presence of 25 µM and 50 µM melatonin, superimposition of both R1 and 
R2 (DMPO-OH) is apparent due to the pronounced intensity of the red lines (B and 
C, Figure 5.20), as observed previously at millimolar concentrations of complex 40. 
Complete suppression of R1 was observed upon the addition of 60 µM melatonin, 
leading only to the formation of R2 (spectrum D, Figure 5.19). As mentioned 
earlier, the “pharmacological” concentrations of melatonin are reported to be in the 
nanomolar (nM) range. This suppression of R1 and formation of R2 in the presence 
of melatonin at low micromolar (M) concentrations suggests the possibility these 
effects could occur in vivo.  
 
Suppression of R1 has potential to be induced from the scavenging of the ●N3 
radicals by melatonin, in agreement with previous literature.37 Furthermore, the 
detection of the DMPO-OH (R2) spin adduct suggests an alternative photo-
decomposition pathway of complex 40 in the presence of melatonin. This was 
investigated by 1H NMR spectroscopy.  
 
5.3.7 1H NMR spectroscopy 
 Aromatic region 
A solution containing trans,trans,trans-[Pt(N3)2(OH)2(py)2] (40, 9 mM) and 
melatonin (9 mM, 1 mol equiv) was prepared in PBS/D2O at pH* 7.4. The 
1H NMR 
resonances of complex 40 and melatonin remained unchanged in the dark, 
confirming no dark reaction occurred (Figure 5.21A). Photo-irradiation at 463 nm 
for 60 min led to a brown-coloured precipitate (Figure 5.22B), which was removed 
by centrifugation prior to recording the 1H NMR spectrum. The extracted 
precipitate could not be dissolved in a variety of solvents either polar (water, 
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ethanol, methanol) or non-polar non-polar (benzene, toluene, dimethylformamide). 
Through 1H NMR integration, ca. a 20% decrease in the Pt-py resonances was 
determined. Additionally, photo-products (e-i) were observed (Figure 5.21B), 
equivalent to those previously characterised in Chapter IV (refer to p 170), and 
quantified to ca. 0.9 mM after 60 min irradiation at 463 nm. Interestingly, in the 
presence of melatonin, ca. a 5% decrease in the 1H NMR resonances of melatonin 
in the aromatic region were observed (Figure 5.21B). Moreover, new photo-
products (▼) were observed only from the irradiation of complex 40 in the presence 
of melatonin. Irradiation for 3 h, induced additional photo-decomposition of 
complex 40 and melatonin by ca. 50% and 15%, respectively, with, an increase in 
all the formed photo-products (Figure 5.21C). The photo-decomposition of 
melatonin only in the presence of complex 40, suggested an interaction between 
irradiated complex 40 and melatonin. Moreover, the formation of new photo-
products (▼) supported that an alternative photo-decomposition pathway of 
complex 40 occurred in the presence of melatonin.  
 
To further establish this alternative photo-decomposition pathway, the aliphatic 
region of the 1H NMR spectrum was monitored. The 1H NMR resonances of 
melatonin in the aliphatic region remained unchanged in the presence of 40, in the 
dark (Figure 5.23A). Irradiation of 40 in the presence of melatonin, led to photo-
decomposition in melatonin of ca. 5% and 20% after 60 min and 3 h irradiation at 
463 nm, respectively. Moreover, new photo-products (▼) were observed after 60 
min (Figure 5.23B), not detected from the irradiation of complex 40 alone. Finally, 
an additional photo-products were observed in the aliphatic region after 3 h 
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irradiation at 463 nm (▼, Figure 5.23C). The photo-decomposition of 40 and 
melatonin is summarised in Table 5.7.  
             
Figure 5.21 The aromatic region of the 1H NMR spectrum of a solution containing 
complex 40 (9 mM) in the presence of melatonin (9 mM, 1 mol equiv) prepared in 
PBS/D2O at pH* 7.4 in (A) the dark and after (B) 60 min; (C) 3 h irradiation at 463 
nm. Assignments: o/p/m, Pt-py peaks; Greek letters, melatonin peaks; e'-i', 
platinum photo-products generated in the absence and presence of melatonin; ▼, 
photo-products only formed in the presence of melatonin. Insets are an expansion 
of the region containing peaks for photo-products. (See Figure 5.23 for aliphatic 
region). 
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Figure 5.22 Precipitate formed after irradiation of a solution containing complex 
40 (9 mM) in the presence of melatonin (9 mM, 1 mol equiv) prepared in PBS/D2O 
at pH* 7.4 after 60 min irradiation at 463 nm. 
      
Figure 5.23 The aliphatic region of the 1H NMR spectra of complex 40 (9 mM) in 
the presence of melatonin (9 mM, 1 mol equiv) prepared in PBS/D2O at pH* 7.4 in 
the (A) dark and after (B) 60 min; (C) 3 h irradiation at 463 nm. Assignments: Greek 
letters, melatonin peaks; ▼, photo-products only formed in the presence of 
melatonin. Insets are an expansion of the region containing peaks for photo-
products. (See Figure 5.21 for aromatic region).  
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Table 5.7 Quantification of the 1H NMR resonances of species shown in Figures 
5.21 and 5.23. 
Time / min a[40] / mM b[MLT] / mM [e'-i'] / mM [▼] / mM 
Dark 9.0 9.0 -c -c 
60  7.2 8.5 0.9 0.2 
3 h 3.0 6.9 1.4 0.6 
a40, trans,trans,trans-[Pt(N3)2(OH)2(py)2]; bMLT, melatonin; e-i, photo-products 
generated as shown in Figure 5.21 (previously assigned in Chapter IV); coloured 
triangles, photo-products formed only in the presence of melatonin as shown in 
Figures 5.21 and 5.23; cpeaks not observed in the dark.  
 
The low S/N ratio of these generated photo-products after 3 h irradiation at 463 nm 
meant that complete spectral assignment was not feasible by 1H NMR spectroscopy 
alone. Therefore, HR-MS was performed in an attempt to elucidate the identity of 
these formed species. 
 
5.3.8 Mass spectrometry and COSY NMR spectroscopy 
A solution of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (40, 9 mM) in the presence of 
melatonin (9 mM, 1 mol equiv) was prepared in H2O and irradiated at 463 nm for 
60 min. After performing a 100-fold dilution of the irradiated solution, mass adducts 
at m/z of 271.085 and 389.103 were detected (Figure 5.24), assigned to 
[C13H16N2O3+Na]
+ (59) and [Pt(OH2)2(py)2]
2+ (60), respectively.  
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Figure 5.24 HR-MS spectra of a solution of complex 40 (9 mM) in the presence of 
melatonin (9 mM, 1 mol equiv) prepared in H2O at pH 7.4 irradiated at 463 nm for 
60 min recorded. Labelled mass adducts are summarised in Table 5.8.  
 
Furthermore, mass adducts at m/z of 430.0712, 452.0531, 603.1806 and 625.1625 
were detected by HR-MS (Figure 5.25), assignable to [Pt(N3)(OH)2(py)2+H]
2+ (61), 
[Pt(N3)(OH)2(py)2+Na]
2+, [Pt(OH2)(py)2(MLT)]
2+ (62) and 
[Pt(OH2)(py)2(MLT)+Na]
3+ respectively,  in agreement with their simulated mass 
spectra. The formation of 59 and 62 are suggested to rationalise the photo-products 
(▼) as shown in Figures 5.21 and 5.23. Mass adducts detected are summarised in 
Table 5.9.  
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Figure 5.25 HRMS spectra of a solution of complex 40 (9 mM) in the presence of 
melatonin (9 mM, 1 mol equiv) prepared in H2O at pH 7.4 irradiated at 463 nm for 
60 min recorded. Labelled mass adducts are summarised in Table 5.8.  
 
The detection of the mass adduct at m/z 430.0712 (calc. m/z 430.0695), assigned to 
[Pt(N3)(OH)2(py)2+H]
2+ (61), suggested the loss of one azide ligand. This loss of 
the azide ligand, as free azide, has potential to account for the observed lag-phase 
in the detection of an EPR signal (Figure 5.19). This mono-azide PtIV reactive 
intermediate is suggested to undergo further reaction, leading to the generation of 
the azidyl and hydroxyl radicals. Moreover, the detection of 62 suggests the binding 
of melatonin to a PtII photo-product. This will be discussed later in section 5.4.2.  
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Table 5.8 Assignment of mass adducts as shown in Figures 5.24 and 5.25.  
Found m/z Structure Formula Calc. m/z 
 
255.1114 
 
 
C13H16N2O2Na 
[MLT+Na]+ 
 
255.2830 
 
271.0853 
 
(Structure determined) 
(59) 
 
C13H16N2O3Na 
[MLT-OH+Na]+ 
 
271.2224 
 
389.1029 
 
 
C10H14N2O2Pt 
[Pt(OH2)(py)2]
2+ 
 
389.0703 
 
430.0712 
 
 
C10H13N5O2Pt 
[Pt(OH)2(N3)(py)2+H]
2+ 
 
430.0695 
 
452.0531 
 
 
C10H12N5O2PtNa 
[Pt(OH)2(N3)(py)2+Na]
2+ 
 
452.0536 
 
603.1806 
 
 
C23H28N4O3Pt 
[Pt(OH)2(py)2+H]
3+ 
 
603.1653 
 
625.1625 
 
 
C23H27N4O3PtNa 
[Pt(OH)2(py)2+Na]
3+ 
 
625.1629 
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The detection of the mass adduct at m/z 271.0853 was assigned as 
[C13H16N2O3+Na]
+ (59), an increase in the sodium adduct of melatonin by 17 mass 
units, suggesting the addition of “OH” to melatonin. Despite the detection of this 
mass adduct as 271.0853 m/z, based on the 1H NMR data, complete structural 
assignment was not feasible. Consequently, a COSY NMR spectrum of the 
irradiated solution was performed to establish a correlation between the newly 
formed photo-products generated in the presence of melatonin. However, due to the 
low S/N ratio of the photo-products, it was not possible to determine correlation 
between the desired resonances. However, a correlation between photo-products, 
e’-i' was observed (Figure 5.26).  
 
Figure 5.26 The aromatic region of the COSY NMR spectrum obtained from a 
solution containing complex 40 (9 mM) in the presence of melatonin (9 mM, 1 mol 
equiv) prepared in PBS/D2O at pH* irradiated for 3 h at 463 nm. 
1H NMR resonance 
and cross-peak represented by  and , respectively. Correlation shown for photo-
products e'-i'.  
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Additional, 13C-DEPT135 NMR spectroscopy was also performed to identify the 
new resonances however no new resonances were observed. The lack of detection 
of new resonances was attributed to their respective concentrations, believed to be 
below the limit of detection for 13C-DEPT135 analysis. The possible products of 
hydroxyl radical addition to melatonin will be discussed in section 5.4.2.  
 
The DMPO-N3 spin adduct was detected, it was ca. 21-fold lower than the DMPO-
N3 detected in the absence of melatonin. Previous literature has reported on the 
quenching ability of melatonin towards the ●N3 radicals.
37 To establish this potential 
interaction in this work, 14N NMR spectroscopy was performed.  
 
5.3.9 Quenching of azidyl radicals  
The 14N NMR resonance at 97.9 ppm from a solution of melatonin (18 mM) 
prepared in PBS/D2O at pH* 7.4 was assigned to the NH of the indole ring present 
in melatonin (Figure 5.27). The other amino resonance is outside the spectral range, 
as reported for other amino functionalities.76 
                                             
Figure 5.27 The 14N NMR spectrum of a solution of melatonin (18 mM) prepared 
in PBS/D2O at pH* 7.4. Resonance at ca. 97.9 ppm assigned to the nitrogen atom 
(NH) of the indole ring of the melatonin molecule.  
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The dark 14N NMR spectrum of a solution of complex 40 (6 mM) in the presence 
of melatonin (2.5 mM) prepared in PBS/D2O at pH* 7.4 displayed 
14N NMR 
resonances for the coordinated azide ligand (A, Figure 5.28). Under these 
experimental conditions, no 14N NMR resonances were detected for melatonin. 
Photo-irradiation of this solution of complex 40 (6 mM) in the presence of 
melatonin (2.5 mM) at 463 nm for 30 min led the observation of an additional peak 
at ca. 77.3 ppm, previously assigned to the central nitrogen (Nβ) of free azide 
(Chapter IV).  
                
Figure 5.28 The 14N NMR spectrum of a solution of complex 40 (6 mM) with 
melatonin (2.5 mM) prepared in PBS/D2O at pH* 7.4 in (A) dark and (B) irradiated 
at 463 nm for 30 min. The appearance of the Nα peak of complex 40 (expected at 
ca. 60 ppm) is too broad to observe under the conditions used.77 Assignments (14N, 
43.3 MHz in D2O): δ = 229.3 ppm, central nitrogen (Nβ) of coordinated azide 
overlapped with the terminal nitrogen (Nγ) of free azide (N3-); 168.1, overlap 
between terminal nitrogen of coordinated azide (Nγ) and nitrogen from pyridine 
ligand (N); 77.3, central nitrogen (Nβ) of free azide (N3-).  
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Despite the detection of free azide (N3
-) from the photo-irradiation of 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (complex 40, 6 mM) with melatonin (2.5 
mM), it was not possible to confirm if this was from the release of the azide ligand 
from irradiated complex 40 in the presence of melatonin or from the quenching of 
the azidyl radicals by melatonin. Previous quenching of the N3 radicals by L-Trp 
(Chapter IV) induced a photo-protective effect. Therefore, to establish the effect 
of melatonin on the photo-cytotoxicity of complex 40, cell viability studies were 
performed in A2780 ovarian cancer cells.  
 
5.3.10 Photo-irradiation in A2780 ovarian cancer cells with melatonin 
Photo-irradiation studies were performed by Dr. Julie Woods at Ninewell’s 
Hospital, Dundee. A2780 ovarian cancer cells were plated with complex 40 (42.4 
µM) with varying doses of melatonin. Photo-irradiation at 420 nm (5 J cm-2) of 
complex 40 (42.4 µM) in A2780 ovarian cancer cells led to ca. 2% cell viability. 
Interestingly, the addition of melatonin (70 µM) led to ca. 17% cell viability (Figure 
5.29). A direct correlation between the successive addition of melatonin (up to 2.2 
mM) and amount of viable cells can be clearly observed from Figure 5.29.  
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Figure 5.29 The percentage cell viability induced from the photo-irradiation of 
complex 40 (42.4 µM, n = 2 independent experiments) in the presence of melatonin 
(different concentrations) in A2780 ovarian cancer cells in the () dark and () 
after irradiation at max = 420 nm (5 J cm-2). NC: negative control (cells only). Data 
represent means ± standard errors for the mean of 6 monolayers from 2 independent 
experiments performed in duplicate.  
 
ALA, precursor of the photosensitiser, protoporhyrin (PpIX) which is widely used 
in PDT therapy. Metabolism of ALA generates PpIX, which upon photo-activation 
with light of appropriate wavelength induces its photo-cytotoxic effect via singlet 
oxygen (1O2) formation.
43 Similar to the ●OH radicals, 1O2 is classified as a ROS 
and has potential to induce a cascade of cytotoxic effects upon formation.78 Previous 
studies have reported on the quenching of 1O2 by melatonin.
79 
 
Therefore, the scavenging of ROS by melatonin was assessed by incubation of 5-
aminolevulinic acid (ALA, 1 mM) in the presence of melatonin (different 
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concentrations) in A2780 ovarian cancer cells. No dark photo-cytotoxicity was 
observed (, Figure 5.30). However, irradiation at 420 nm (5 J cm-2) led to a 
decrease in cell viability across the range of melatonin. It appeared that under these 
experimental conditions, melatonin could not quench 1O2 formed from PpIX 
generated from the precursor ALA.  
                            
Figure 5.30 The percentage cell viability induced from 5-aminolevulinic acid 
(ALA, 1 mM, n = 2 independent experiments) in the presence of melatonin 
(different concentrations) in A2780 ovarian cancer cells in the () dark and () 
after irradiation at max = 420 nm light (5 J cm-2). NC: negative control (solvent 
only). Data represent means ± standard errors for the mean of 6 monolayers from 2 
independent experiments performed in duplicate.  
 
In the absence of melatonin, trans,trans,trans-[Pt(N3)2(OH)2(py)2] (complex 40) 
induced a photo-cytotoxic effect. However, successive addition of melatonin, led to 
a photo-protective effect. Contrary to previous literature, melatonin was unable to 
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quench the 1O2 formed from irradiated ALA, under these conditions, leading to a 
cytotoxic effect in A2780 ovarian cancer cells.  
 
5.4 Discussion 
5.4.1 Hydroxyl radical characterisation  
Photo-irradiation of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (complex 40) in the 
absence of melatonin, led to the detection of the DMPO-N3 spin adduct after 42 s 
irradiation at 463 nm (Chapter III, p 99). However, in the presence of melatonin 
an EPR signal was detected after irradiation for 21 min at 463 nm. The EPR signal 
detected after 21 min irradiation was identified as the superimposition of two 
DMPO nitrone spin adducts from the photo-irradiation of complex 40 and DMPO 
in the presence of melatonin. Using semi-continuous irradiation (irradiation for 14 
min at 463 nm, after which the irradiation source is switched off), a quartet EPR 
spectrum in the ratio of 1:2:2:1 was identified and assigned to the hydroxyl radical 
DMPO-OH (R2) spin adduct.  
 
However, the DMPO-OH spin adduct can be mistakenly detected from the 
spontaneous decay of the DMPO-OOH spin adduct (t½ = 56 s).
80,81 Therefore, the 
method for ●OH radical detection, described by Finkelstein,18 was used. This 
involved the addition of ethanol which led to the detection of the DMPO-α-
hydroxyl-ethyl radical (R5), formed from the interaction of the ●OH radicals with 
ethanol. Moreover, the phosphorus spin trap, DEPMPO generates distinct EPR 
signals for both the DEPMPO-OH and DEPMPO-OOH spin adducts.70 Therefore, 
in this work, substitution of the DMPO spin trap to DEPMPO led to the detection 
of an 8-lined EPR spectrum assigned to the DEPMPO-OH (R4) spin adduct. 
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Consequently, the detection of DEPMPO-OH (R4) and DMPO-EtOH (R5) spin 
adducts confirmed that the initial quartet EPR spectrum was due to the trapping of 
the OH radicals by DMPO. Photo-irradiation of complex 40 alone, did not lead to 
the detection of the OH radicals by EPR spin trapping (refer to Chapter III). 
Therefore, in this Chapter the generation of the OH radicals was believed to be 
mediated by melatonin.  
 
5.4.2 Photo-protective effect 
Photo-irradiation of complex 40 in the presence of melatonin led to the quenching 
of the ●N3 radicals by melatonin and the formation of the 
●OH radicals. Reactions 
of ●N3 radicals with melatonin have been reported to occur with a rate constant of 
ca. 9.8  109 M-1 s-1,37 considerably faster than ●N3 radicals trapped by DMPO (1.6 
 109 M-1 s-1),82 further accounting for the pronounced quenching of the DMPO-N3 
spin adduct in the presence of melatonin. Moreover, melatonin possesses a 
reduction potential of ca. 0.73 V,83 in contrast to the ●N3 radical possessing a 
reduction potential of ca. 1.33 V.35 This suggests a one-electron donation from 
melatonin to the ●N3 radical occurs favourably, leading to the formation of free 
azide (N3
-) and a melatonin radical cation (A, Figure 5.31). N3
- is a toxic species, 
however its toxicity has been reported to be dose-dependent.84 In this work, the 
concentration of free azide is believed to be below the level to induce a cytotoxic 
effect.  
 
Moreover, the melatonin radical cation MLT●+ radical has been previously reported 
by Lewis to be non-toxic to cells.85 Similar to the L-Trp●+ species, rapid 
deprotonation of MLT●+ may occur at pH 7 forming the neutral MLT● species. 
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Polymerisation of various indole radicals is a well-reported phenomenon,86,87 and 
in one study polymerisation was shown to be mediated via the indole radical 
cation.88  Therefore, in this work, the brown-coloured precipitate (refer to Figure 
5.22) formed from the photo-irradiation of complex 40 in the presence of melatonin 
is believed to be a MLT-based polymer species.   
 
Figure 5.31 Reaction of melatonin with (A) the azidyl, ●N3; (B-E) the hydroxyl, 
●OH radicals leading to the formation of various species.  
 
Additionally, the formation of the MLT● radical is suggested to account for the 
detection of 62, assigned to [Pt(OH2)(py)2(MLT)]
2+ by HR-MS. Previous studies 
have reported on the binding of melatonin to various metal ions,62,89 through 
absorptive stripping voltammetry. However, such studies have not, at present, 
identified the metal coordination site present in melatonin. Melatonin (Figure 5.3) 
does not illustrate any potential PtII-binding sites. However, the formation of the 
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MLT● radical, at the nitrogen atom of the indole (A and E, Figure 5.31) has potential 
to react with the PtII intermediate, as shown in section 5.4.3. 
 
Consequently, the observation of a photo-protective, from the quenching of the 
azidyl radicals, was similar to that previously reported in Chapter IV. Interestingly, 
the detection of ●OH radicals, initially proposed an enhancement in the photo-
cytotoxicity of complex 40. However, a photo-protective effect was still observed. 
Additional photo-products were detected by 1H NMR spectroscopy (refer to Figure 
5.21 and Figure 5.23), yet due to their low concentrations, complete characterisation 
of the formed photo-products was not feasible. HR-MS identified a mass adduct at 
m/z 271.085 (59), which was calculated to be 17 a.m.u higher than the parent 
sodium adduct of melatonin, m/z 255.111. Whilst, the structure of this species could 
not be completely determined by 1H or COSY NMR, the increase in 17 a.m.u, 
suggested the addition of the hydroxyl radical to melatonin.  
 
The hydroxyl radical has potential to coordinate to melatonin at the C2, C3 and C7 
positions (B-D, Figure 5.31. Moreover, addition of the hydroxyl radical at the C7 
position can induce enol-keto tautomerism leading to a thermodynamically more 
stable 3-cyclic-hydroxy-melatonin species (D, Figure 5.31). The latter species 
previously reported by Tan et al., to a main metabolite of hydroxyl radical reaction 
with melatonin.38 Furthermore, the formed hydroxyl radicals have potential to 
undergo a one-electron transfer reaction with melatonin (E, Figure 5.31), leading to 
the formation of the hydroxide ion (-OH) and the MLT●. Lastly, the formed 
hydroxyl radicals also possess the potential to react with N3
- (formed from A, Figure 
5.31), leading to the formation of both hydroxide ions and azidyl radicals, a 
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previously reported reaction by Neta et al.90 Consequently, from this reaction, it is 
possible the formed hydroxide ions have potential to react with both/either 
melatonin and a PtII intermediate species. In summary, it appears from Figure 5.31, 
that both the azidyl and hydroxyl radicals can undergo numerous reactions 
pathways, such that neither radicals are available to induce their cytotoxic effect.  
 
5.4.3 Mechanism of action  
The detection of the mass adduct at m/z 430.0712, assigned to 
[Pt(N3)(OH)2(py)2+H]
2+, suggested the loss of one coordinated azide ligand. 
However, the equivalent decrease in the N3PtIV LMCT band of complex 40 in 
both the absence and presence of melatonin, as observed by UV-visible 
spectroscopy, confirmed that both azide ligands are lost from complex 40. The 
superimposition of the azidyl and hydroxyl radical DMPO spin adducts suggested 
the simultaneous trapping of the azidyl and hydroxyl radical by spin trap, DMPO. 
From these results, the photo-decomposition pathway of complex 40 in the presence 
of melatonin is proposed in Figure 5.32.  
 
Briefly, photo-irradiation of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (complex 40) in 
the presence of melatonin leads to an initial loss of one azide ligand, generating a 
reactive PtIV mono-azide intermediate species, as detected by HR-MS (61) and free 
azide (N3
-) as detected by 14N NMR spectroscopy. This initial loss of coordinated 
azide, as free azide, is consistent with the lag-phase in the detection of an EPR 
signal. Continued irradiation of 61 gives rise to two one-electron donations from 
the remaining azide and one hydroxyl ligands to the PtIV metal centre, forming a 
PtII intermediate, azidyl and hydroxyl radicals. Then, two possible reaction 
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pathways are proposed for the PtII intermediate species. Firstly, the melatonin 
radical (MLT●) formed from the quenching of the azidyl radicals by melatonin has 
potential to react with the PtII intermediate, generating a PtII-melatonin species as 
detected by HR-MS at m/z 603.1806, assigned to [Pt(OH2)(py)2(MLT)]
2+ (62, 
where MLT represents melatonin).  
 
Figure 5.32 Proposed photo-decomposition pathway of complex 40 in the presence 
of melatonin. Curly brackets represent non-detected species. Coordination site of 
melatonin has not been explicitly determined, therefore shown as Pt-MLT bond.   
 
The second pathway, is more complicated but also appears possible. Initially, the 
hydroxyl radicals can react with melatonin (E, Figure 5.31) or with free azide and 
generate hydroxide ions, as previously reported reaction by Neta et al.90 
Consequently, from this reaction, it is possible the formed hydroxide ions react with 
the PtII intermediate species and generate [Pt(OH2)2(py)2]
2+ (60), as detected by HR-
MS. The detection of the melatonin-PtII species (62), suggests the amount of PtII 
available to react with the N7 atom of guanine (DNA nucleobase) is reduced in 
A2780 ovarian cancer cells, leading to the observed photo-protective effect. 
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Interestingly, dimerisation of ●OH radicals can also form hydrogen peroxide 
(H2O2), a well-known ROS. H2O2 does not damage DNA directly. However, readily 
diffusible across cells, H2O2 is a major contributor of additional ROS, far from the 
site of production.91 For example, disproportionation of H2O2 mediated by various 
inorganic catalysts92 leads to the generation of singlet oxygen (1O2),
93 the species 
responsible for inducing cell death in current PDT treatments.94 The compound 5-
aminolevulinic acid (ALA) is used in PDT therapy (Chapter I).95 Its cytotoxic 
effect is induced through the formation of 1O2. Previous in vivo studies by Princ et 
al. reported the ability of melatonin (0.5 – 2 mM) to diminish the cytotoxic effect 
of ALA in rat cerebellum.79,96 In this work, photo-irradiation of ALA with blue light 
in the presence of melatonin led to a photo-cytotoxic effect in the A2780 ovarian 
cancer cells. Interestingly, it appears under conditions used here, melatonin was 
unable to quench 1O2. Therefore, due to the observed photo-protective effect from 
the photo-irradiation of complex 40 in the presence of melatonin, suggests ●OH 
radical dimerisation does not occur.  
 
Melatonin regulates the circadian rhythms in humans and animals. Its maximum 
production is during sleep hours,97 and the amount of melatonin produced is 
dependent on age,98 as shown in Figure 5.34. In this work, it would appear that 
treatment of cancerous tissue(s) with complex 40 during levels of melatonin 
production would reduce the platinum(IV) diazido anticancer complex photo-
cytotoxicity. Interestingly, this work incorporates into the new research field of 
Chronopharmacology.99 This field has identified the optimum time-of-day to 
administer a drug to achieve sufficient metabolism and/or therapeutic efficiency. 
For example, the treatment of asthma has been determined to be most effective at 
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low plasma concentrations of dyspneas.100,101 Furthermore, patients undergoing 
elective gynaecological surgery showed an increase in plasma levels of melatonin, 
having been anaesthetised with isoflurane in contrast to propofol.102 Therefore, 
successful treatment of cancer via photo-chemotherapy may be achieved under non-
anaesthetised conditions.  
 
      
Figure 5.33 Serum concentration of melatonin in human at various age, grey area 
refers to darkness period (figure from ref 98).  
 
5.5 Conclusion 
This Chapter investigated the photo-irradiation of trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (complex 40) in the presence of melatonin. Electron 
paramagnetic resonance (EPR) studies led to the detection and characterisation of 
both the azidyl (N3) and hydroxyl (OH) radicals using both continuous and semi-
continuous irradiation modes. The quartet EPR spectrum in the ratio of 1:2:2:1 was 
assigned to the DMPO-OH (R1) spin adduct. However, the quartet EPR spectrum 
can be easily detected from the spontaneous decay of unstable DMPO spin adducts. 
Therefore, the confirmation of OH radical production was deduced from the 
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detection of the DMPO-EtOH (R5) spin adduct, formed from the interaction of the 
OH radical with ethanol. Moreover, substitution of the spin trap DMPO by the 
phosphorus analogue DEPMPO, led to the observation of an eight-lined EPR 
spectrum. This was assigned to the DEPMPO-OH (R4) spin adduct in agreement 
with previous reported values.  
 
1H NMR spectroscopy of complex 40 in the presence of melatonin, led to the 
formation of new photo-products in both the aromatic and aliphatic region. MS 
identified mass adducts at m/z of 271.085, 430.0712 and 603.1806, assigned to 
[C13H16N2O3+Na]
+ (59), [Pt(OH)2(N3)(py)2+H]
2+ (61) and [Pt(OH2)(py)2(MLT)]
2+ 
(62), respectively. The detection of the mono-azide PtIV species (61) suggested the 
loss of coordinated azide, as free azide. However, UV-visible spectroscopy 
identified an equivalent photo-decomposition in the N3PtIV LMCT band in both 
the absence and presence of melatonin, which suggested that both azide ligands 
were lost. The superimposition of the azidyl and hydroxyl radical DMPO spin 
adducts, confirmed the simultaneous release of the azide and hydroxyl ligands, in 
radical form. Despite the detection of the DMPO-N3 spin adduct, it was ca. 21-fold 
lower compared to the DMPO-N3 spin adduct formed in the absence of melatonin. 
Consequently, this suppression in the DMPO-N3 spin adduct was partially 
attributed to the quenching of the azidyl radicals by melatonin. Quenching of the 
azidyl radicals by melatonin was supported by the detection of free azide, as 
detected by 14N NMR spectroscopy. The quenching of the azidyl radicals, also 
proposed the formation of the melatonin radical (MLT, undetected). Melatonin 
does not exhibit metal-binding sites in its structure, consequently, the detection of 
62 assigned to [Pt(OH2)(py)2(MLT)]
2+, was suggested to form via the interaction of 
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MLT with the PtII intermediate. New 1H NMR resonances were observed in both 
the aromatic and aliphatic region suggested to be related to a hydroxy-melatonin 
species (59). However, due to a low S/N of these formed photo-products complete 
characterisation was not possible.  
 
Photo-irradiation of complex 40 in the presence of melatonin in A2780 ovarian 
cancer cells induced a photo-protective effect. The quenching of the N3 by 
melatonin and detection of 59, confirmed neither of these RNS and ROS were 
available to induce their cytotoxic effect. The formation of the platinum(II)-
melatonin species (62) is believed to reduce amount of PtII to bind to the guanine 
nucleobase of DNA to induce a cyto-toxic effect.  
 
The concentration of melatonin varies dependent on the light-dark cycle and in 
accordance to age in humans. Children exhibit the highest production of melatonin 
in the period of darkness, in contrast to the elderly which show a slight change in 
melatonin production from the light-dark cycle. This study suggests treatment of 
antineoplastic tissue with complex 40 and possibly other structurally related 
platinum(IV) diazido complexes would be ineffective during the hours of melatonin 
production. Further, in vivo studies are required to confirm this effect.  
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Previous studies have reported on the unreactive nature of platinum(IV) diazido 
anticancer complexes towards sulfur containing bio-molecules in the dark.1,2 However, 
there are few studies of reactions between sulfur-based biomolecules and photo-
irradiated platinum(IV) diazido complexes. In this Chapter, the photo-irradiation of 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (complex 40) in the presence of a sulfur-
containing drug, cimetidine, was investigated.  
 
6.1 Introduction 
Platinum-based anticancer complexes are widely used in the treatment of a variety of 
human cancer malignancies. However, the development of intrinsic and/or acquired 
resistance mechanisms limits their continued clinical efficiency.3 Platinum resistance, 
a multi-factorial process, is commonly associated with the inhibition of DNA-
platination or drug-induced damage mechanisms.4 Platinum resistance has also been 
correlated with reduced cellular accumulation and to date, this is considered a primary 
marker of platinum resistance.5 Copper transporter (CTR) proteins,6,7 organic cation 
transporters (OCTs)8 and other specific platinum influx transporters9 have been 
identified as mediators of platinum accumulation. OCTs are a subgroup of the solute 
carrier, SLC22 family, which belong to the major facilitator superfamily. The OCTs 
subgroup consists of subtypes OCT1, OCT2 and OCT3, also known as SLC22A1, 
SLC22A2 and SLC22A3, respectively.10 Expression in the liver (OCT1), kidneys 
(OCT2) and intestines (OCT3) suggests these transporters participate in the absorption, 
distribution and excretion of platinum anti-neoplastic agents.11  
 
Early studies identified a relationship between high expression levels of OCT2 and 
platinum toxicity,12 suggesting OCT2 mediated platinum accumulation. This study and 
others11,12 led to the investigation into the role of OCT2-mediated uptake of platinum 
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anticancer complexes. To date the involvement of both SLC22A1 and SLC22A3 on 
platinum transport remains unclear.13,14 However, there is compelling evidence to 
support the contribution of SLC22A2 in both the absorption and cyto-toxicity of 
numerous platinum anticancer complexes.15,16 Expression of SLC22A2 significantly 
enhanced the uptake and cytotoxicity of picoplatin (62) and pyriplatin (63) (Figure 
6.1).13,17  
            
Figure 6.1 Platinum anticancer complexes whose absorption has been reported to be 
mediated by the cation transporter, SLC22A2.  
 
Moreover, oxaliplatin (4) is regarded as an excellent SLC22A2 substrate. Its uptake 
was ca. 24-fold higher in transfected HEK293 (human embryonic kidney)-OCT2 cells 
compared to normal control cells.18 The presence of SLC22A2 inhibitors such as 
tetraethyl ammonium (TEA, Figure 6.2A) and methyl-4-phenylpyridinium (MPP+, 
Figure 6.2B), completely abolished the SLC22A2-mediated uptake of both oxaliplatin 
and picoplatin.13,17 
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Figure 6.2 Structures of (A) tetraethyl ammonium (TEA) and (B) 1-methyl-4-
phenylpyridinium (MPP+) inhibitors of the SLC22A2 transporter.  
 
Cimetidine (Figure 6.3A) is an H2-receptor antagonist, an FDA approved drug, and is 
also classified as a SLC22A2 inhibitor. It is generally prescribed for the treatment of 
heartburn and peptic ulcers.19 At physiological pH 7.4, ca. 20% of cimetidine exists in 
its cationic form (Figure 6.3B), which is essential for its transport via OCT2. The 
amount of cationic cimetidine increases with decreasing pH (ca. 67% at pH 6.5).20 
Therefore, similar to TEA and MPP+, the uptake of platinum anticancer complexes 
mediated by SLC22A2, has potential to be inhibited in the presence of cimetidine.  
 
Surprisingly, the pharmacological effects of cimetidine have been contradictory. Co-
administration of cis-platin with cimetidine suppressed cis-platin induced 
nephrotoxicity, without affecting the pharmacological activity of cis-platin.21,22 Dorr et 
al. found that the co-administration of CDDP with cimetidine did not affect the 
antitumour activity of the PtII anticancer complex in murine lymphocytic leukemia cell 
line. However, cimetidine increased the lethality of CDDP in normal mice cells, which 
was otherwise inactive.23 Adverse side-effects of cis-platin therapy, such as oto- and 
nephro-toxicity were completely and partially supressed, respectively, in the presence 
of cimetidine.24  In contrast, cimetidine completely suppressed cis-platin induced 
apoptosis in HEK293-OCT2, human embryonic kidney cells transfected with OCT2. 
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Moreover, the uptake of oxaliplatin was significantly reduced in the presence of 
cimetidine.25 These results supported the OCT2-mediated platinum accumulation. 
       
Figure 6.3 Structure of cimetidine in (A) neutral (ca. 80%) and (B) cationic (ca. 20%) 
form at physiological pH.  
 
The expression of SLC22A2 was investigated in the NCI-60 panel of human cancer 
cells and was found to be readily expressed in OVAR-5, SKOV-3 and IGROV-1 
ovarian cancer cells.26 Despite this finding, the uptake of cis-platin in SKOV-3 ovarian 
cancer cells was not inhibited in the presence of cimetidine.14,27 The majority of 
platinum compounds transported by the SLC22A2 have been noted to possess a 
heterocyclic aromatic ligand.28 Therefore, is it apparent that further studies are required 
to determine if there is a direct correlation between the expression of SLC22A2 and 
accumulation of platinum.  
 
The main pharmacological effect of cimetidine has been suggested to be mediated via 
interaction with transition metal ions.29 Cimetidine, similar to histamine, can act like a 
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chelating agent. Previous studies have isolated a 1:2 polymeric CuII-cimetidine 
complex, with the CuII coordinated via the imidazole (N4) and the nitrile (N20) nitrogen 
atoms, as determined from its X-ray crystal structure.30 Therefore, it appears cimetidine 
can compete against biological ligands such as albumin, for CuII.31 Moreover, 
Kanumfre reported on the ability of cimetidine to chelate various metal ions in both the 
blood plasma and surrounding tissues.32 Consequently, numerous studies have 
investigated the interaction of cimetidine with various metal ions, in particular those 
present in trace quantities in vivo,33-35 such as CuII, NiII and ZnII.36,37 It was found that 
cimetidine coordinates to these metal ions via the thioether (S11) and imidazole 
nitrogen (N4) atoms, forming stable five-membered rings (Figure 6.4A), except where 
three ligands were coordinated to the metal ion, which led to coordination via the 
imidazole nitrogen atom only (Figure 6.4B).38 Additional studies characterised the 
formation of [Cr(cim)2(Cl)2]Cl.3H2O, a five-membered ring complex via infrared and 
UV-visible spectroscopy.38 DFT calculations performed by Olea-Román identified the 
imidazole nitrogen (N4) and sulfur (S11) atoms, as the most reactive sites present in 
cimetidine. This further supported the formation of stable five-membered ring 
complexes. 
 
Platinum(II) exhibits a strong binding affinity for sulfur in both L-methionine and L-
cysteine residues. L-methionine (L-Met, Figure 6.5B) and L-cysteine (L-Cys, Figure 
6.5C) amino acids are present in a wide variety of proteins and peptides.39 N-donor 
atoms, such as 5'-guanosine monophosphate (5'-GMP) have the ability to displace Pt-
S(thioether) bonds. Consequently, these Pt-S(thioether) bonds were termed as “drug 
reservoirs”.40  
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Figure 6.4 Example of transition metal-cimetidine complexes previously characterised 
by both UV-visible/NMR spectroscopic and DFT methods. Coordination of the 
transition metal to cimetidine via (A) both the sulfur (S11) and imidazole nitrogen (N4) 
atoms, and (B) imidazole nitrogen (N4) atom only (structures from ref 38).  
 
However, displacement of the Pt-S (thioether) bond does not always occur. Chelate ring 
formation has been reported from the interaction of cis-platin with both L-methionine 
and the protein, ubiquitin (UBQ). A major metabolite of CDDP treatment, [Pt(L-Met)2] 
has been identified to undergo facile cis-trans isomerisation in aqueous solution, 
characterised by 195Pt and 1H NMR spectroscopy (Figure 6.6B).41  
 
 
Figure 6.5 Amino acids (A) L-methionine and (B) L-cysteine 
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A small polypeptide of ca. 8 kDa, UBQ contains seven lysines, four arginines, one 
histidine and one L-methionine residues,42,43 and has been associated with an indirect 
role in tumour propagation. Indirect methods have identified the Met1 as the primary 
binding site of PtII in UBQ.44,45 Modification of the Met1 residue inhibited PtII binding, 
supporting Met1 as the main binding site. A more comprehensive study, involving a 
travelling-wave-based ion mobility-tandem mass spectrometry approach, elucidated the 
formation of a stable six-membered ring (Figure 6.6B), formed between cis-platin and 
UBQ via the Met1 and His68 residues.46 
          
Figure 6.6 Structure of six-membered ring complexes formed by coordination of PtII 
to the sulfur and nitrogen atoms of (A) L-methionine (B) UBQ (structures from ref 41 
and 46, respectively).   
 
Cimetidine possesses a thioether and imidazole ring functional groups. Therefore, the 
binding of PtII appears kinetically favoured at the sulfur (S11) atom, which may 
undergo chelate ring formation due to the presence of the imidazolic ring. The 
coordination of PtII to cimetidine has been primarily investigated to elucidate the 
pharmacological action of the FDA approved drug. Interestingly, Nurchi et al. first 
reported on a PtII-cimetidine related species. Coordination of PtII was reported to occur 
via the cyano-guanidine moiety of cimetidine. This was deduced from the equivalent 
1H NMR resonances for both free and coordinated cimetidine.47 In contrast, Crisponi 
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reported on the distinct 1H NMR resonances for both free and coordinated cimetidine, 
indicative of both PdII and PtII coordination via both the sulfur (S11) and imidazole 
nitrogen (N4) atoms of cimetidine.48 Moreover, Onoa et al. synthesised a [Pt(cim)2]
2+ 
species to investigate both its binding and anticancer properties.49 The X-ray crystal 
structure of this [Pt(cim)2]Cl2.12H2O complex revealed two molecules of cimetidine 
coordinated to the PtII centre via the thioether and imidazole nitrogen atoms (Figure 
6.7).49 
             
Figure 6.7 X-ray crystal structure of [Pt(cim)2]
2+ complex, where counter ions, 
hydrogen atoms and solvent are not shown (structure adapted from ref 49).  
 
These studies by Crisponi and Onoa, are in agreement with the well-known tendency 
of PtII to preferentially coordinate via the sulfur atom. Unlike previous studies which 
led to the displacement of the PtII-sulfur bond in the presence of N-donor complexes,40 
the presence of the competing N-donor atom of the imidazolic ring in cimetidine, led to 
chelate ring formation. Interaction of platinum(II) anti-cancer agents with L-methionine 
and L-cysteine, (Figure 6.5) common sulfur-containing amino acids present in an array 
of proteins and peptides forming PtII-S based species, has been correlated with adverse 
toxic side-effects and platinum resistance mechanisms.50 The biological activity of the 
[Pt(cim)2]
2+ complex obtained by Onoa et al. (refer to Figure 6.7), was not performed 
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due to the lack of hydrolysable groups in the coordination sphere. Consequently, the 
biological activity of such PtII-cimetidine complexes, remain unknown. Instead, the 
anti-proliferative activity of a PdII-cimetidine derivative was investigated and the 
derivative was found to be non-cytotoxic towards a number of cancer cell lines.49 This 
is in agreement with the facile hydrolysis of palladium complexes, ca. 105  faster than 
the corresponding platinum derivatives. This rapid dissociation generates reactive 
species unable to reach the target site and to induce cell death.51  
 
Platinum(IV) diazido anticancer complexes 36 and 40 (Figure 6.8) have been shown to 
be stable in the presence of glutathione, in the dark.2 Photo-irradiation of complex 36 
with 365 nm UVA, was reported to reduce PtIV to PtII via two one-electron reductions 
from the azide ligands.52 Therefore, the PtII photo-products have potential to interact 
with sulfur-containing molecules. Recently, Ronconi investigated the photo-irradiation 
of complex 36 in the presence of dimethyl-sulfide (DMS). Surprisingly, an alternative 
photo-decomposition pathway of complex 36 was observed in the presence of DMS. 
Initial loss of N2 gas led to the formation of a Pt-N nitrene complex and formation of 
O2 gas (detected by PO2 measurement).
53 This study illustrated that the photo-activation 
and photo-decomposition pathway(s) of platinum(IV) diazido anticancer complexes are 
dependent on the irradiation conditions.   
            
Figure 6.8 Platinum(IV) diazido complexes stable in the presence of glutathione in the 
dark.  
                                           Chapter VI: Photo-irradiation in the presence of cimetidine 
272 
 
In this Chapter, the photo-irradiation of trans,trans,trans-[Pt(N3)2(OH)2(py)2] 
(complex 40) in the presence of SLC22A2 inhibitor cimetidine was performed. Primary 
studies focused on establishing the effect of cimetidine on photo-irradiated complex 40, 
monitored by UV-visible, EPR, MS and multinuclear NMR spectroscopy. Additional 
cellular studies on the photo-cytotoxicity and uptake of complex 40 in HaCaT 
keratinocytes cells, in the presence of cimetidine, were performed.  
 
6.2 Experimental 
A brief description of sample preparation is provided below specific to this Chapter. 
More detailed information regarding instrumental and irradiation setup are provided in 
Chapter II.  
 
6.2.1 Materials 
Cimetidine, pyridine, L-methionine, hexamethyl-disiloxane (HMDSO, 1H NMR 
internal reference) and histamine were purchased from Sigma Aldrich.  
 
6.2.2 EPR spectroscopy 
Samples were prepared in PBS/D2O at pH* 7.4 containing trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (complex 40, 1 mM or 450 µM) and DMPO (2 mM or 900 µM) in 
the absence and presence of cimetidine (2 or 4 mol equiv).  
 
6.2.3 NMR Spectroscopy  
 1H NMR 
Solutions were prepared in deuterated phosphate buffer (PBS/D2O) containing complex 
40 (4 mM) in the absence and presence of cimetidine (8 mM) at pH* 7.4. Due to the 
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overlap (in some instances) between 1,4 dioxane (δ = 3.75 in D2O) with 1H NMR 
resonances of the sample under investigation, samples were internally referenced to 
HMDSO (δ = 0.28 in D2O). An additional solution of complex 40 (4 mM) with DMPO 
(8 mM) in the presence of cimetidine (8 mM) was prepared in PBS/D2O at pH* 7.4.  
 
 14N NMR 
Individual solutions of cimetidine (18 mM) and pyridine (10 mM) were prepared in 
PBS/D2O at pH* 7.4 to record their 
14N NMR spectra. Solutions of complex 40 (4 mM) 
were prepared in PBS/D2O at pH* 7.4 in both the absence and presence of cimetidine 
(8 mM). Spectra were recorded as described in Chapter II.  
 
 13C-DEPT135 NMR 
Spectra were obtained on a Bruker-DRX-500 (13C, 125.8 MHz) spectrometer at 298 K. 
Spectra were recorded with the standard 13C NMR deptcp135 pulse programme and 
acquired with 2048 transients into 65 k data points with a spectral width of 250 ppm. 
Samples were irradiated in a transparent glass vial and transferred to the NMR tube to 
record the NMR spectrum. Spectra were processed with an exponential line-broadening 
of 2.0. All 13C NMR spectra were internally referenced to 1,4 dioxane (67.19 ppm in 
D2O).
54 The advantage of 13C-DEPT135 is that it allows the distinction between signals, 
where CH and CH3 are positively and CH2 signals are negatively represented. 
 
 195Pt NMR 
Spectra were recorded on a Bruker-DRX-500 (195Pt, 107.5 MHz) NMR spectrometer at 
298 K and externally referenced to 15 mM K2PtCl6 in D2O (δ 0 ppm). 195Pt NMR was 
performed on a solution containing complex 40 (4 mM) in the presence of cimetidine 
                                           Chapter VI: Photo-irradiation in the presence of cimetidine 
274 
 
(8 mM) irradiated with 463 nm light for 60 min prepared in PBS/D2O at pH* 7.4. The 
195Pt NMR spectra were recorded in the region of -1500 – -4000 ppm for the 
characterisation of PtII-cimetidine species. The following parameters were used d1 = 0 
s, TD 2k, DE 30 μs, digmod baseopt, 256 k scans.5a,b However, no 195Pt NMR 
resonances were detected in the region of interest.  
 
6.2.4 UV-visible spectroscopy  
Solutions of complex 40 (50 µM) were prepared in the absence and presence of 
cimetidine (different mol equiv) in PBS/D2O at pH* 7.4. Samples were irradiated with 
463 nm light (64 mW cm-2) for 5, 15, 30 and 60 min in a 1 ml transparent glass vial. 
Irradiated solutions (ca. 650 µL) were transferred to a black 1 cm quartz UV-visible 
cuvette, where the UV-visible spectra of the irradiated solutions were recorded.  
 
6.2.5 Mass Spectrometry  
 Electrospray Ionisation (ESI) MS 
Samples containing spin trap and/or cimetidine were run in positive mode between the 
range of 50-500 m/z, whereas samples containing complex 40, spin trap and/or 
cimetidine were run in positive mode between ranges of 50-500 m/z and 500-1000 m/z. 
Automatic washes were pre-programmed by the computer software and spectra were 
acquired for ca. 3 min 21 s. Data were processed using the Bruker Daltonics software 
data analysis programme. The instrumentation setup was as described in Chapter II.  
 
 Inductively Coupled Plasma (ICP) MS 
Samples of HaCaT cells treated with complex 40 (42.4 µM) and cimetidine (0.5 mM) 
were provided by Dr. Julie Woods, Photobiology Unit, Ninewell’s Hospital, Dundee, 
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UK for platinum determination. The samples were separated by Dr Julie Woods into 
cell pellets, medium and washes and analysed at Warwick University. ICP-MS was 
performed on both dark and irradiated (λmax = 420 nm, 5 J cm-2) cell samples co-
incubated with complex 40 (42.4 µM) in the absence and presence of cimetidine (500 
µM) in HaCaT immortal human keratinocyte cells. Sample preparation and the 
instrumentation setup for 195Pt ICP-MS analysis were as described in Chapter II.  
 
6.2.6 pKa* Determination 
The experimental pH NMR titration data were fitted to the formula below derived from 
the Henderson–Hasselbalch equation in which Ka, is the dissociation constant for 
protonated cimetidine, δA, and δB are the limiting chemical shifts of protonated 
cimetidine and neutral cimetidine, respectively. 
 
δ= 
δA .  10-pH* + δB .  10-pKa
10-pH* +10-pKa
 
 
The pH* titration curve was fitted using the program ORIGIN version 6.0 (Microcal 
Software Ltd.) In this work the resultant pKa is represented as pKa* due to the value 
measured in D2O, without correction for effects of deuterium on glass electrode. D2O 
can decrease the acidity of acids and affect the binding affinity of protonated groups, in 
comparison to H2O. However, it is possible to convert the pKa
* determined in D2O, to 
the pKa value (and vice versa), using the equation as previously reported by Krȩżel et 
al.55 
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6.3 Results 
6.3.1 Stability of cimetidine  
Prior to studying the effect cimetidine induced on the photo-activation of 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (complex 40), both the photo- and solvent 
stability of cimetidine were investigated. As reported by Greenway, cimetidine exhibits 
two ππ* transitions at 197 nm and 215 nm, attributed to the imidazole ring and 
guanidine moiety, respectively.30 In this work, absorption spectra were recorded in the 
range of 200 – 800 nm, consequently only one ππ* transition at ca. 216 nm was 
observed (Figure 6.9) for cimetidine. This absorption was unaffected after 30 min 
irradiation at 463 nm.    
                   
Figure 6.9 Absorbance spectra of cimetidine (50 µM) prepared in PBS/D2O at pH* 7.4 
both before (−) and (---) irradiation for 30 min at 463 nm.  
 
Next, the photo-stability of cimetidine was monitored by 1H NMR spectroscopy. A 
solution of cimetidine (8 mM) in PBS/D2O was prepared at pH* 7.4. 
1H NMR 
resonances of cimetidine remained stable up to 48 h in the dark. Irradiation at 463 nm 
for 30 min did not induce a change in the 1H NMR resonances of cimetidine (Figure 
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6.10), confirming the photo-stability of cimetidine both in solution and towards 
irradiation at 463 nm.  
                                                      
Figure 6.10 1H NMR spectra of cimetidine (8 mM) prepared in PBS/D2O at pH* 7.4 in 
(A) the dark and (B) after 30 min irradiation at 463 nm, where () refers to internal 
reference, 1,4 dioxane (δ = 3.75).   
 
The stability of cimetidine both before and after irradiation was confirmed by high 
resolution mass spectrometry (HR-MS, Figure 6.11). The mass adducts detected at m/z 
of 253.122 and 275.105 were assigned to [Cim+H]+ and [Cim+Na]+ species, 
respectively. Both adducts remained present in solution throughout the course of 
monitoring the solvent and photo-stability of cimetidine.  
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Figure 6.11 HRMS spectrum of an aqueous solution of cimetidine showing (A) 
protonated [Cim+H]+ and (B) sodium [Cim+Na]+ adducts of cimetidine, in agreement 
with their calculated m/z of 253.3480 and 275.3298, respectively.   
 
An additional solution of cimetidine (8 mM) in the presence of spin trap DMPO (8 mM) 
was prepared in PBS/D2O at pH* 7.4. Despite an overlap between cimetidine (H12) 
and DMPO (Hb) 1H NMR resonances, no reaction was observed either before or after 
irradiation at 463 nm for 30 min (Figure 6.12). The photo-stability of cimetidine 
rendered it a suitable molecule for studying its effect on the photo-irradiation of 
complex 40.  
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Figure 6.12 1H NMR spectra of a solution of cimetidine (8 mM) with DMPO (8 mM) 
prepared in PBS/D2O at pH* 7.4 in (A) dark and (B) after irradiation at 463 nm for 30 
min. Assignments (1H, 500 MHz): Cimetidine peaks, (1-17); DMPO peaks, (a-d); 
overlap between H12 of cimetidine with Hb of DMPO, (); internal reference, 1,4 
dioxane (δ = 3.75), ().  
 
6.3.2 Irradiation of complex 40 in the presence of cimetidine 
The dark UV-visible spectrum of complex 40 exhibits an absorption band at ca. 294 nm 
assigned as the N3PtIV LMCT band, commonly used to monitor the photo-
decomposition of complex 40. Addition of cimetidine (up to 8 mol equiv) had no effect 
on this LMCT band in the dark (Figure 6.13). The absorbance of cimetidine at ca. 214 
nm was masked by the absorbance of complex 40. Consequently, the rise in absorbance 
at ca. 245 nm is attributed to the presence of cimetidine in solution (, Figure 6.13).  
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Figure 6.13 Dark UV-visible spectra of solutions containing complex 40 (50 µM) in 
the (A) absence and presence of (B) 10 µM; (C) 25 µM; (D) 50 µM; (E) 100 µM; (F) 
200 µM; (G) 300 µM; (H) 400 µM cimetidine prepared in PBS/D2O at pH* 7.4. Rise 
in absorbance at ca. 245 nm () attributed to cimetidine absorbance.  
 
Photo-irradiation of complex 40 (50 µM) at 463 nm for 5, 15, 30 and 60 min led to a 
successive decrease in the N3→PtIV LMCT band, indicating the photo-release of the 
azide ligand, as previously reported (A, Figure 6.14).1 Similar irradiations of complex 
40 (50 µM) in the presence of (B) 10 µM; (C) 25 µM; (D) 50 µM; (E) 100 µM; (F) 200 
µM; (G) 300 µM; (H) 400 µM cimetidine induced an equivalent photo-decomposition 
of ca. 60% (ca. 30 µM) in the LMCT band (B-H, Figure 6.14) of complex 40. 
Interestingly, addition of 200 µM cimetidine led to the formation of an isosbestic point 
(a', insets F1, Figure 6.14), together with a rise in the absorbance between 340 – 400 
nm with a maximum absorbance at ca. 354 nm. This absorbance increased with 
successive addition of cimetidine (insets G1 and H1, Figure 6.14), summarised in 
(Figure 6.15). Consequently, it appears that the formation of this new species with λmax 
at ca. 354 nm, is dependent on the amount of cimetidine present 
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Figure 6.14 UV-visible spectra of solutions in the (–) dark and after (–) 5 min; (–) 15 
min; (–) 30 min and (–) 60 min irradiation at 463 nm containing complex 40 (50 µM) 
in (A) absence and presence of (B) 10 µM; (C) 25 µM; (D) 50 µM; (E) 100 µM; (F) 
200 µM; (G) 300 µM; (H) 400 µM cimetidine prepared in PBS/D2O at pH* 7.4. 
Decrease () observed in the N3→PtIV LMCT band in all spectra (A-H). Insets F1 – H1 
shows isosbestic point at ca. 337 nm (a'). Band at ca. 354 nm attributed to LMCT 
transition. 
 
.  
                                           Chapter VI: Photo-irradiation in the presence of cimetidine 
282 
 
   
Figure 6.15 Increase in the absorbance at ca. 354 nm upon the successive addition of 
cimetidine (µM) to a solution containing complex 40 after 60 min irradiation at 463 nm 
prepared in PBS/D2O at pH* 7.4.  
 
The equivalent decrease in the N3Pt band of complex 40 in both the absence and 
presence of cimetidine as observed from Figure 6.14, suggested an equivalent amount 
of N3 radicals were generated. However, the increase in absorbance at ca. 354 nm 
suggested an alternative photo-decomposition pathway of complex 40 in the presence 
of cimetidine. This is believed to be induced from a reaction between cimetidine with 
the PtII intermediate formed from the photo-irradiation of complex 40. Additionally, as 
discussed in Chapter IV, N3 radicals are known to readily undergo one-electron 
oxidation transfer reactions.56 Consequently, this interaction between the formed N3 
radicals with cimetidine could also contribute to the rise in absorbance. This potential 
interaction between the N3 radicals with cimetidine was investigated by EPR 
spectroscopy.  
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6.3.3 Azidyl radical trapping  
Photo-irradiation of a solution of complex 40 (1 mM) in the presence of DMPO (2 mM) 
at 463 nm for 7 min and 14 min led to the formation of ca. 6.8% and 10.5% (per mol of 
complex 40), respectively, of the DMPO-N3 spin adduct (previously characterised in 
Chapter III), in the absence of cimetidine ( Figure 6.16A). In the presence of 
cimetidine (2 and 4 mol equiv, Figure 6.16A), ca. 4% and 8.5% of the DMPO-N3 spin 
adduct was formed after 7 min and 14 min, respectively, upon irradiation at 463 nm. 
 
Figure 6.16 Quantification of the DMPO-N3 spin adduct formed after 7 min and 14 
min irradiation at 463 nm from a solution containing (A) complex 40 (1 mM) and 
DMPO (2 mM); (B) complex 40 (450 µM) and DMPO (900 µM) both in the () 
absence and presence of () 2 mol equiv, () 4 mol equiv cimetidine, prepared in 
PBS/D2O at pH* 7.4. No EPR signal was observed in the dark. Error bars represent 
standard error of two independent experiments.   
 
The concentration of complex 40 was reduced to more physiologically relevant 
conditions to observe the quenching of the N3 radicals by cimetidine. Photo-irradiation 
of complex 40 (450 M) with DMPO (900 M) in both the absence and presence of 
cimetidine (4 mol equiv) irradiated at 463 nm for 14 min prepared in PBS/D2O at pH* 
7.4, also led to the formation of the DMPO-N3 spin adduct. However, in the presence 
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of cimetidine, the amount of the DMPO-N3 spin adduct was ca. three-fold lower, after 
7 min irradiation with 463 nm light, compared to the spin adduct formed in the absence 
of cimetidine, (Figure 6.16B). This suppression in N3 radical trapping became less 
effective with further irradiation. This reduction in N3 radicals trapped by DMPO 
suggested the possible quenching of the N3 radicals by cimetidine. To confirm this, 
NMR spectroscopy was performed.  
 
6.3.4 1H NMR spectroscopy  
6.3.4.1 Aromatic region 
A solution of complex 40 (4 mM) in the presence of cimetidine (8 mM) was prepared 
in PBS/D2O solution at pH* 7.4. Neither the 
1H NMR proton resonances of complex 
40 nor cimetidine in the dark were affected (A, Figure 6.17). An initial 15 min 
irradiation with 463 nm light reduced the concentration of complex 40 to ca. 3.5 mM 
(12% photo-decomposition per mol of complex 40), with sequential photo-
decomposition of complex 40 observed with further (B-D, Figure 6.17) irradiation 
(Table 6.1). Both a decrease and a slight downfield shift of the 1H NMR resonance of 
the imidazolic proton (H5, 7.6 ppm) of cimetidine were observed upon prolonged 
irradiation.  
 
As can be seen from Figure 6.17, photo-irradiation of complex 40 with 463 nm light 
led to the generation of photo-products e (8.73 ppm); f (8.25 ppm); g (8.0 ppm); h 
(7.77 ppm) and i (7.56 ppm). These photo-products were observed from the photo-
irradiation of complex 40 only (Figure 6.17), previously characterised in Chapter IV. 
However, photo-products j (8.7 ppm); k (8.55 ppm); n (7.88 ppm) and q (7.47 
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ppm) were observed only from the photo-irradiation of complex 40 in the presence of 
cimetidine (Figure A6.1).  
         
Figure 6.17 The aromatic region of the 1H NMR spectra of complex 40 (4 mM) in the 
presence of cimetidine (8 mM) prepared in PBS/D2O at pH* 7.4 in the (A) dark and 
after (B) 15 min; (C) 30 min and (D) 60 min irradiation at 463 nm. Assignments: Pt-py 
peaks, (o/p/m); cimetidine peak (5); photo-generated Pt-species in both the 
absence/presence of cimetidine, (f'-i'); photo-generated species only in the presence of 
cimetidine, (). See Figure 6.22 for aliphatic region.  
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Table 6.1 Quantification of complex 40 and platinum photo-products (f'-i') from Figure 
6.17, by 1H NMR integration.  
Time / (min) [40] / (mM) [f'-i']/ mM 
0 4 - 
15 3.5  0.2 
30 3.3  0.5 
60 1.9  0.8 
       
The generation of these new photo-products (j'', k, n and q) supports the UV-visible 
data that an alternative photo-decomposition pathway of photo-irradiated complex 40 
occurs in the presence of cimetidine.  
 
In an attempt to characterise the photo-products (j, k, n and q, Figure 6.17B), a 
comparison between 1H NMR resonances of complex 40, PtII-py products (intermediate 
species formed during the synthesis of complex 40, previously characterised in 
Chapter II) and free pyridine were made. After 15 min irradiation at 463 nm, the 1H 
NMR resonance j at 8.7 ppm, appeared as a doublet (Figure 6.17B). Additional 
irradiation (60 min at 463 nm), changed the multiplicity of this 1H NMR resonance to 
a pseudo-quartet (inset, Figure 6.17D). This change is likely to be related to the 
transition of mono- to bi-dentate coordination of cimetidine to the PtII photoproduct. 
The remaining photo-generated peaks k (8.55 ppm), n (7.88 ppm) and q (7.47 ppm) 
were compared with the 1H NMR resonances of pyridine (2 mM, PBS/D2O),
54 and were 
in agreement (Figure 6.18).  
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Figure 6.18 The aromatic region of the 1H NMR spectra of (A) free pyridine and (B) 
photo-irradiation of complex 40 (4 mM) in the presence of cimetidine (8 mM) at 463 
nm for 60 min prepared in PBS/D2O at pH* 7.4. Assignments: pyridine peaks, 
(O/P/M); Photo-peaks k, n and q assigned to the Hortho, Hpara and Hmeta resonances 
of pyridine, respectively. Remaining peaks as assigned in Figure 6.17.  
 
6.3.4.2 Mass Spectrometry  
The formation of a PtII-cimetidine species and detection of photo-released pyridine 
from irradiated complex 40 was investigated, by performing mass spectrometry. MS of 
an irradiated solution of complex 40 (4 mM) and cimetidine (8 mM) at 463 nm for 60 
min prepared in H2O at pH 7.4, was recorded in the range of 500 – 1000 m/z. Low 
resolution MS led to the detection of mass adducts at m/z of 567.2, 622.2, 647.0 and 
722.2 (Figure 6.19A). Performing HR-MS on the same sample led to the detection of a 
mass adduct at ca. m/z of 647.1755, assignable to [Pt(py)2(OH2)(cim)+Na]
3+ (67, Figure 
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6.19B), in agreement with its simulated mass spectrum. Consequently, the mass adduct 
at ca. m/z of 622.2 was assignable to trans-[Pt(py)2(OH2)(cim)+H]
3+. Furthermore, the 
mass adduct at ca. m/z of 567.2 was deduced to be trans-[Pt(py)(OH2)(cim)+Na]
3+ (68).  
 
The detection of a bi-dentate platinum(II)-cimetidine species may rationalise the 
change in the 1H NMR resonance j''. Finally, the MS adduct at m/z of ca. 722.2 was 
assigned to [Pt(cim)2+Na]
3+ (69). None of these MS adducts were detected in the 
absence of cimetidine. These data confirmed photo-irradiation of complex 40 in the 
presence of cimetidine led to an alternative photo-decomposition pathway. 
Furthermore, HR-MS detected a peak at ca. m/z 159.070, assigned to a pyridine dimer, 
[2(py)+H]+ (Figure 6.20), a species previously reported.57 All photo-generated MS 
peaks are summarised in Table 6.2.  
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Figure 6.19 Mass spectrum from a solution containing complex 40 (4 mM) in the 
presence of cimetidine (8 mM) irradiated at 463 nm for 60 min prepared in H2O at pH 
7.4. Mass adducts together with simulated mass spectra detected at (A) low resolution 
and (B) high resolution. Mass adduct at m/z of ca. 646.1647 is assigned to trans-
[Pt(py)2(OH2)(cim)+Na]
3+ species, 67; 567.2 is assigned to [Pt(py)(OH2)(cim)+Na]
3+, 
68; and 722.2 is assigned to [Pt(cim)2+Na]
3+ (69), in agreement with their isotopic 
distribution models.  
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Figure 6.20 Lower m/z region of HR-MS spectrum from a solution containing complex 
40 (4 mM) in the presence of cimetidine (8 mM) irradiated at 463 nm for 60 min. 
Release of pyridine from complex 40 gave rise to fragment at m/z 159.0701 (A) [2(py) 
+ H]+, m/z calc. 159.0844. Mass adducts at m/z 253.1227 and 494.0630 were previously 
assigned to [Cim+H]+ and [Complex 40+Na]+, respectively, refer to section 6.3.1 and 
as reported by Farrer.1  
 
The detection of the species [Pt(py)2(OH2)2]
2+ (60, previously detected in Chapter V) 
at m/z of 389.056, further supported the release of the two azide ligands. Furthermore, 
the quantification of pyridine released from photo-irradiated complex 40 was 
determined via 1H NMR integration (Table 6.3).  
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Table 6.2 Assignment of MS adducts found in Figures 6.19 and 6.20 
Found m/z Structure Formula Cal. m/z  
 
159.0698a 
 
 
C10H11N2 
[(py2)+H]
+ 
 
159.0844 
 
389.0561a 
          
 
C10H14N2O2Pt 
[Pt(OH2)2(py)2]
2+ 
 
389.0703 
 
567.2b 
 
 
C15H23N7OPtSNa 
[Pt(py)(OH)2(cim)+Na]
3+ 
 
567.1 
 
622.2b 
 
 
C20H29N8OPtS 
[Pt(py)2(OH2)(cim) H]
3+ 
 
622.2 
 
646.1647a 
  
 
C 2 0 H 2 8 N 8 O P t S N a 
[Pt(py)2(OH2)(cim)+Na]
3+ 
 
646.1652 
 
722.2b 
 
 
C20H32N12PtS2Na 
[Pt(cim)2+Na]
3+ 
 
722.2 
aHR-MS; blow resolution MS 
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Table 6.3 Quantification of pyridine released from photo-irradiated complex 40 (4 
mM) in the presence of cimetidine (8 mM) as depicted in Figure 6.17.  
Time / min Pyridine / mM  
Dark -  
15 0.2  
30 0.4  
60 0.9  
 
From the above data, it is apparent that cimetidine is involved in the photo-
decomposition pathway of photo-irradiated complex 40. To further confirm the 
involvement of cimetidine, analysis of its 1H NMR resonances was performed.  
 
6.3.4.3 pKa* of cimetidine  
The down-field shift of the H5 peak in the 1H NMR spectrum of cimetidine has been 
previously associated with metal coordination via the sulfur (S11) atom of cimetidine. 
The imidazolic nitrogen (N4) has a reported pKa value of ca. 6.9 (Figure 6.3). As shown 
in the previous section, photo-irradiation of complex 40 (4 mM) in the presence of 
cimetidine (8 mM) led to a stepwise decrease in the pH* of the solution (refer to Figure 
6.17). Therefore, a solution of cimetidine (8 mM) was prepared in PBS/D2O at pH* 7.4. 
The pH* of this solution was adjusted using 0.1 M NaOH and 0.1 M HCl, to obtain a 
plot of the chemical shift of the H5 resonance of cimetidine as a function of change in 
pH*. From Figure 6.21, the downfield shift of the H5 peak increased with decreasing 
pH*, a similar effect as observed in the presence of irradiated complex 40. Moreover, 
the pKa
*
 value of 7.1 ± 0.07 obtained is in good agreement with previous literature,
58 
slight differences can be attributed to the pKa measured on a pH electrode without 
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correction effects for D2O (refer to section 6.2.6). Therefore, in this work, the downfield 
chemical shift of the H5 NMR resonance of cimetidine, cannot be attributed to metal 
coordination.       
               
Figure 6.21 The pH* values plotted against the 1H NMR chemical shifts (δ) for a 
solution of cimetidine (8 mM) prepared in PBS/D2O at pH* values ranging from 7.4 -
2.3. The pKa
* value of 7.1 ± 0.07 was determined as described in experimental section 
and is in agreement with previously reported value for the imidazolic NH group.58  
 
6.3.4.4 Aliphatic region  
Next, the 1H NMR resonances of cimetidine were analysed from the solution containing 
complex 40 (4 mM) and cimetidine (8 mM) prepared in PBS/D2O at pH* 7.4 in both 
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the dark and after 60 min irradiation at 463 nm. In the dark, cimetidine exhibited six 1H 
NMR resonances (Figure 6.22A), unaffected by the presence of complex 40.  
   
Figure 6.22 1H NMR spectra of a solution of complex 40 (4 mM) in the presence of 
cimetidine (8 mM) in (A) the dark and (B) after 60 min irradiation at 463 nm. 
Assignments: free cimetidine peaks (1-17); photo-generated species (α-κ). Spectra 
internally referenced to HMDSO (0.28 ppm in D2O) due to overlap of 
1H NMR 
resonances of cimetidine with 1,4 dioxane. Photo-products (α-κ) assigned to a structure 
as shown, where M = PtII metal ion and R refers to amine/H2O ligands.  
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After 60 min irradiation with 463 nm light, ca. 40% (3 mM) of cimetidine photo-
decomposed, as determined by 1H NMR integration (Figure 6.22B). Additionally, new 
1H NMR resonances were observed (inset spectra, Figure 6.22B) and were distinct from 
1H NMR resonances of free cimetidine. The photo-products (α-κ) were compared to the 
1H NMR resonances of both [Pd(cim)Cl2]
 and [Pt(cim)2]Cl2 species, previously 
characterised by Onoa.49 The 1H NMR resonances of the photo-products (α-κ) are in 
closer agreement with those values previously reported for the [Pd(cim)Cl2]
 complex 
(Table 6.4).  
 
Table 6.4 Comparison of the 1H NMR chemical shifts (ppm) of photo-products (α-κ) 
as observed from Figure 6.22B with a previously reported [Pd(cim)Cl2]
 species.49  
Complex H5 H10 H13 H17 H12 H6 
aPd-cim 7.93 (s) 4.13 - 4.08 
(d) 
3.52 (m)  2.69 (d)  3.08 (t) 2.18 (s) 
  3.91 – 3.86 
(d) 
    
b68 8.2 (κ, 
s) 
4.25 - 4.20 
(α) 
3.54 (γ, 
m)   
2.5 (η, 
d) 
3.12 (β, 
t)   
2.4 (θ, 
s) 
  4.17 – 4.11 α'     
σ 0.6 -1.0 -0.24 0.3 -0.47 0.2 
aspectra registered in DMSO-d6 at RT (values from ref 49); bspectra registered in 
PBS/D2O at RT from the photo-irradiation of complex 40 (4 mM) in the presence of 
cimetidine (8 mM) with 463 nm light after 60 min; s, singlet; b, broad; m, multiplet; σ 
refers to chemical shift (ppm) difference between free and coordinated cimetidine.  
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Consequently, the photo-products (α-κ) are assigned to [Pt(py)(OH2)(cim)]2+ (68) 
species. This further supports the MS data on the detection of the mass adduct at m/z of 
ca. 567.2, assigned to [Pt(py)(OH2)(cim)+Na]
3+. The minor differences in the 1H NMR 
resonances of 68 and [Pd(cim)Cl2]
  species as observed in Table 6.4, are attributed to 
the different solvents (PBS/D2O vs. DMSO-d6) used to register the species and central 
metal ions (PtII vs. PdII) present in both 68 and [Pd(cim)Cl2]
 species, respectively. 
Moreover, the presence of free pyridine and additional photo-products in the irradiated 
solution can also influence the resultant chemical shift values of 68 compared to the 
[Pd(cim)Cl2]
  species. A similar photo-irradiation of complex 40 (4 mM) and cimetidine 
(8 mM) was performed in the presence of spin trap, DMPO (8 mM, Figure 6.23).  
 
Equivalent photo-products in both the aromatic and aliphatic region were observed in 
the presence of DMPO, as previously described in section 6.3.4.1 and 6.3.4.2, 
respectively. Consequently, the presence of the spin trap, DMPO did not appear to 
affect the formation of 68. New photo-products were observed in the aliphatic region 
(inset iii, Figure 6.23B), previously assigned to the DMPO-N3 hydroxylamine species 
(Chapter IV). Interestingly, in the absence of cimetidine, the DMPO 1H NMR 
resonances decreased by ca. 25%, in comparison to ca. 10% in the presence of 
cimetidine. This supports the partial quenching of the ●N3 radicals by cimetidine, as 
observed by EPR spectroscopy. The quenching of ●N3 radicals by cimetidine is 
investigated further by 14N NMR spectroscopy, in section 6.3.5. Additionally, 13C-
DEPT135 NMR spectroscopy was performed to further elucidate a distinction between 
free and coordinated cimetidine peaks.  
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Figure 6.23 1H NMR spectra from the photo-irradiation of complex 40 (4 mM), 
cimetidine (8 mM) in the presence of DMPO (8 mM) prepared in PBS/D2O at pH* 7.4 
in (A) the dark and (B) after 60 min irradiation with 463 nm light. Additional () 1H 
NMR resonances assigned to the DMPO-N3 hydroxylamine species; other resonances 
as labelled previously in Figures 6.17 and 6.22.  
 
6.3.4.5 13C-DEPT135 NMR 
A solution of complex 40 (9 mM) with DMPO (2 mol equiv) in the presence of 
cimetidine (2 mol equiv) was prepared in PBS/D2O at pH* 7.4. The dark 
13C-DEPT135 
NMR spectrum displayed resonances for all CH, CH3 and CH2 groups present in 
complex 40, DMPO and cimetidine (Figure 6.24A). Carbon atoms without bound 
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hydrogen were not detected. Irradiation at 463 nm for 60 min led to a decrease in all 
13C-DEPT135 NMR resonances of complex 40, DMPO and free cimetidine. Additional 
13C-DEPT135 NMR signals were observed (Figure 6.24B). These new peaks were 
compared to 13C NMR data from previously reported [Pd(cim)Cl2] species (Table 
6.5).49           
 
      
Figure 6.24 13C-DEPT135 NMR spectra of complex 40 (9 mM), DMPO (2 mol equiv) 
in the presence of cimetidine (2 mol equiv) prepared in PBS/D2O at pH* 7.4 in (A) dark 
and (B) irradiated for 30 min at 463 nm. Assignments: pyridine carbons, (o/p/m); 
DMPO, (a-d); free cimetidine, (5-17); coordinated cimetidine, (α-θ); internal reference 
1,4-dioxane, (▲).  
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A downfield shift in the 13C-DEPT135 NMR resonances of both C5 and C10 was 
observed for 68 (Table 6.5), in agreement with those reported for [Pd(cim)Cl2] species. 
These data further support 68 as being a bidentate-cimetidine platinum(II) species, as 
assigned by 1H NMR and mass spectrometry. 
 
Table 6.5 Comparison of 13C and 13C-DEPT135 NMR chemical shifts for [Pd(cim)Cl2] 
and 62 species, respectively.  
Complex C5 C2 C10 C13 C17 C12 C6 
aPd-cim 137.05 117.95 32.55 40.52 28.52 37.68 10.01 
b68 136.0 121.0 28.55 50.9 48.6 36.2 9.4 
aspectra registered in DMSO-d6 at RT (values from ref 49); bspectra registered in 
PBS/D2O at RT, refer to Figure 6.24B.  
 
Moreover, Norman et al. reported on the 195Pt NMR chemical shifts of 1:1 platinum-L-
methionine complexes in the region of -2500 – 4000 ppm.59 In this work, 195Pt NMR 
spectra were recorded across the range of -1500 - -4000 ppm. However, no 195Pt NMR 
peak(s) were detected. This is attributed to the amount of 68 being formed, which is 
below the detection limit for 195Pt NMR spectroscopy.  
 
Next, the partial quenching of the N3 radicals by cimetidine was investigated. Azidyl 
radicals are well-known to undergo one-electron oxidation reactions, leading to the 
formation of free azide (N3ˉ). To confirm the reaction between the azidyl radicals with 
cimetidine, 14N NMR was performed.  
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6.3.5 Quenching of the azidyl radicals by cimetidine  
Prior to investigating an interaction between the formed ●N3 radicals with cimetidine 
various control experiments were performed. Individual solutions of pyridine (6 mM) 
and cimetidine (18 mM) were prepared in PBS/D2O at pH* 7.4. In addition to 
atmospheric nitrogen gas (N2), a broad peak was detected at ca. 271 ppm assigned to 
the nitrogen atom of free pyridine (Figure 6.25). The 14N NMR spectrum of free 
cimetidine (25 mM) prepared in PBS/D2O at pH* 7.4, displayed a resonance at ca. 
168.2 ppm, assignable to the imidazole nitrogen (N1) present in cimetidine (Figure 
6.25). The remaining 14N resonances present in cimetidine have been reported by solid-
state (SS) NMR to be outside the investigated region, N4, -155 ppm; N14, -20 ppm; 
N16, - 70 ppm; N18, -65 ppm;  N20, -95 ppm.60 
                                              
Figure 6.25 14N NMR spectra of solutions of (A) pyridine (6 mM) and (B) cimetidine 
(25 mM) prepared in PBS/D2O at pH* 7.4. Assignments: nitrogen resonance from free 
pyridine, (N, 272.2 ppm); imidazolic nitrogen of cimetidine, (N1, 168.2 ppm).  
 
The 14N NMR spectrum of a solution of complex 40 (6 mM) in the presence of 
cimetidine (12 mM) prepared in PBS/D2O at pH* 7.4 displayed resonances of 
coordinated azide and pyridine as well as atmospheric N2 (Figure 6.25A) in the dark. A 
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decrease in both coordinated azide and pyridine 14N NMR resonances were observed, 
after 60 min irradiation with 463 nm light. An additional peak at ca. 78.1 ppm was 
assigned to the central (Nβ) nitrogen of free azide (Figure 6.26B), as previously 
observed in Chapter IV.  
        
Figure 6.26 14N NMR spectra of complex 40 (6 mM) in the presence of cimetidine (12 
mM) prepared in PBS/D2O at pH* 7.4 in (A) the dark and (B) after irradiation with 463 
nm light for 60 min. Assignments: atmospheric nitrogen gas, (N2, 289.2 ppm); inset 
illustrating distinction between central nitrogen (Nβ) of coordinated azide with terminal 
nitrogen (Nγ) of free azide (N3ˉ), (Nβ/Nγ, 229.1 ppm); overlap between terminal 
nitrogen of coordinated azide with nitrogen of coordinated pyridine (N), (Nγ/N, 166.5 
ppm); central nitrogen of free azide, (Nβ, 77.3 ppm). 
 
Interestingly, an increase in the 14N NMR resonance of N2 (289.2 ppm) was observed 
suggesting azidyl radical decomposition to form molecular nitrogen (Figure 6.26B). 
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The resonance at 166.5 ppm, appeared to exhibit a broadening after irradiation, thought 
to be due to the coordination of the imidazolic nitrogen (N4) of cimetidine to the PtII 
metal centre. This is in agreement with previous reports of PtII coordination to 1-
methylimidazole via the imidazolic NH atom.61 The broadening in the 14N NMR 
resonance at 166.5 ppm, further supports the 13C-dept135 downfield shifts of both C5 
and C10, attributed to PtII coordination to both the sulfur (S11) and imidazolic nitrogen 
(N4) atoms of cimetidine. Free azide (N3ˉ) has not been reported from the photo-
irradiation of complex 40 alone (see Chapter IV). Consequently, detection of N3ˉ in 
this work confirms the interaction between the formed azidyl radicals with cimetidine. 
However, from these data the site at which the ●N3 radical abstracts an electron was not 
apparent.  
 
Therefore, in an attempt to elucidate the site of N3 radical reactivity, two molecules, 
L-methionine and histamine were chosen to represent the thioether (Figure 6.27A) and 
imidazole (Figure 6.27B) moieties present in cimetidine.  
               
Figure 6.27 Structure of (A) L-methionine and (B) histamine at physiological pH 7.0  
 
6.3.5.1 Thioether or imidazole radical formation 
Individual solutions of complex 40 (4 mM), DMPO (8 mM) in the absence and presence 
of L-methionine (2 mol equiv) and histamine (2 mol equiv) were irradiated with 463 
nm light for 14 min prepared in PBS/D2O at pH* 7.4 (Figure 6.28).  
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Figure 6.28 EPR spectra of the DMPO-N3 spin adduct formed from the photo-
irradiation of complex 40 (4 mM), DMPO (8 mM) with 463 nm light after 7 min 
prepared in PBS/D2O at pH* 7.4 in the absence and presence of L-methionine (8 mM, 
2 mol equiv) and presence of histamine (8 mM, 2 mol equiv). Decrease (ca. 20%) in 
the DMPO-N3 spin adduct determined in the presence of histamine. 
 
An equivalent formation in the DMPO-N3 spin adduct (previously characterised in 
Chapter III), was observed in both the absence and presence of L-methionine. This 
suggests that neither the thioether nor the amino (-NH2) groups, are the site of N3 
radical reaction. In contrast, a ca. 20% reduction in the DMPO-N3 spin adduct was 
observed in the presence of histamine (blue line, Figure 6.28). This decrease supports 
the suggestion that the imidazole ring is the site of one-electron transfer. Moreover, 
one-electron transfer of cimetidine to the N3 radicals suggests formation of a cimetidine 
radical cation), which has potential to deprotonate at neutral pH 7 and form the neutral 
cimetidine radical.  
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Interestingly, no precipitate was observed from the photo-irradiation of complex 40 in 
the presence of cimetidine. This suggests that the formed cimetidine neutral radical did 
not undergo polymerisation, in contrast to L-tryptophan and melatonin radicals (refer 
to Chapter IV and Chapter V).  
 
To conclude this section, EPR, 1H/13C-dept135 NMR spectroscopy and mass 
spectrometry detected and characterised various photo-products, including azidyl 
radicals, free azide, PtII-cimetidine species and free pyridine. Formation of Pt-
S(thioether) species have been associated with adverse toxic effects and resistance 
mechanisms.50 Therefore, cellular studies were performed to determine the photo-
cytotoxicity of complex 40 in the presence of cimetidine in HaCaT immortal human 
keratinocyte cells.  
 
6.3.7 Cell studies 
6.3.7.1 Cell viability in HaCaT keratinocytes cells  
To assess the photo-cytotoxicity of complex 40 in the presence of cimetidine, cell 
viability in both the dark and after irradiation with 420 nm (5 J cm-2) light was 
determined for the co-incubation of cimetidine (0.15 and 1.5 mM) in the presence of 
complex 40 (different concentrations) in HaCaT keratinocytes cells. None of the 
solutions exhibited dark toxicity (filled markers, Figure 6.29). Increasing the 
concentration of complex 40 from ca. 1.7 µM to ca. 107 µM, efficiently demonstrated 
its potent anti-proliferative activity in HaCaT cells (open squares, ; Figure 6.29). 
Photo-irradiation of complex 40 (3.3 µM) with 420 nm light reduced the viability of 
HaCaT cells by ca. 7%, in contrast to ca. 4% viable cells remaining after photo-
irradiation of 53 µM complex 40. Interestingly, photo-irradiation of complex 40 (53 
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µM) but in the presence of cimetidine (0.15 mM) led to ca. 91% of viable cells (, 
Figure 6.29). The photo-cytotoxicity of complex 40 (different concentrations) was 
completely suppressed in the presence of 1.5 mM cimetidine.  
             
Figure 6.29 The percentage cell viability induced by the photo-irradiation of complex 
40 (various concentrations) in the presence of cimetidine (0.15 mM and 1.5 mM) in 
HaCaT keratinocytes cells in the (filled markers) dark and (open markers) after 
irradiation with λmax = 420 nm light (5 J cm-2). Error bars represent ± standard errors 
for the mean of two experiments performed in triplicate, where * refers to one 
experiment performed in triplicate.  
 
To assess the dose-dependent nature of this protective effect, the cell viability in both 
the dark and after irradiation with 420 nm (5 J cm-2) was determined from the co-
incubation of complex 40 (42.4 µM) in the presence of cimetidine (various 
concentrations) in HaCaT keratinocytes cells. As before no dark toxicity was observed. 
Interestingly, irradiation of complex 40 (42.4 µM) with 420 nm light led to an 
equivalent photo-protective effect in the presence of both the lowest (46.9 µM) and 
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highest (1.5 mM) concentrations of cimetidine (Figure 6.30). These data confirmed that 
the photo-protective effect induced by cimetidine was dose independent.  
            
Figure 6.30 The percentage cell viability induced by the photo-irradiation of complex 
40 (42.4 µM) in the presence of cimetidine (various concentrations) in HaCaT 
keratinocytes cells in the () dark and () after irradiation with λmax = 420 nm light (5 
J cm-2). Error bars represent ± standard deviation for the mean of two independent 
experiments performed.  
 
The induction of this photo-protective effect had potential to be due to a reduced 
platinum accumulation in the presence of cimetidine. Therefore, ICP-MS was 
performed to determine the Pt accumulation in HaCaT keratinocyte cells, in both the 
absence and presence of cimetidine.  
 
6.3.7.2 Platinum accumulation in the presence of cimetidine 
ICP-MS was performed on both dark and irradiated cell samples provided by Dr. Julie 
Woods. Cell samples contained complex 40 (20 µg/ml) in both the absence and 
presence of cimetidine (0.5 mM) and were prepared for ICP-MS as described in 
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Chapter II. In the dark, an equivalent accumulation of 195Pt was observed for both 
samples (ca. 0.0010 ± 0.002 ppb/106 cells, A and B, Figure 6.31). However, irradiation 
of complex 40 at max = 420 nm (5 J cm-2) in the presence of cimetidine led to reduction 
of ca. 20% in platinum uptake in HaCaT cells (Figure 6.31D).    
        
Figure 6.31 Platinum accumulation determined by ICP-MS for HaCaT cells co-
incubated with complex 40 (50 µM) in both the absence and presence of cimetidine 
(0.5 mM) in both the dark (A and B) and after irradiation (C and D) with 420 nm light 
(5 J cm-2). Error bars represent ± standard error of the mean for two independent 
experiments performed in duplicate.  
 
These results indicated the ability of cimetidine to suppress the photo-cytotoxicity of 
complex 40. Interestingly, previous photo-irradiation studies of 36 (Figure 6.8) in the 
presence of DMS, led to an alternative photo-decomposition pathway, as reported by 
Ronconi.53 Consequently, it appears that sulfur-containing complexes have the ability 
to induce alternative photo-decomposition pathways of platinum(IV) diazido anticancer 
complexes.  
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6.4 Discussion  
6.4.1 Bi-dentate cimetidine-platinum(II) complex 
A decrease in the N3PtIV LMCT band at ca. 294 nm of photo-irradiated complex 40, 
has been previously attributed to the loss of the coordinated azide ligands, in azidyl 
(N3) radical form. Photo-irradiation of complex 40 in the presence of cimetidine led to 
the successive and equivalent decrease in the N3PtIV LMCT band, as previously 
observed. Therefore, the initial photo-decomposition pathway of complex 40 appeared 
to be unaffected by the presence of cimetidine. The release of the azide ligands was 
confirmed by detection of the DMPO-N3 spin adduct, by EPR spectroscopy.  
 
Photo-irradiation of complex 40 in the presence of cimetidine (0.2 – 8 mol equiv) led 
to the formation of an isosbestic point at ca. 337 nm and an increase in absorbance at 
ca. 354 nm. The rise in absorbance at ca. 354 nm was determined to be directly 
dependent on the amount of photo-decomposed cimetidine. Deducing ca. 15 µM (50% 
of the photo-decomposed complex 40) reacts with cimetidine (H1, Figure 6.14), an 
extinction coefficient of ca. 7334 M-1 cm-1 is obtained. This high ε value suggests this 
band at ca. 354 nm is due to a ligand-metal-charge transfer (LMCT) transition.  
 
Previous studies of MII transition metals (e.g. CuII, PdII and PtII) bound to sulfur ligands 
have reported on the occurrence of SM2+, ligand-to-metal-charge-transfer transitions. 
These have been attributed to the presence of the lone pair on the sulfur atom residing 
at a lower energy than the dx
2-y
2 orbital62 of the MII (refer to Chapter I, p. 10 for d-
orbital splitting in square planar complexes). Consequently, the absorbance observed at 
ca. 354 nm is in agreement with a SPtII, LMCT transition. The observation of this 
absorbance suggested the formation of a PtII-cimetidine related species. Consequently, 
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this rationalised the presence of the isosbestic point at ca. 337 nm. This is in agreement 
with previous characterisation of transition metal-cimetidine complexes where various 
absorption bands in the visible region of the absorption spectrum were attributed to 
LMCT transitions.63 
 
1H NMR spectroscopy revealed that photo-irradiation of trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (40) in the presence of cimetidine led to the release of coordinated 
pyridine from complex 40, which increased with prolonged irradiation. Moreover, 
additional 1H NMR resonances in the aromatic region were attributed to a PtII-
cimetidine related species. A change in the 1H NMR resonance j'' from a doublet to a 
multiplet may be due to a transition from a mono- to a bi-dentate coordination of 
cimetidine to platinum(II). PtII is a soft metal ion and exhibits a strong affinity for sulfur, 
a soft ligand. Therefore, an initial reaction between the platinum(II) photo-product, 
trans-[Pt(py)2(OH)2]
2+, as detected by MS is believed to undergo mono-dentate 
coordination of cimetidine, through substitution of a water ligand. This was confirmed 
by the detection of the mass adduct at 646.1647 (Figure 6.19) assigned to 
[Pt(OH2)(py)2(cim)+Na]
3+ (67).  
 
Previous studies by Chen reported that the imidazole ring of L-histidine can displace 
the Pt-S(thioether) bond, at pH > 6.64 However, additional reactions of cis-platin 
performed with L-methionine and/or UBQ, identified six-membered S,N ring species 
as products. In this work, cimetidine contains an imidazole ring. The observation of 
free pyridine from the photo-irradiation of complex 40 in the presence of cimetidine, 
suggests ring closure occurs opposed to transformation of PtII-S(thioether) to PtII-
N(imidazole ring). The distinct change in the H10 1H NMR resonance from an “A2” to 
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an “AB” type system was indicative of the formation of a stereogenic centre at the 
sulfur (S11) atom of cimetidine (refer to Figure 6.22). This supported the formation of 
a mono-cimetidine platinum(II) species. Additionally, the downfield shifts of C5 and 
C10 13C-DEPT135 NMR resonances were indicative of PtII coordination via both the 
sulfur and imidazole nitrogen atoms, in agreement with the MS data from the detection 
of [Pt(py)(OH2)(cim)+Na]
3+ (68). Additionally, these NMR spectroscopic results were 
in agreement with a previous characterisation of a mono-cimetidine palladium 
complex, [Pd(cim)Cl2]. These results were in contrast to the high 
1H NMR multiplicity 
and pronounced downfield 13C chemical shifts for both C5 and C10 resonances, from a 
previously characterised Pt(cim)2]Cl2 species. This further supported the formation of 
a mono-cimetidine platinum(II) species. Finally, the formation of 68 is consistent with 
the detection of coordinated pyridine release.  
 
6.4.2 Mechanism of action  
The proposed formation of 68 is depicted in Figure 6.32. Firstly, reduction of the PtIV 
centre of complex 40 to PtII occurs via the loss of two azide ligands, in azidyl radical 
form. The OH groups become protonated, assigned to [Pt(OH2)2(py)2]
2+ (60) by HR-
MS as species 60. Then, two possible pathways can occur. Firstly, one water ligand can 
be substituted for cimetidine and binds to PtII via coordination through the sulfur (S11) 
atom of cimetidine. This generates species 67, [Pt(py)2(OH2)(cim)+Na]
3+, as detected 
by mass spectrometry. However, once formed this species is believed to undergo 
additional reaction, rationalising the detection of free pyridine. Within this pathway, 
there are two possible routes for pyridine release. As shown by pathway A (Figure 
6.32), ring closure followed by pyridine release can occur due to the imidazolic ring 
present in cimetidine, forming a stable five-membered ring species [Pt(py)(OH2)(S,N-
                                           Chapter VI: Photo-irradiation in the presence of cimetidine 
311 
 
cim)]2+. This process can be repeated, ultimately forming a [Pt(cim)2]
2+ (69), minor 
species, as detected by MS.  
 
Alternatively, the presence of the PtII-S(thioether) bond can lead to the release of the 
H2O ligand due to the large trans effect of the sulfur thioether, which upon release 
induces coordination of second cimetidine molecule (B, Figure 6.32). Then, ring 
closure of both coordinated cimetidine molecules would occur, followed by loss of 
coordinated pyridine and the final step leading to the equivalent formation of the 
[Pt(cim)2]
2+ (69).  
 
The quenching of the N3 radicals and the reaction of the Pt
II intermediate with 
cimetidine, is believed to be a simultaneous reaction occurring on the same molecule 
of cimetidine. Consequently, the PtII atom in 67 has potential to coordinate to either the 
imidazolic nitrogen or the NH (14, inset Figure 6.32) both of which can lead to the 
formation of stable five-membered ring species. However, the bidentate coordination 
of PtII to the imidazolic nitrogen of cimetidine is believed to be favoured to the presence 
of unpaired electron at that nitrogen atom, formed from the one-electron transfer of 
cimetidine to the N3 radicals (Figure 6.33). Consequently, the formed cimetidine 
radical is not available to undergo a polymerisation reaction, forming a cimetidine 
polymer-type species. Therefore, this also accounts for the lack of observed precipitate 
in this work. In this work, the NMR spectroscopic data, 1H NMR signals were in closer 
agreement to that of a [Pt(cim)2Cl2] (1:1) species, compared to a [Pt(cim)2]Cl2 (1:2) 
species. This suggested the major species after 60 min irradiation with 463 nm light is 
assignable to [Pt(py)(OH2)(cim)]
2+ (68), formed via 67. 
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Figure 6.32 Proposed photo-decomposition pathway of irradiated complex 40 in the 
presence of cimetidine forming PtII-cimetidine species through (A) stepwise and (B) 
simultaneous loss of coordinated pyridine from complex 40. Curly brackets refer to 
species not detected in this work, remaining species characterised by EPR, MS and 1H 
NMR spectroscopic methods.  
 
Therefore, the MS detected at m/z of ca. 722.2, assigned to [Pt(cim)2+Na]
3+ appears to 
be the minor species, under these experimental conditions. This work was performed 
with therapeutically relevant irradiation doses, whereby irradiation >60 min at 463 nm 
is beyond the region of interest. Consequently, the formation of the [Pt(cim)2]
2+ is not 
believed to induce the observed photo-protective effect.  
 
                                           Chapter VI: Photo-irradiation in the presence of cimetidine 
313 
 
 
Figure 6.33 One-electron transfer of cimetidine to the ●N3 radicals forming free azide 
and a cimetidine radical cation, the latter which can deprotonate at pH 7 to the neutral 
cimetidine radical.  
 
6.4.3 Azidyl radical quenching 
Previous studies have reported the abstraction of an electron from the NH moiety of an 
indole ring present in L-Trp (Chapter IV). At pH 7.4, ca. 20% of cimetidine exists in 
protonated form (refer to Figure 6.3), this suggests ●N3 radicals may undergo one-
electron transfer reaction at the imidazolic NH(1) or NH(4) atoms present in cimetidine. 
Additionally, N3 radicals have been reported to undergo one-electron transfer with 
thioether compounds, generating a thioether radical cation (R2S
+) and free azide 
(N3ˉ).65 Cimetidine exhibited a partial quenching of the azidyl radicals. The imidazolic 
ring of cimetidine was attributed to the target moiety at which the one-electron transfer 
between the N3 radicals and cimetidine occurred. The redox couple (Met+/Met) has a 
reduction potential of ca. 1.65 V.66 However, the N3 radicals with a reduction potential 
of ca. 1.33 V [E(N3/ N3)],
67 suggests a one-electron transfer between the N3 radicals 
and methionine to be unfavourable. Consequently, this accounts for the equivalent 
formation of the DMPO-N3 spin adduct in both the absence and presence of L-Met. In 
this work, the reduction in the DMPO-N3 spin adduct was attributed to the quenching 
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of the N3 radicals by histamine. However,  a reduction potential of ca. 1.40 V was 
reported for the redox couple (His+/His).68 However, as reported by Solar et al. 
reduction potentials are known to be dependent on experimental conditions.56 
Consequently, in this work, histamine must possess a lower reduction potential to that 
as previously reported, to account for the decrease in N3 radicals trapped by DMPO in 
the presence of histamine. Webber et al. reported on a the reduction potential of the 
cimetidine couple (Cim+/Cim)69 in the range of -0.8 – -1.0 V70 which supports the 
quenching of the N3 radicals by cimetidine. However, unlike the quenching of the N3 
radicals by L-Trp (Chapter IV) and melatonin (Chapter V), the quenching by 
cimetidine is less effective. Consequently, the reaction of the N3 radicals with indole 
related compounds appears to be more favourable, under the conditions used in this 
work.   
 
6.4.4 Photo-protective effect  
As mentioned in Chapter IV, N3ˉ is a well-known cytotoxic species. However, its 
cytotoxicity is concentration dependent.71 Partial suppression of the N3 radicals by 
cimetidine suggests the concentration of N3ˉ formed would be below the level required 
to induce a cytotoxic effect. The quenching of the N3 radicals reduced their ability to 
induce a photo-cytotoxic effect. Moreover, the detection of N3ˉ also suggests the 
formation of a cimetidine radical cation (undetected). Previous gamma-ray irradiation 
studies have reported the detection of a ring-based radical from a crystal of cimetidine 
by EPR spectroscopy.72 The cytotoxic effect(s) of the cimetidine radical is currently 
unknown. Since the cimetidine radical possesses an unpaired electron it is envisaged 
that it would react rapidly either through radical dimerisation of two cimetidine radicals 
or with a biological target.  
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Inhalation or ingestion of pyridine can induce nausea, dizziness and severe abdominal 
pain. Pyridine has also been associated with minor genotoxic, neurotoxic and 
clastogenic effects.73 However, pyridine is not classified as a cytotoxic species. 
Moreover, Gadberry et al. reported on the morphology of liver present in mice treated 
with pyridine which were determined to be equivalent to the control liver without any 
treatment with pyridine.74 Therefore, pyridine is not expected to induce a cytotoxic 
effect.  
 
The accumulation of platinum was also investigated to rationalise the observed photo-
protective effect. A reduction of ca. 20% in platinum uptake in HaCaT cells supports a 
minor deactivation in the photo-cytotoxic activity of complex 40 in the presence of 
cimetidine. However, in this work, ca. 90% of HaCaT cells remained viable. This 
suggested the observed photo-protective effect was due to the formation of the PtII-
cimetidine species, [Pt(py)(OH2)(cim]
2+ (68). Previous literature has reported on the 
association of “non-leaving ligands” also referred as carrier ligands, with the level of 
antitumour activity.75 The presence of carrier ligands has the ability to distort the DNA 
molecule and prevent enzyme recognition pathways, thereby, inducing cell death. 
Moreover, the loss of the ammine ligand from cis-platin has been associated with 
reduced anticancer activity and subsequent resistance mechanisms.76,77 Additionally, 
substitution of ammine ligands by amine ligands in platinum(IV) diazido anticancer 
complexes enhanced their photo-cytotoxic activity.78 Previous photo-irradiation studies 
of complex 40 in the presence of 5'-GMP have reported on formation of both mono-
[Pt(py)2(N3)(GMP)]
+ and bis-[Pt(py)2(GMP)2]
2+ species.1 The formation of these 
adducts correlates with the potent photo-cytotoxic activity of complex 40.  
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Consequently, it appears that thioether molecules affect the photo-decomposition of 
platinum(IV) anticancer diazido complexes. An array of intracellular molecules possess 
thioether moieties, such that further investigations of photo-activatable platinum(IV) 
diazido anticancer complexes in the presence of these biomolecules are warranted, to 
provide a greater understanding of the in cellulo mechanism of action of platinum(IV) 
diazido anticancer complexes.  
 
6.5 Conclusion  
In vivo platinum accumulation has been reported to be mediated by a variety of 
transporters including copper transporter proteins (CTRs) and organic cation 
transporters (OCTs). Previous literature has correlated the expression of OCT2 
(subgroup of the OCT family) in cells with both the uptake and cytotoxicity of platinum 
anticancer complexes. This was confirmed in the presence of OCT2 inhibitors such as 
TEA and cimetidine, which reduced the uptake of the platinum anticancer complexes.  
 
Therefore, in this Chapter the effect on the photo-activation and photo-decomposition 
of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (complex 40) in the presence of the OCT2 
inhibitor, cimetidine, was investigated. It was determined photo-irradiation of 40 in the 
presence of cimetidine induced an alternative photo-decomposition pathway.. 
Reduction of the PtIV to PtII of complex 40 occurred via two successive one-electron 
donations from the azide ligands. This was later confirmed by the detection of the 
DMPO-N3 spin adduct by EPR spectroscopy.  
 
Photo-irradiation of complex 40 in the presence of cimetidine led to an increase in the 
amount of photo-decomposed cimetidine, whilst the percentage photo-decomposition 
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of cimetidine remained consistent. From these data, it was deduced that the rise in 
absorbance at ca. 354 nm was dependent on the amount of photo-decomposed 
cimetidine. An extinction coefficient of ca. 7,300 M-1 cm-1 was deduced for this 
transition, consequently, it was attributed to a SPtII ligand-to-metal-charge-transfer 
(LMCT) band. This suggested the formation of a PtII-cimetidine species.  
 
1H NMR studies revealed the release of coordinated pyridine from complex 40. 
Additionally, new 1H NMR resonances in both the aromatic and aliphatic region were 
consistent with PtII coordination via the sulfur atom of cimetidine forming a sterogenic 
centre. This was in agreement with the mass spectrometry data from the detection of a 
mass adduct assignable to [Pt(py)2(OH2)(cim)+Na]
3+ (67). Complex 67 was suggested 
to undergo S,N chelate ring formation leading to the release of pyridine, generating 
[Pt(py)(OH2)(cim)]
2+ (68). This was confirmed by MS upon the detection of a mass 
adduct assignable to [Pt(py)(OH2)(cim)+Na]
3+. The formation of the bidentate 
coordination of PtII to cimetidine, believed to be mediated by the cimetidine radical, 
formed from the one-electron transfer reaction between the cimetidine to the azidyl 
radicals. Moreover, 13C-DEPT135 NMR observed downfield chemical shifts for both 
C5 and C10, supported the bi-dentate coordination of cimetidine to PtII via the thioether 
and imidazole nitrogen atoms. These results were in agreement with previous reports 
of a mono-cimetidine palladium(II), [Pt(cim)Cl2] complex. 
 
The quenching of the N3 radicals by cimetidine was confirmed from the detection of 
N3ˉ, by 14N NMR spectroscopy. Photo-irradiation of complex 40 with L-methionine 
and histamine, identified a reduction in the DMPO-N3 spin adduct, only in the presence 
of histamine. Consequently, the imidazole ring was the suggested site of one-electron 
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transfer of the N3 radicals. The –NH groups in the imidazole ring of cimetidine present 
a more favourable site of one-electron donation, due to their lower reduction potential 
relative to the N3 radicals, in contrast to the thioether moiety. The presence of a Pt-
S(thioether) complex was believed to enhance the photo-cytotoxicity of complex 40 in 
the presence of cimetidine.  
 
However, cell studies of co-incubated complex 40 with cimetidine irradiated at 420 nm 
light led to an observed photo-protective effect. At constant concentrations of photo-
irradiated complex 40 (42.4 µM), ca. 90% of HaCaT cells remained viable across a 
range of cimetidine concentrations. This established the photo-protective effect induced 
by cimetidine was dose independent. Consequently, the amount of N3ˉ formed was 
believed to be below the level needed to induce a cyto-toxic effect. The formation of 
[Pt(py)(OH2)(cim)]
2+ (68), through the loss of a carrier (pyridine) ligand, is attributed 
for the reduced photo-cytotoxic nature of complex 40. An array of biological substrates 
possess thioether moieties, consequently this observed effect has potential to occur in 
cellulo.  
 
This work was undertaken to assess the photo-irradiation of trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (complex 40) in the presence of an OCT2 inhibitor molecule, 
cimetidine. To date, the expression of OCT2 in HaCaT keratinocytes cells remains 
unknown.26 Photo-activation of complex 40 in the presence of cimetidine led to the 
formation of PtII-cimetidine species, due to the strong affinity for PtII for sulfur. The 
observed photo-protective effect was attributed to the formation of [Pt(py)(OH2)(cim]
2+ 
(68). Therefore, from this reaction it was not feasible to deduce if complex 40 was 
mediated by OCT2. Further investigations of photo-irradiated complex 40 in the 
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presence of other OCT2 mediated molecules, such as TEA and MPP+, compounds 
lacking a sulfur atom, have potential to deduce the involvement of OCT2 in 
platinum(IV) diazido anticancer complexes accumulation/photo-cytotoxicity.  
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This thesis is concerned with investigating the photo-decomposition pathways of 
photo-activatable platinum(IV) diazido anticancer complexes. Previous studies 
suggested photo-activation of such complexes have potential to lead to the 
generation of various reactive oxygen and nitrogen species (ROS/RNS).1-3 Prior to 
this thesis direct detection of radical species produced from the photo-activation 
of platinum(IV) diazido complexes has not been performed.  
 
7.1 Conclusions 
Chapter III focused on the photo-irradiation of various platinum(IV) diazido 
complexes using spin trapping EPR spectroscopy. Photo-irradiation of complexes 
40 and 44 with blue light (λ = 450 nm and 463 nm), in addition to the photo-
irradiation of complexes 56-58 with both blue (463 nm) and green (517 nm) light 
sources led to a quartet of triplets4 EPR spectrum assigned to the DMPO-14N3 spin 
adduct. Confirmation that the azidyl radicals arose from the platinum(IV) diazido 
complex was established from the photo-irradiation of 15N-complex 40 (50% 15N 
at Nα). This led to a quartet of doublets
5 EPR spectrum assigned to the DMPO-
15N3 spin adduct. The trapping of the 
●N3 radicals was also observed for spin 
traps, 4-POBN generating a triplet of quartets6 EPR spectrum and phosphorus spin 
trap DEPMPO leading to the formation of an octet of triplets7 EPR spectrum, 
assigned to the DEPMPO-N3 spin adduct. Quantification of the spin adducts, 
determined the DEPMPO-N3 spin adduct trapped a greater quantity of the 
●N3 
radicals compared to both 4-POBN-N3 and DMPO-N3 spin adducts. This was 
attributed to DEPMPO possessing a faster rate constant for the trapping of the ●N3 
radicals.  
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Solvent and wavelength of irradiation were both varied to explore the optimum 
condition of azidyl radical release from the photo-irradiation of 40. A higher yield 
of the DMPO-N3 spin adduct was formed in PBS/D2O, which was attributed to the 
Brownian motion8 of the N3 radicals. In contrast, EPR spin trapping in RPMI-
1640 led to a reduction in the amount of DMPO-N3 spin adduct formation. This 
lower yield in spin adduct formation was assigned to the numerous constituents 
present in the cell culture medium which possess the potential to behave as N3 
radical quenchers. Irradiation of complex 40 at 517 nm light led to the observation 
of the DMPO-14N3 spin adduct only in the cell culture medium. This was 
attributed to the minor absorption transitions present in complex 40, as determined 
from previous DFT calculations.1 
 
Chapter IV focused on the reactivity of the formed azidyl radicals generated from 
irradiated complex 40 in the presence of various amino acids. EPR spectroscopy 
established the unreactive nature of the N3 radicals towards the amino acids 
glycine and L-tyrosine, under the conditions used in this work. However, in the 
presence of L-tryptophan, the DMPO-N3 spin adduct was supressed. This was 
attributed to the quenching of the N3 radicals by L-Trp. The detection of free 
azide via 14N NMR spectroscopy, determined this quenching mechanism 
proceeded through a one-electron transfer pathway. Furthermore, photo-
irradiation of complex 40 co-incubated with L-Trp in A2780 ovarian cancer cells 
led to an observed photo-protective effect. This photo-protective effect was 
attributed to the quenching of the N3 radicals by L-Trp. Consequently, it was 
deduced the photo-cytotoxicity of 40 is comprised of both an acute (radical) and 
chronic (DNA platination)-based mechanisms.  
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Chapter V investigated the photo-decomposition pathway of 40 in the presence 
of melatonin.  Melatonin, an analogue of L-Trp has been reported to enhance the 
cytotoxic activity of chemotherapeutic drugs.9-11 Both the anti-oxidant and metal-
chelation ability of melatonin have been previously reported.12-15 EPR 
spectroscopy established the superimposition of two radical spin adducts assigned 
to both the DMPO-N3 (R1) and DMPO-OH (R2) spin adducts, although the 
DMPO-N3 spin adduct was present at a reduced intensity. Irradiation conditions 
were varied to confirm OH radical formation via the addition of ethanol forming 
the DMPO-EtOH (R5) spin adduct and the substitution of the spin trap DMPO for 
the phosphorus analogue, DEPMPO generating the DEPMPO-OH (R4) spin 
adduct.7 The detection of hydroxyl (●OH) radicals suggested the possible 
enhancement in the photo-cytotoxicity complex 40 in the presence of melatonin. 
However, detection by HR-MS of a mass adduct 17 a.m.u higher than that of the 
sodium adduct of melatonin, suggested the addition of the hydroxyl radical to 
melatonin. However, due to the low S/N of the formed photo-products, complete 
structural assignment was not feasible. Photo-irradiation of complex 40 co-
incubated with melatonin in A2780 ovarian cancer cells induced a photo-
protective effect. This photo-protective effect was attributed to the one-electron 
transfer reaction between the N3 radicals and melatonin and the addition reaction 
of the OH radicals to melatonin. Consequently, both the RNS/ROS were not 
available to induce their cytotoxic effect. Furthermore, the detection of 
[Pt(py)2(OH2)(MLT)]
2+ (62), was suggested to reduce the amount of PtII available 
to bind to the N7 of guanine nucleobase of DNA and thereby inhibit cell death.  
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Numerous studies have identified various transporters which mediate the 
accumulation of platinum anticancer complexes16-19 In particular, the expression 
of the organic cation transporter OCT2 has been correlated with high platinum 
toxicity.20 Therefore, Chapter VI focused on the photo-irradiation of complex 40 
in the presence of cimetidine, an OCT2 inhibitor.21 UV-visible spectroscopy led to 
the observation of an isosbestic point, becoming more pronounced with increasing 
concentrations of cimetidine. 1H NMR spectroscopy identified the formation of 
free pyridine, new platinum-photo products and evidence of coordinated 
cimetidine peaks. HR-MS identified a mass adduct at a m/z of 646.1647, assigned 
to [Pt(OH2)(py)2(cim)+Na]
3+. The loss of coordinated pyridine was attributed to 
either ring closure or due to the trans effect, mediated by cimetidine radical, 
formed from the one-electron transfer of cimetidine to the azidyl radicals. Finally, 
photo-irradiation of 40 co-incubated with cimetidine in HaCaT keratinocytes cells 
demonstrated a potent photo-protective effect at low concentrations (μM) of 
cimetidine. The extent of the photo-protective effect was attributed to both azidyl 
radical quenching and formation of the platinum(II)-cimetidine complex.  
 
Overall, this thesis identified the release of azidyl radicals from photo-activated 
platinum(IV) diazido anticancer complexes. Varying the experimental conditions 
led to alternative photo-decomposition pathways which induced a direct effect on 
the photo-cytotoxicity of complex 40. Therefore, the studies presented in this 
thesis offer the potential to contribute to the overall understanding on the 
reactivity of photo-irradiated platinum(IV) diazido complexes and their generated 
photo-products.  
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7.2 Future Work  
This work was concerned with the primary identification and characterisation of 
azidyl radicals from the photo-irradiation of platinum(IV) diazido anticancer 
complexes in vitro. Performing in cellulo spin trapping EPR has the ability to 
elucidate a more comprehensive understanding of azidyl radical reactivity under 
biologically relevant conditions. In cellulo spin trapping EPR has been reported 
for both the superoxide (O2
-●) and hydroxyl (●OH) radicals.22,23 Additionally, due 
to their non-toxic nature both DMPO and DEPMPO spin traps are commonly used 
for in cellulo and in vivo spin trapping EPR.24,25 The cell contains a variety of 
constituents, such that monitoring the photo-decomposition of platinum(IV) 
diazido anti-tumour complexes has potential to further contribute to the 
understanding of their induced photo-cytotoxicity.  
 
Interestingly, previous reports have documented Gly as a cyto-protective agent26 
against a number of injurious agents.27-29 Zhong et al. reported on the protective 
ability of Gly in both liver and renal tissues caused by hepatic/renal toxins and/or 
drugs. Platinum chemotherapeutic agents are commonly excreted through the 
kidneys, inducing renal damage as reported from treatment with cis-platin. 
Consequently, assuming complex 40 is excreted through the kidneys similar to 
cis-platin, the unreactive nature of the N3 radicals towards Gly postulates the 
induction of a photo-cytotoxic effect whilst protecting against renal toxicity from 
the photo-irradiation of complex 40 in the presence of Gly. Although prior studies 
to assess the accumulation of complex 40 in the kidneys would have to be 
performed. 
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Secondly, L-tryptophan, melatonin and cimetidine radicals were suggested to 
form during this work. The tryptophanyl radical could be detected via spin 
trapping EPR spectroscopy using spin trap, 3,5-dibromo-4-nitrobenzene-sulfonic 
acid (DBNBS),30,31 however the availability of this spin trap is difficult to source. 
Therefore, a more reliable method for trapping of amino acid radicals and 
derivatives is rapid freeze quench (RFQ) EPR spectroscopy. RFQ-EPR freezes the 
sample and slows down the molecular tumbling rates of the radical under 
investigation. The L-Trp radical present in proteins/peptides has been previously 
detected by RFQ-EPR at both X-and W-band.32 The melatonin radical has been 
identified by other spectroscopic techniques14,33,34 but not directly via EPR 
spectroscopy. Gamma ray radiation of a crystal of cimetidine identified a ring-
based radical by X-band EPR spectroscopy.35 These radical species have potential 
to be involved in the observed photo-protective effect, such that detection of these 
radical species is paramount for the complete understanding of induced photo-
protective effect. 
 
Thirdly, investigating the expression levels of the autophagic proteins LC3-I and 
LC3-II via various cell assays as described by Tanida et al.,36 has potential to 
determine if the suggested L-Trp radical interacts with the LC3-I autophagic 
protein, providing a deeper understanding of the induced photo-protective effect 
in the presence of L-Trp.  
 
Fourthly, the detection of a platinum(II)-cimetidine complex highlights the 
necessity to investigate the photo-irradiation of platinum(IV) diazido complexes 
in the presence of various sulfur-containing compounds. Earlier studies by 
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Ronconi also reported on the ability of DMS (another sulfur-containing complex) 
to alter the photo-decomposition of complex 36.37 The displacement of the 
pyridine ligand from complex 40 was attributed to the observed photo-protective 
effect. However, this may be avoided in the presence of platinum(IV) diazido 
complexes possessing alternative equatorial ligands than that of pyridine. 
Consequently, this preliminary study suggests additional photo-cytotoxicity 
studies of platinum(IV) diazido complexes in the presence of sulfur-containing 
species is a prerequisite for more in-depth knowledge about their in vivo 
mechanism of action.   
 
Fifthly, photo-irradiation of 40 in the presence of melatonin led to the detection of 
the hydroxyl (●OH) radical. An additional method of ●OH radical detection could 
be observed from the synthesis of 17O-labelled38 complex 40. Therefore, the 
trapping of the 17●OH would be expected to exhibit an alternative EPR spectrum 
upon trapping with spin trap, DMPO. This could also provide information on the 
release of the hydroxyl ligands from the platinum(IV) diazido complexes. This 
could also be expanded to NMR spectroscopy.  
 
Numerous photo-products were detected in this thesis. Complete characterisation 
of these photo-products by NMR spectroscopy alone, was not feasible. Therefore, 
performing detailed High Performance Liquid Chromatography (HPLC)39 analysis 
on all irradiated solutions has the ability to elucidate all formed photo-products 
and their time of evolution. Consequently, the photo-cytotoxicity/photo-protective 
effect could then be directly correlated to the formed photo-products.  
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Finally, various insoluble precipitates were observed in this work, consequently, 
solution phase experiments were not possible. Although their formation is 
believed to be triggered at millimolar (mM) concentrations and not believed to 
contribute to the photo-cytotoxicity of complex 40, identification of these 
precipitates is still of interest for future NMR spectroscopic studies. Primarily 
solid state NMR spectroscopy has the potential to identify the species present in 
the formed precipitates. Although 1H SSNMR is not proposed due to the broad 
spectra obtained owning to the strong homonuclear dipole couplings, as reported 
by Lucier,40 analysis of 195Pt and 14N nuclei appear to be more suitable by 
SSNMR spectroscopy.41 The development of a new pulsing sequence referred to 
as wideband uniform rate smooth truncation-Carr-Purcell Meiboom-Gill 
(WURST-CPMG)42 offers the ability of rapid acquisition for 195Pt SSNMR. Both 
195Pt and 15N SSNMR spectroscopy have been previously reported for various 
platinum(IV) and platinum(II)-anticancer complexes.43 Alternatively, X-ray 
fluorescence (XRF),44 synchrotron-radiation induced X-ray emission (SRIXE),45,46 
and X-ray absorption near-edge structure (XANES)47 have been performed on 
platinum anti-cancer complexes. These X-ray based techniques can provide 
insight into the various oxidation states of the species providing additional 
information of the formed species.  
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Figure A2.1 Spectral output of blue LED light source (463 nm, 64 mW cm-2).  
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Figure A3.1 Spectral output of 517 nm green (33 mW cm-2) light source. 
 
 
 
Figure A3.2 593 nm (17 mW cm-2) yellow LED light source. 
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Figure A3.3 Dark EPR spectra of the different spin traps used in this work. Aqueous solutions 
of (A) DMPO; (B) POBN and (C) DEPMPO prepared at 8 mM at pH 7.4. No background EPR 
signals from either of the spin traps.  
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Figure A3.4 EPR spectra of (A) dark aqueous solution complex 1; (B) irradiated for 7 min 
with 463 nm light; (C) dark aqueous solution of complex 1 in the presence of DMPO. 
Substituting spin trap DMPO with 4-POBN and DEPMPO generated EPR spectrum equivalent 
to C.  
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Figure A3.5 Quantification of the DMPO-N3 spin adduct formed from the photo-irradiation at 
463 nm after 7 min, 14 min and 21 min intervals from a solution containing complex 40 (5 
mM) in the presence of DMPO (2 mol equiv relative to complex 40) prepared in H2O () and 
PBS/H2O () at pH 7.4. No spin adduct was observed in the dark (0 min). Error bars represent 
standard error of three independent experiments.  
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Figure A3.6 Components of cell culture medium RMPI-1640 without L-glutamine*, 
*information adapted from Sigma Aldrich.  
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DMPO-N3 Spin Density Structure 
1  C -0.021989  
 
 
 
 
 
 
2  C -0.015911 
3  C 0.000796 
4  C 0.001167 
5  H 0.012612 
6  H 0.000895 
7  H 0.000651 
8  H -0.000343 
9  H 0.000339 
10  O 0.528840 
11  N 0.411518 
12  N 0.013552 
13  N    0.007677 
14  N 0.038469 
15  C 0.021260 
16  H    0.001813 
17  H 0.002161 
18  H -0.000309 
19  C 0.017718 
20  H -0.000209 
21  H -0.001319 
22  H -0.000408 
 
Figure 3A.7 Spin density values for all atoms present in the DMPO-N3 spin adducts, as 
determined from DFT calculations.  
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DEPMPO-N3 Spin Density Structure 
1  C -0.028644  
 
 
 
 
 
 
 
 
 
 
 
2  C -0.018967 
3  C 0.000356 
4  C 0.002835 
5  H 0.000602 
6  H 0.000595 
7  H 0.000519 
8  H -0.000377 
9  O 0.515280 
10  N     0.422550 
11  C     0.017319 
12  H    0.001265 
13  H    0.000582 
14  H     0.000127 
15  P     0.026697 
16  O     0.001884 
17  C 0.002083 
18  C 0.000126 
19  H -0.000094 
20  H -0.000103 
21  H 0.000195 
22  H 0.000003 
23  H -0.000003 
24  C 0.001997 
25  C -0.000298 
26  H 0.001471 
27  H -0.000058 
28  H 0.000176 
29  H 0.000157 
30  H 0.000003 
31  O 0.001099 
32  O 0.002096 
33  N 0.012383 
34  N -0.006576 
35  N 0.031643 
36  H 0.014771 
 
Figure 3A.8 Spin density values for all atoms present in the DMPO-N3 spin adducts, as 
determined from DFT calculations.  
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4-POBN-N3 Spin Density  Structure  
1  C -0.004927  
 
 
 
 
 
 
 
2  C -0.003988 
3  C 0.007854 
4  C 0.012194 
5  C 0.003748 
6  H 0.000211 
7  H 0.000468 
8  H -0.000305 
9  H -0.001045 
10  N 0.003864 
11  O 0.008436 
12  C -0.027121 
13  H 0.001697 
14  N 0.442148 
15  O 0.533465 
16  C -0.022259 
17  C 0.023610 
18  C 0.014544 
19  H -0.000707 
20  H 0.000208 
21  H -0.001513 
22  H 0.000249 
23  H -0.001405 
24  H -0.000430 
25  C 0.000571 
26  H -0.001006 
27  H -0.000220 
28  H 0.000401 
29  N 0.011496 
30  N 0.000550 
31  N -0.000785 
 
Figure 3A.9 Spin density values for all atoms present in the 4-POBN-N3 spin adducts, as 
determined from DFT calculations.  
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Figure A4.1 Dark EPR spectra of deuterated phosphate buffered solutions all 
containing complex 1 (4 mM); (A) complex 1 only; addition of (B) Gly; (C) L-
Tyr and (D) L-Trp. No EPR signals formed in the dark.  
 
 
 
Figure A4.2 The aromatic region of the 1H NMR spectra from a solution of complex 40 
(4 mM) and DMPO (8 mM) prepared in D2O buffer at pH* 7.4 in (A) dark and (B) after 
30 min irradiation with 463 nm light. Assignments: Pt-py peaks, (o/p/m); platinum 
photoproducts, (e'-i').   
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Figure A5.1 Dark EPR spectra of solutions containing (A) melatonin with DMPO 
and (B) complex 1, DMPO and melatonin prepared in PBS/D2O at pH* 7.4.  
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Figure A6.1 Comparison of 1H NMR spectra of photo-products formed from a 
solution containing complex 40 (4 mM) prepared in PBS/D2O in the (A) absence 
and (B) presence of cimetidine irradiated at 463 nm  for 60 min. Assignments: Pt-
py peaks, (o/p/m); cimetidine peak, (5); photo-generated Pt-species in both the 
absence/presence of cimetidine, (e'-i'); photo-generated species only in the 
presence of cimetidine, (). 
 
